4,4-DISUBSTITUTED-3,4-DIHYDRO-2(1H)-QUINAZOLINTHIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS

Abstract: The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinthiones of formula (I), wherein: R<1> is C1-3 alkyl substituted with 1-7 halogen; R<2> is selected from C1-5 alkyl substituted with 1-2 R<4>, C2-5 alkenyl substituted with 1-2 R<4>, and C2-5 alkynyl substituted with 1 R<4>; R<4> is selected from C3-5 cycloalkyl substituted with 0-2 R<3>, phenyl substituted with 0-5 R<3>, and a 5- 6-membered heterocyclic system containing 1-3 heteroatoms selected from O, N, and S, substituted with 0-2 R<3>; and compounds of formula (II), wherein R<2> is CC-R<4a>; R<4a> is selected from methyl, ethyl, n-propyl, i-propyl, i-butyl, t-butyl, and i-pentyl; R<3> at each occurrence, is independently selected from C1-4 alkyl, OH, C1-4 alkoxy, F, Cl, Br, I, NR<5>R<5a>, NO2, CN, C(O)R<6>, NHC(O)R<7>, and NHC(O)NR<5>R<5a>; alternatively, if two R<3>'s are present and are attached to adjacent carbons, then they may combine to form -OCH2O-; R<8> is selected from H, C3-5 cycloalkyl, and C1-3 alkyl; and n is selected from 0, 1, 2, 3, and 4 or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

Description: TITLE 4,4-DISUBSΗTUTED-3,4-DIHYDR0-2(1H)-QUINAZ0LINTHI0NE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS FIELD OF THE INVENTION This invention relates generally to 4 , 4-disubstituted- 3 , 4-dihydro-2 (IH) -quinazolinthiones which are useful as inhibitors of HIV reverse transcriptase, pharmaceutical compositions and diagnostic kits comprising the same, methods of using the same for treating viral infection or as assay standards or reagents, and intermediates and processes for making the same . BACKGROUND OF THE INVENTION Two distinct retroviruses , human immunodeficiency virus (HIV) type-1 (HIV-1) or type-2 (HIV-2), have been etiologically linked to the immunosuppressive disease, acquired immunodeficiency syndrome (AIDS) . HIV seropositive individuals are initially asymptomatic but typically develop AIDS related complex (ARC) followed by AIDS. Affected individuals exhibit severe immunosuppression which predisposes them to debilitating and ultimately fatal opportunistic infections . The disease AIDS is the end result of an HIV-1 or HIV-2 virus following its own complex life cycle. The virion life cycle begins with the virion attaching itself to the host human T-4 lymphocyte immune cell through the bonding of a glycoprotein on the surface of the virion 's protective coat with the CD4 glycoprotein on the lymphocyte cell. Once attached, the virion sheds its glycoprotein coat, penetrates into the membrane of the host cell, and uncoats its RNA. The virion enzyme, reverse transcriptase, directs the process of transcribing the RNA into single-stranded DNA. The viral RNA is degraded and a second DNA strand is created. The now double-stranded DNA is integrated into the human cell's genes and those genes are used for virus reproduction. At this point, RNA polymerase transcribes the integrated DNA into viral RNA. The viral RNA is translated into the precursor gag-pol fusion polyprotein. The polyprotein is then cleaved by the HIV protease enzyme to yield the mature viral proteins. Thus, HIV protease is responsible for regulating a cascade of cleavage events that lead to the virus particle's maturing into a virus that is capable of full infectivity. The typical human immune system response, killing the invading virion, is taxed because the virus infects and kills the immune system's T cells. In addition, viral reverse transcriptase, the enzyme used in making a new virion particle, is not very specific, and causes transcription mistakes that result in continually changed glycoproteins on the surface of the viral protective coat. This lack of specificity decreases the immune system's effectiveness because antibodies specifically produced against one glycoprotein may be useless against another, hence reducing the number of antibodies available to fight the virus . The virus continues to reproduce while the immune response system continues to weaken. Eventually, the HIV largely holds free reign over the body's immune system, allowing opportunistic infections to set in and without the administration of antiviral agents, immunomodulators , or both, death may result. There are at least three critical points in the virus's life cycle which have been identified as possible targets for antiviral drugs: (1) the initial attachment of the virion to the T-4 lymphocyte or macrophage site, (2) the transcription of viral RNA to viral DNA (reverse transcriptase, RT) , and (3) the processing of gag-pol protein by HIV protease. Inhibition of the virus at the second critical point, the viral RNA to viral DNA transcription process, has provided a number of the current therapies used in treading AIDS . This transcription must occur for the virion to reproduce because the virion 's genes are encoded in RNA and the host cell reads only DNA. By introducing drugs that block the reverse transcriptase from completing the formation of viral DNA, HIV- 1 replication can be stopped. A number of compounds that interfere with viral replication have been developed to treat AIDS. For example, nucleoside analogs, such as 3 ' -azido-3 ' -deoxythymidine (AZT) , 2 ' , 3 ' -dideoxycytidine (ddC) , 2 ' , 3 ' -dideoxythymidinene (d4T) , 2 ' , 3 ' -dideoxyinosine (ddl) , and 2 ' , 3 ' -dideoxy-3 ' -thia-cytidine (3TC) have been shown to be relatively effective in halting HIV replication at the reverse transcriptase (RT) stage. An active area of research is in the discovery of non- nucleoside HIV reverse transcriptase inhibitors. As an example, it has been found that certain benzoxazinones and quinazolinones are active in the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS . U.S. 5,519,021 describe reverse transcriptase inhibitors which are benzoxazinones of the formula: wherein X is a halogen, Z may be S. EP 0,530,994 and WO 93/04047 describe HIV reverse transcriptase inhibitors which are quinazolinones of the formula A: A wherein G is a variety of groups, R 3 and R 4 may be H, Z may be S, R 2 may be unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted heterocycle, and optionally substituted aryl, and R 1 may be a variety of groups including substituted alkyl. WO 95/12583 also describes HIV reverse transcriptase inhibitors of formula A. In this publication, G is a variety of groups, R 3 and R 4 may be H, Z may be S, R 2 is substituted alkenyl or substituted alkynyl, and R 1 is cycloalkyl, alkynyl, alkenyl , or cyano . Synthetic procedures for making quinazolinones like those described above are detailed in the following references: Houpis et al, Tetr. Lett. 1994, 35 (37) , 6811-6814; Tucker et al, J. Med. Chem. 1994, 37, 2437-2444; and, Huffman et al , J. Org. Chem . 1995, 60 , 1590-1594. DE 4,320,347 illustrates quinazolinones of the formula: wherein R is a phenyl, carbocyclic ring, or a heterocyclic ring and X may be S . Compounds of this sort are not considered to be part of the present invention. Even with the current success of reverse transcriptase inhibitors, it has been found that HIV patients can become resistant to a single inhibitor. Thus, it is desirable to develop additional inhibitors to further combat HIV infection. SUMMARY OF THE INVENTION Accordingly, one object of the present invention is to provide novel reverse transcriptase inhibitors. It is another object of the present invention to provide a novel method for treating HIV infection which comprises administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt form thereof. It is another object of the present invention to provide a novel method for treating HIV infection which comprises administering to a host in need thereof a therapeutically effective combination of (a) one of the compounds of the present invention and (b) one or more compounds selected form the group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors . It is another object of the present invention to provide pharmaceutical compositions with reverse transcriptase 4 inhibiting activity comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt form thereof. It is another object of the present invention to provide a method of inhibiting HIV present in a body fluid sample which comprises treating the body fluid sample with an effective amount of a compound of the present invention. It is another object of the present invention to provide a kit or container containing at least one of the compounds of the present invention in an amount effective for use as a standard or reagent in a test or assay for determining the ability of a potential pharmaceutical to inhibit HIV reverse transcriptase, HIV growth, or both. These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of formula (I): I wherein R 1 , R 2 , R 3 , and R 8 are defined below, stereoisomeric forms, mixtures of stereoisomeric forms, or pharmaceutically acceptable salt forms thereof, are effective reverse transcriptase inhibitors . DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS [1] Thus, in a first embodiment, the present invention provides a novel compound of formula I : I or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: R 1 is Cι- 3 alkyl substituted with 1-7 halogen; R 2 is selected from Cχ- 5 alkyl substituted with 1-2 R 4 , C 2 - 5 alkenyl substituted with 1-2 R 4 , and C 2 - 5 alkynyl substituted with 1 R 4 ; R 3 , at each occurrence, is independently selected from C 1 - 4 alkyl, OH, Cι_ alkoxy, F, Cl, Br, I, NR 5 R 5a , N0 2 , CN, C(0)R 6 , NHC(0)R 7 , and NHC (0)NR 5 R 5a ; alternatively, if two R 3 ' s are present and are attached to adjacent carbons, then they may combine to form -OCH 2 O-; R 4 is selected from C 3 - 5 cycloalkyl substituted with 0-2 R 3 , phenyl substituted with 0-5 R , and a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from 0, N, and S, substituted with 0-2 R 3 ; R 5 and R 5a are independently selected from H and C 1 - 3 alkyl; R 6 is selected from H, OH, C 1 -. 4 alkyl, C 1 - 4 alkoxy, and NR 5 R 5a ; R 7 is selected from Cι_ 3 alkyl and C 1 -. 3 alkoxy; R 8 is selected from H, 0 3 . 5 cycloalkyl, and C 1 - 3 alkyl; and, n is selected from 0, 1, 2, 3, and 4. [2] In a preferred embodiment, the present invention provides a novel compound of formula I, wherein: R 1 is C 1 - 3 alkyl substituted with 1-7 halogen; R 2 is selected from C 1 - 5 alkyl substituted with 1 R 4 , C 2 - 5 alkenyl substituted with 1 R 4 , and C 2 - 5 alkynyl substituted with 1 R 4 ; R 3 , at each occurrence, is independently selected from C 1 - 4 alkyl, OH, C 1 - 4 alkoxy, F, Cl, Br, I, NR 5 R 5a , N0 2 , CN, C(0)R 6 , NHC(0)R 7 , and NHC (0)NR 5 R 5 ; alternatively, if two R 3 ' s are present and are attached to adjacent carbons, then they may combine to form -OCH 2 O-; R 4 is selected from C 3 - 5 cycloalkyl substituted with 0-2 R 3 , phenyl substituted with 0-2 R 3 , and a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from 0, N, and S, substituted with 0-1 R 3 ; R 5 and R 5a are independently selected from H, CH 3 and C 2 H 5 ; R 6 is selected from H, OH, CH 3 , C 2 H 5 , OCH 3 , OC 2 H 5 , and NR 5 R 5a ; R 7 is selected from CH 3 , C 2 H 5 , OCH 3 , and OC 2 H 5 ; R 8 is selected from H, cyclopropyl, CH 3 and C 2 H 5 ; and, n is selected from 0, 1, 2, and 3. [3] In a more preferred embodiment, the present invention provides a novel compound of formula I, wherein: R 1 is selected from CF 3 , and C 2 F 5 ; R 2 is selected from C 1 - 3 alkyl substituted with 1 R 4 , C 2 - 3 alkenyl substituted with 1 R 4 , and C 2 - 3 alkynyl substituted with 1 R 4 ; R 3 , at each occurrence, is independently selected from Cι_ 3 alkyl, OH, C 1 - 3 alkoxy, F, Cl, Br, I, NR 5 R 5a , N0 2 , CN, C(0)R 6 , NHC(0)R 7 , and NHC (0)NR 5 R 5a ; alternatively, if two R 3 ' s are present and are attached to adjacent carbons, then they may combine to form -OCH 2 O-; R 4 is selected from C 3 - 5 cycloalkyl substituted with 0-2 R 3 , phenyl substituted with 0-2 R 3 , and a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from 0, N, and S, substituted with 0-1 R 3 ; R 5 and R 5a are independently selected from H, CH 3 and C 2 H 5 ; R 6 is selected from H, OH, CH 3 , C 2 H 5 , OCH 3 , OC 2 H 5 , and NR 5 R 5 ; R 7 is selected from CH 3 , C 2 H 5 , OCH 3 , and OC 2 H 5 ; R 8 is selected from H, CH 3 and C 2 H 5 ; and, n is selected from 0, 1, and 2. [4] In an even more preferred embodiment, the present invention provides a novel compound of formula I, wherein: R 1 is CF 3 ; R 2 is selected from Cχ_ 3 alkyl substituted with 1 R 4 , C 2 - 3 alkenyl substituted with 1 R 4 , and C 2 - 3 alkynyl substituted with 1 R 4 ; R 3 , at each occurrence, is independently selected from C 1 - 3 alkyl, OH, Cι_ 3 alkoxy, F, Cl, NR 5 R 5a , N0 2 , CN, C(0)R 6 , NHC(0)R 7 , and NHC (0)NR 5 R a ; alternatively, if two R 3 ' s are present and are attached to adjacent carbons, then they may combine to form -OCH 2 O-; R 4 is selected from cyclopropyl substituted with 0-1 R 3 , phenyl substituted with 0-2 R 3 , and a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from 0, N, and S, substituted with 0-1 R 3 , wherein the heterocyclic system is selected from 2-pyridyl, 3- pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, 3- thienyl, 2-oxazolyl, 2-thiazolyl, 4-isoxazolyl, and 2- imidazolyl ; R 5 and R 5a are independently selected from H, CH 3 and C 2 H 5 ; R 6 is selected from H, OH, CH 3 , C 2 H 5 , OCH 3 , OC 2 H 5 , and NR 5 R 5a ; R 7 is selected from CH 3 , C 2 H 5 , OCH 3 , and OC 2 H 5 ; R 8 is selected from H, CH 3 and C 2 H 5 ; and, n is selected from 1 and 2. [5] In a further preferred embodiment, wherein the compound is of formula la Rj 2 B la. [6] In a further preferred embodiment, wherein the compound is of formula lb: lb. [7] In a further preferred embodiment, the compound of formula I is selected from: (+/-) -4-Cyclopropylethynyl-5, 6-difluoro-4-trifluoromethyl-3 , 4- dihydro-2 (IH) -quinazolinthione; (+/-) -6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-3 , 4- dihydro-2 (IH) -quinazolinthione; (+/-) -4-Cyclopropylethynyl-5, 6-difluoro-4-trifluoromethyl-3 , 4- dihydro-2-methyl (IH) -quinazolinthione; and, (+/-) -6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-3 , 4- dihydro-2-methyl (IH) -quinazolinthione; or a pharmaceutically acceptable salt thereof. [8 ] In a second embodiment , the present invention provides a novel compound of formula II : II or a stereoisomer or pharmaceutically acceptable salt thereof , wherein : R 2 is C≡C-R 4a ; R 3 is selected from C 1 - 4 alkyl, OH, C 1 - 4 alkoxy, F, Cl, Br, I, NR 5 R 5a , N0 2 , CN, C(0)R 6 , NHC(0)R 7 , and NHC (0)NR 5 R 5a ; R 4a is selected from methyl, ethyl, n-propyl , i-propyl, i-butyl, t-butyl, and i-pentyl; R 5 and R 5a are independently selected from H and Cι__ 3 alkyl; R 6 is selected from H, OH, Cι_ 4 alkyl, Cι_ 4 alkoxy, and NR 5 R 5a ; R 7 is selected from C 1 - 3 alkyl and C 3. -. 3 alkoxy; 10 R 8 is selected from H, C 3 - 5 cycloalkyl, and Cχ_ 3 alkyl; and, n is selected from 0, 1, 2, 3, and 4. [9] In another preferred embodiment, the present invention provides a novel compound of formula II, wherein: R 2 is C≡C-R 4a ; R 3 is selected from C 1 - 4 alkyl, OH, C 1 - 4 alkoxy, F, Cl, Br, I, NR 5 R a , N0 2 , CN, C(0)R 6 , and NHC(0)R 7 ; R 4a is selected from methyl, ethyl, n-propyl, i-propyl, i-butyl, t-butyl, and i-pentyl; R 5 and R 5a are independently selected from H, CH 3 and C 2 H 5 ; R β is selected from H, OH, CH 3 , CH 5 , OCH 3 , 0C 2 H 5 , and NR 5 R 5a ; R 7 is selected from CH 3 , C 2 H 5 , OCH 3 , and OC 2 H 5 ; R 8 is selected from H, cyclopropyl, CH 3 and C 2 H 5 ; and, n is selected from 0, 1, and 2. [10] In a further preferred embodiment, wherein the compound is of formula Ila CF 3 2 ,R 8 N' Ila. 11 [11] In a further preferred embodiment, wherein the compound is of formula lib: CF 3 .R 2 lib. In a third embodiment, the present invention provides a novel pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I or II or pharmaceutically acceptable salt form thereof. In a fourth embodiment, the present invention provides a novel method for treating HIV infection which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of formula I or II or pharmaceutically acceptable salt form thereof. In a fifth embodiment, the present invention provides a novel method of treating HIV infection which comprises administering, in combination, to a host in need thereof a therapeutically effective amount of: (a) a compound of formula I or II; and, (b) at least one compound selected from the group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors. In another preferred embodiment, the reverse transcriptase inhibitor is selected from AZT, ddC, ddl, d4T, 3TC, delavirdine, nevirapine, Ro 18,893, trovirdine, MKC-442, HBY 097, ACT, UC-781, UC-782, RD4-2025, and MEN 10979, and the protease inhibitor is selected from saq inavir , ritonavir, 12 indinavir, amprenavir, nelfinavir, palinavir, BMS-232623, GS3333, KNI-413, KNI-272, LG-71350, CGP-61755, PD 173606, PD 177298, PD 178390, PD 178392, U-140690, and ABT-378. In an even more preferred embodiment, the reverse transcriptase inhibitor is selected from AZT and 3TC and the protease inhibitor is selected from saquinavir, ritonavir, nelfinavir, and indinavir. In a still further preferred ebodiment, the reverse transcriptase inhibitor is AZT. In another still further preferred embodiment, the protease inhibitor is indinavir. In a sixth embodiment, the present invention provides a pharmaceutical kit useful for the treatment of HIV infection, which comprises a therapeutically effective amount of: (a) a compound of formula I or II; and, (b) at least one compound selected from the group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors, in one or more sterile containers. In a seventh embodiment, the present invention provides a novel method of inhibiting HIV present in a body fluid sample which comprises treating the body fluid sample with an effective amount of a compound of formula I or II. In a eighth embodiment, the present invention to provides a novel a kit or container comprising a compound of formula I or II in an amount effective for use as a standard or reagent in a test or assay for determining the ability of a potential 13 pharmaceutical to inhibit HIV reverse transcriptase, HIV growth, or both. DEFINITIONS As used herein, the following terms and expressions have the indicated meanings. It will be appreciated that the compounds of the present invention contain an asymmetrically substituted carbon atom, and may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis, from optically active starting materials. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated. The processes of the present invention are contemplated to be practiced on at least a multigram scale, kilogram scale, multikilogram scale, or industrial scale. Multigram scale, as used herein, is preferably the scale wherein at least one starting material is present in 10 grams or more, more preferably at least 50 grams or more, even more preferably at least 100 grams or more. Multikilogram scale, as used herein, is intended to mean the scale wherein more than one kilogram of at least one starting material is used. Industrial scale as used herein is intended to mean a scale which is other than a laboratory scale and which is sufficient to supply product sufficient for either clinical tests or distribution to consumers . As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms . Examples of alkyl include, but are not limited to, methyl, ethyl, n- propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s- pentyl . "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -C V F W where v = 1 to 3 and w = 1 to (2v+l) ) . Examples of haloalkyl include, but are not limited 14 to, trifluoromethyl , trichloromethyl, pentafluoroethyl, and pentachloroethyl . "Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s- pentoxy. "Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. "Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl and the like. "Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl and the like. "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo and iodo . "Counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate and the like. As used herein, "aryl" or "aromatic residue" is intended to mean an aromatic moiety containing the specified number of carbon atoms, such as phenyl or naphthyl . As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 5- membered monocyclic ring, which may be saturated or partially unsaturated. Examples of such carbocyles include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, biphenyl, naphthyl, indanyl, ada antyl, or tetrahydronaphthyl (tetralin) . As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5- to 6- membered monocyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and from 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and S. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable 15 structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and 0 atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and 0 atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic system" is intended to mean a stable 5- to 6- membered monocyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 3 heterotams independently selected from the group consisting of N, 0 and S. It is preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heterocycles include, but are not limited to, 2-pyrrolidonyl, 2H-pyrrolyl, 4-piperidonyl, 6H-1,2,5- thiadiazinyl, 2H, 6H-1 , 5 , 2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, isoxazolyl, morpholinyl, oxadiazolyl , 1, 2 , 3-oxadiazolyl, 1,2,4- oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, oxazolidinyl . , oxazolyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl , pyranyl, pyrazinyl, pyrazolidinyl , pyrazolinyl, pyrazolyl, pyridazinyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, 6H-1, 2 , 5-thiadiazinyl , 1,2,3- thiadiazolyl , 1, 2 , 4-thiadiazolyl, 1, 2 , 5-thiadiazolyl, 1,3,4- thiadiazolyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1, 2 , 4-triazolyl, 1, 2 , 5-triazolyl, and 1,3,4- triazolyl . Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, and oxazolidinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles . As used herein, "HIV reverse transcriptase inhibitor" is intended to refer to both nucleoside and non-nucleoside inhibitors of HIV reverse transcriptase (RT) . Examples of nucleoside RT inhibitors include, but are not limited to, AZT, 16 ddC, ddl, d4T, and 3TC. Examples of non-nucleoside RT inhibitors include, but are no limited to, delavirdine (Pharmacia and Upjohn U90152S) , nevirapine (Boehringer Ingelheim) , Ro 18,893 (Roche), trovirdine (Lilly), MKC-442 (Triangle) , HBY 097 (Hoechst) , ACT (Korean Research Institute) , UC-781 (Rega Institute) , UC-782 (Rega Institute) , RD4-2025 (Tosoh Co. Ltd.), and MEN 10979 (Menarini Farmaceutici) . As used herein, "HIV protease inhibitor" is intended to refer to compounds which inhibit HIV protease. Examples include, but are not limited, saquinavir (Roche, Ro31-8959) , ritonavir (Abbott, ABT-538) , indinavir (Merck, MK-639) , amprenavir (Vertex/Glaxo Wellcome) , nelfinavir (Agouron, AG- 1343), palinavir (Boehringer Ingelheim), BMS-232623 (Bristol- Myers Squibb), GS3333 (Gilead Sciences) , KNI-413 (Japan Energy) , KNI-272 (Japan Energy) , LG-71350 (LG Chemical) , CGP- 61755 (Ciba-Geigy) , PD 173606 (Parke Davis), PD 177298 (Parke Davis), PD 178390 (Parke Davis), PD 178392 (Parke Davis), U- 140690 (Pharmacia and Upjohn), and ABT-378. Additional examples include the cyclic protease inhibitors disclosed in WO93/07128, WO 94/19329, WO 94/22840, and PCT Application Number US96/03426. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic , sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, 17 hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic , fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences , 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio. "Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) or other formulas or compounds of the present invention in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of the present invention, for example formula (I) , are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of the present invention wherein the hydroxy or amino group is bonded to any group that, when the prodrug is administered to a mammalian subject, cleaves to form a free hydroxyl or free amino, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention, and the like. "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. Only stable compounds are contempleted by the present invention. "Substituted" is intended to indicate that one or more hydrogens on the atom indicated in the expression using "substituted" is replaced with a selection from the indicated group (s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =0) group, then 2 hydrogens on the atom are replaced. "Therapeutically effective amount" is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit HIV infection or treat the symptoms of HIV infection in a host. The combination of compounds is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv. Enzyme Regul . 22:27-55 (1984), occurs when the effect (in this case, inhibition of HIV replication) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components. SYNTHESIS The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic 19 chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include but are not limited to those methods described below. Each of the references cited below are hereby incorporated herein by reference. Scheme 1 represents a method for synthesizing 4,4- disubstituted 3 , 4-dihydro-2 (IH) -quinazolinthiones from their corresponding 4, 4-disubstituted 3 , 4-dihydro-2 (IH) - quinazolinones . SCHEME 1 1. POCl 3 2. H 2 NCSNH 2 *» Scheme 2 represents a method for preparing N (3) -methyl analogs of 4, 4-disubstituted 3 , 4-dihydro-2 (IH) - quinazolinthiones. SCHEME 2 CH 3 NCO EtOHt-l R J a. 1. b. Li -≡-cycPr 2. In addition to the syntheses of quinazolinones described in the references noted in the Background section, Schemes 3-6 20 describe routes to prepare 4 , 4-disubstituted 3,4-dihydro- 2 (IH) -quinazolinones . These quinazolinones can be converted to quinazolinthiones as shown in Schemes 1 and 2. SCHEME 3 COOH HN(CH 3 )OCH 3 NH 2 TMSC1, base ,, RiMgX Scheme 3 illustrates a method of preparing keto-anilines from an appropriately substituted 2-aminobenzoic acid. The acid is converted to its N-methoxy-N-methyl amide derivative which can then be displaced to obtain the R^-substituted ketone. The keto-anilines are useful intermediates for the presently claimed compounds. SCHEME 4 I 2 , NaHC0 3 Me 3 CCOCl [|\^ NaHC0 3 l \^ NH NH 2 NH 2 O n-BuLi CF 3 ^ 6N-HC1 CF 3 C0 2 Et NH O Scheme 4 describes another method of preparing keto- anilines, this time from an appropriately substituted aniline. After iodination and amine protection, a group such as trifluoromethyl can be introduced using a strong base and ethyl trifluoroacetate . Deprotection provides the keto- aniline. Additional means of preparing keto-anilines are known to one of skill in the art, e.g, Houpis et al, Tetr. Lett. 1994, 35(37), 6811-6814, the contents of which are hereby incorporated herein by reference. SCHEME 5 R C °° H HN ( CH 3 ) OCH 3 | R γ C ° N ( ° CH3 ' CH3 ^" H 2 \^NH 2 TrBr _ DIPEA ^ R Ay > N ( OCH 3 ) CH 3 ^^ . ^ R CH0 CH 2 C1 2 ^^ (H)Tr ^^ (H)Tr R 3 Ϊ F3 R 3 U CF 3 TMS, TBAF ^ >s^γ^0H oxidation^ ^ ^ THF ^^ (H)Tr ^^ (H) r Another method of making 2-trif luoroacetylanilines is shown in Scheme 5. After forming the protected aniline, the amide is then reduced and the trif luorome thy 1 group added. Oxidation with an oxidant, such as Mnθ 2 , provides the useful intermediate. 22 SCHEME 6 a) TMSNCO DMAP/THF 4 A mol . b) TBAF/THf sieves Using the general method detailed in Scheme 6, one can prepare compounds of the present invention. Keto-aniline 1, which may be prepared by the methods desribed in Schemes 3 and 4, is treated with trimethylsilyl isocyanate in dry tetrahydofuran in the presence of dimethylaminopyridine followed by tetrabutylammonium fluoride to give the hydroxy- urea 2 . The hydroxy-urea 2 is then dehydrated with a dehydrating agent such as 4A molecular sieves in refluxing toluene or xylenes to give the ketimine 3_. A substituted acetylenic R 2 group is added by treating the ketimine 3. with a lithium acetylide, which is prepared in a separate vessel by reacting the corresponding substituted acetylene with n- butyllithium in dry tetrahydrofuran, to give the 4,4- disubstituted 3 , 4-dihydro-2 (IH) -quinazolinone 4, a compound of formula I . The acetylenic bond of the compound 4 . may be reduced, e.g., by catalytic hydrogenation, to give the corresponding alkenyl group (not shown) or the saturated compound .5. 23 Other R 2 groups may also be introduced by directly reacting the imine 3_ with a lithiate RLi or a Grignard reagent RMgX in the presence or absence of Lewis acid catalyst, such as BF 3 etherate. See also Huffman et al, J. Org. Chem . 1995, 60, 1590-1594, the contents of which are hereby incorporated herein by reference. One enantiomer of a compound of Formula I may display superior activity compared with the other. Thus, the following stereochemistries are considered to be a part of the present invention. la lb When required, separation of the racemic material can be achieved by HPLC using a chiral column as exemplified in Examples 27-34 (Scheme 4) or by a resolution using a resolving agent such as camphonic chloride as in Thomas J. Tucker, et al, J " . Med. Chem. 1994, 37, 2437-2444. A chiral compound of Formula I may also be directly synthesized using a chiral catalyst or a chiral ligand, e.g. Mark A. Huffman, et al, J. Org. Chem . 1995, 60, 1590-1594. Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof. Examples Abbreviations used in the Examples are defined as follows: "°C" for degrees Celsius, "d" for doublet, "dd" for doublet of doublets, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "mL" for milliliter or milliliters, "H" for hydrogen or hydrogens, "hr" for hour or hours, "m" for multiplet, "M" for molar, "min" for minute or minutes, "MHz" for megahertz, "MS" for mass spectroscopy, "nmr" or "NMR" for nuclear magnetic resonance 24 spectroscopy, "t" for triplet, "TLC" for thin layer chromatography, "EDAC" for 1- ( 3 -dimethylaminopropyl ) -3- ethylcarbodiimide hydrochloride, "DIPEA" for diisopropylethylamine, "TBAF" for tetrabutylammonium fluoride, "LAH" for lithium aluminium hydride, and "TEA" for triethylamine . INTERMEDIATES Preparation of (+/- ) -6-Chloro-4-cyclopropylethynyl-4- trifluoromethyl-3, 4-dihydro-2 (IH) -quinazolinone (R 4 = Cyclopropyl ) a) TMSNCO CF3 ,OH DMAP/THF PhCH 3 Ti b) TBAF/THF NH 4 A mol. sieves CF3 I-a a . THF/n-BuLi /HCCR 4 b . BF 3 -OEt 2 111 -a IV-a Step 1. Synthesis of II-a from I-a. To a solution of compound I-a (4.55 g, 20.2 mmol) in anhydrous THF (40 mL) was added dimethylaminopyridine (0.25 g, 2.02 mmol) and trimethylsilyl isocyanate (6.05 g, 7.11 mL, 52.5 mmol). The mixture was stirred at room temperature for approximately 16 hours, then tetrabutylammonium fluoride (21 mL of 1 M solution in THF) was added. The thick slurry was diluted with additional THF (20 mL) and stirred at room temperature for 0.5 hours . The THF was removed under reduced pressure, the residue was taken up in EtOAc (100 mL) and washed sequentially with 1 N HCl (70 mL) , saturated aqueous NaHC0 3 (70 mL) and saturated aqueous NaCl (50 mL) . The organic phase was dried over MgS0 4 , filtered and concentrated ' under reduced pressure to afford a light yellow solid. The 25 yellow color was removed upon trituration with hexanes to afford Ila (5.09 g, 94%) as a white solid: X H NMR (300 MHz, acetone-d 6 ) δ 9.06 (br s, 1 H) , 7.48 (s, 1 H) , 7.40 (br s, 1 H) , 7.34 (dd, J = 8.8, 2.6 Hz, I H), 6.97 (d, J= 8.8 Hz, 1 H) ; 19 F NMR (282 MHz, acetone-d 6 ) δ -86.33, -86.35; IR (KBr Pellet) 1724, 1678, 1398, 1198, 1174 cπr 1 ; MS (CD m/e 266 (MH + , 100) . Step 2. Synthesis of Ill-a from II-a. A suspension of II-a (5.09 g, 19.1 mmol) in toluene (150 mL) containing 4 A molecular sieves (approximately 100 mg) was heated at reflux for 16 hours . The resulting clear yellow solution was cooled to room temperature, the precipitated solids were dissolved in acetone and the molecular sieves were removed by vacuum filtration. The filtrate was concentrated under reduced pressure, and triturated with hexanes to afford Ill-a (4.25 g, 89%) as a yellow solid: X H NMR (300 MHz, acetone-d 6 ) δ 7.86-7.82 (m, 2 H) , 7.61 (d, J = 8.8 Hz, 1 H) ; 19 F NMR (282 MHz, acetone-d 6 ) δ -67.88. Step 3. Synthesis of IV-a from Ilia. A solution of cyclopropylacetylene (13.0 mL of 30 wt% solution in toluene/THF/hexanes, 59.0 mmol) in anhydrous THF (118 mL) was cooled to -78 °C, treated with n-BuLi (32.8 mL of 1.6 M solution in hexanes, 52.4 mmol), warmed to 0 °C in an ice bath, and aged for 0.5 h. To a solution of Ill-a (3.12 g, 12.6 mmol) in anhydrous THF (66 mL) at -78 °C was added the lithium acetylide over approximately 10 minutes. To this was added boron trifluoride etherate (0.89 g, 0.80 mL, 6.28 mmol), followed by removal of the cooling bath. The reaction was allowed to reach room temperature and stirred at room temperature for 4 hours before quenching with 1 M citric acid (100 mL) . The mixture was concentrated under reduced pressure to 1/2 original volume, diluted with EtOAc (200 mL) , the aqueous phase was removed and the organic phase was sequentially washed with saturated aqueous aHCθ 3 (100 mL) , 26 and saturated aqueous NaCl (100 mL) . The organic phase was dried over MgSθ 4 , filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography (3% MeOH/CH 2 Cl 2 ) to afford a thick yellow oil from which was obtained crystalline IV-a (R 4 = cyclopropyl) (3.85 g, 97%) as a white solid: mp 86.6-88 °C; X H NMR (300 MHz, acetone-d 6 ) δ 8.95 (br s, 1 H) , 7.51 (br s, 1 H) , 7.43 (br s, 1 H) , 7.40 (dd, J = 8.8, 2.4 Hz, 1 H) , 7.02 (d, J = 8.8 Hz, 1 H) , 1.49-1.41 (m, 1 H) , 0.93-0.82 (m, 1 H) , 0.77-0.74 (m, 1 H) ; 19 F NMR (282 MHz, acetone-d 6 ) δ -82.96; IR (KBr Pellet) 1696, 1172 cm" 1 ; MS (Cl) m/e calc'd for C 14 H 10 CIF 3 N 2 O: 315.051201, found 315.051626; 315 (MH + , 51), 332 (M+NH 4 + , 100); Analysis calc'd for Ci 4 HιoN 2 ClF 3 0- 0.25 H 2 0: C, 52.68; H, 3.32; N, 8.78; found: C, 52.61; H, 3.35; N, 8.28. Preparation of ( +/-) -4-Cyclopropylethynyl-5, 6- dif luoro-4- trif luoromethyl-3, 4-dihydro-2 (IH) - quinazolinone (R 4 = Cyclopropyl) v a) TMSNCO CF 3 IU . b) _ X-a IX-a Xl-a a. b. BF, 3--OUECt1.2 Xll-a Step 1. Synthesis of X-a from IX-a. A solution of IX-a (6.46 g, 28.7 mmol) was treated with dimethylaminopyridine and trimethylsilyl isocyanate as described in Step 1 of Example 1 to afford 6.74 g (88%) of the desired product: λ H NMR (300 MHz, acetone-d δ ) δ 9.13 (br s, 1 27 H) , 7.45-7.32 (m, 2 H) , 7.18 (br s, 1 H) , 6.85-6.80 (m, 1 H) ; 19 F NMR (282 MHz, acetone-d 6 ) δ -86.6 (d, 17.2, 3) , -137.52- 137.68 (m, 1), -148.47-148.59 (m, 1) . Step 2. Synthesis of Xl-a from X-a. A solution of X-a (6.74 g, 25.1 mmol) was heated in xylenes at reflux as described in Step 2 of Example 1, substituting xylenes for toluene, to afford 6.3 g (100%) of the desired product: !H NMR (300 MHz, acetone-d 6 ) δ 7.92-7.83 (m, 1 H) , 7.46-7.44 (m, 1 H) ; 19 F NMR (282 MHz, acetone-d 6 ) δ -70.7 (d, 38.7, 3), -136.72 (s, 1), -146.47-146.57 (m, 1). Step 3. Synthesis of Xll-a from Xl-a. A solution of Xl-a (6.28 g, 25.1 mmol) was treated with the the lithium acetylide derived from cyclopropylacetylene (24.9 mL of 30 wt% solution in toluene/THF/hexanes, 0.113 mol) according to the procedure of Step 3 of Example 1. The resulting crude yellow oil was dissolved in acetone and concentrated under reduced pressure to deliver a yellow solid. Crystallization from acetone afforded 5.98 g (75%) of the desired material: mp 86.5-88.5 °C; X H NMR (300 MHz, acetone- d 6 ) δ 9.01 (br s, 1 H) , 7.46 (br s, 1 H) , 7.44-7.35 (m, 1 H) , 6.86-6.81 (m, 1 H) , 1.41-1.37 (m, 1 H) , 0.90-0.83 (m, 1 H) , 0.74-0.69 (m, 1 H) ; 19 F NMR (282 MHz, acetone-d 6 ) δ -83.3 (d, J = 12.9, 1) , -136.04-136.23 (m, 1) , -148.14-148.26 (m, 1) ; IR (KBr Pellet) 1706, 1516, 1442, 1246, 1214, 1196 cm "1 ; MS (Cl) m/e calc'd for C14H1 0 F5 2O: 317.071329, found 317.070836; 317 (MH + , 100) , 334 (M+NH + , 62) ; Analysis calc'd for C14H9F5N2O: C, 53.17; H, 2.88; N, 8.87; found: C, 53.30; H, 3.16; N, 8.53. Example 1 Preparation of ( +/- ) -4-Cyclopropylethynyl-5 , 6- difluoro- 4 -trif luoromethyl-3 , 4-dihydro-2 (IH) - quinazolinthione 28 A solution of (+/-) -4-cyclopropylethynyl-5, 6-difluoro-4- trifluoromethyl-3 , 4-dihydro-2 (IH) -quinazolinone (0.32 g, 1.0 mmol) in phosphorous oxychloride (5 mL) containing Na 2 C0 3 (160 mg, 1.5 mmol) was heated at 95 °C overnight. After cooling to room temperature, the phosphorus oxychloride was removed under reduced pressure. The residue was dissolved in ethanol (5 mL) and thiourea (0.44 g, 5.7 mmol) was added. The resulting mixture was heated at reflux for 24 hours, cooled to room temperature and concentrated. The material was dissolved in EtOAc (75 mL) and washed sequentially with saturated aqueous NaHC0 3 (50 mL) and saturated aqueous NaCl (50 mL) . The organic extract was dried over MgS0 4 , filtered and concentrated. The crude material was purified by flash chromatography (38% EtOAc/hexanes) to afford the title compound as a white solid (142 mg, 43%) : mp 241-243 °C; λ K NMR (300 MHz, acetone-d 6 ) δ 7.52-7.43 (m, IH) , 7.06-7.03 (m, IH) , 1.43-1.40 (m, IH) , 0.89-0.86 (m, 2H) , 0.79-0.74 (m, 2H) ; 19 F NMR (282 MHz, acetone-dg) δ -83, -136, -145; Analysis calc'd for C 14 H 9 F 5 N 2 S: C, 50.60; H, 2.73; N, 8.43; found: C, 50.46; H, 2.78; N, 8.31. Example 2 Preparation of ( +/- ) -6-Chloro-4-cyclopropylethynyl-4- trifluoromethyl-3 , 4 -dihydro-2 ( IH) -quinazolinthione A solution of (+/-) -6-chloro-4-cyclopropylethynyl-4- trifluoromethyl-3 , 4-dihydro-2 (IH) -quinazolinone (0.33 g, 1.0 mmol) in phosphorous oxychloride (5 mL) containing Na 2 C0 3 (160 mg, 1.5 mmol) was heated at 95 °C overnight. After cooling to room temperature, the phosphorus oxychloride was removed under reduced pressure. The residue was dissolved in ethanol (5 mL) and thiourea (0.35 g, 4.6 mmol) was added. The resulting mixture was heated at reflux for 24 hours, cooled to room temperature and concentrated. The material was dissolved in EtOAc (75 mL) and washed sequentially with saturated aqueous NaHC0 3 (50 mL) and saturated aqueous NaCl (50 mL) . The organic extract was dried over MgS0 4 , filtered and concentrated. The crude material was purified by flash 29 chromatography (25% EtOAc /hexanes) to afford the title compound as a white solid (129 mg, 37%) : mp 259-260; 1 H NMR (300 MHz, acetone-d 6 ) δ 10.3 (br s, IH) , 8.95 (br s, IH) , 7.56 (d, J = 1.1 Hz, IH) , 7.48 (dd, J = 8.4, 2.6 Hz, IH) , 7.20 (d, J = 8.4 Hz, IH) , 1.49-1.44 (m, IH) , 0.93-0.85 (m, 2H) , 0.80- 0.76 ( , 2H) ; 19 F NMR (282 MHz, acetone-d 5 ) δ -82; MS (Cl) calc'd for C 14 H 1Q C1F 3 N 2 S : m/z 330.020533, found 330.019821; 331 (MH + ) . Example 3 Preparation of (+/-) -4-Cyclopropylethynyl-5, 6- difluoro-4 -trifluoromethyl-3, 4 -dihydro-2 -methyl (IH) - quinazolinthione CH 3 NCO COCF, EtOHtl NH, a. MsCl/TEA/THF 1. POCI 3 b. Li -=-cvcPr 2. H 2 NCSNH 2 ' • ► ► 11 12 Step 1. Synthesis of 10 from 5. To a solution of aniline 5 (0.56 g, 2.5 mmol) in ethanol (30 mL) was added methyl isocyanate (0.59 mL, 10 mmol). The resulting solution was heated at reflux for 15 hours, cooled to room temperature and concentrated. The resulting solid was triturated with hexanes to remove unreacted 5 to deliver 10 (0.55 g, 79%): 1 H NMR (300 MHz, acetone-d 6 ) δ 9.16 (br s, IH) , 7.44-7.35 (m, 2H) , 6.86-6.81 (m, IH) , 3.06-3.05 (m, 3H) ; 19 F NMR (282 MHz, acetone-d 6 ) δ -83, -137, -148. 30 Step 2. Synthesis of 11 from 10. A solution of cyclopropylacetylene (0.58 mL of 30 wt% solution in toluene/THF/hexanes, 2.6 mmol) in anhydrous THF (5.2 mL) was cooled to -78 °C, treated with n-BuLi (1.6 mL of 1.6 M solution in hexanes, 2.6 mmol), warmed to 0 °C in an ice bath, and aged for 40 minutes. To a solution of 10 (0.25 g, 0.87 mmol) in anhydrous THF (10 mL) at 0 °C was added methanesulfonyl chloride (0.17 g, 0.12 mL, 1.5 mmol) followed by triet ylamine (0.44 g, 0.61 mL, 4.3 mmol) . The resulting solution became bright orange with the formation of a precipitate. The solution was stirred at 0 °C for 50 min, at which time a 0 °C solution of lithium acetylide was added to the orange solution over approximately 5 minutes . The mixture was stirred at 0 °C for 1 hour, quenched by the addition of 1 M citric acid (40 mL) and diluted with EtOAc (50 mL) . The aqueous phase was removed and the organic phase was washed sequentially with saturated aqueous NaHC0 3 (100 mL) and saturated aqueous NaCl (100 mL) . The organic phase was dried over MgS0 4 , filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography (50% EtOAc/hexanes) to afford 11 as a white solid (0.12 g, 41%): mp 178-180 °C; L H NMR (300 MHz, acetone-d 6 ) δ 9.12 (br s, IH) , 7.44-7.35 ( , IH) , 6.84-6.79 (m, IH) , 3.20 (s, 3H) , 1.53- 1.45 (m, IH) , 0.95-0.90 (m, 2H) , 0.80-0.75 (m, IH) ; 19 F NMR (282 MHz, acetone-d 6 ) δ -80, -135, -148. Step 3. Synthesis of 12 from 11. A solution of 11 (66 mg, 0.20 mmol) in phosphorus oxychloride (5 mL) and Na 2 C0 3 (45 mg, 0.40 mmol) was heated at 95 °C for three days . The phosphorus oxychloride was removed under reduced pressure, and then EtOAc (10 mL) was added and the resulting mixture was concentrated under reduced pressure. The residue was dissolved in CH 2 C1 2 , concentrated and dissolved in ethanol (5 mL) . To the ethanol solution was added thiourea (0.35 g, 4.6 mmol) and the mixture was heated 31 at reflux for 24 hours. The ethanol was removed under reduced pressure, the residue was dissolved in EtOAc (90 mL) , washed sequentially with saturated aqueous NaHC0 3 (30 mL) and saturated aqueous NaCl (30 mL) . The organic solution was dried over MgS0 , filtered and concentrated to afford a white solid. The crude material was purified by flash chromatography (20% EtOAc/hexanes) to deliver 12 as a white solid (40 mg, 58%): mp 143-145 °C; 1 H NMR (300 MHz, acetone- d 6 ) δ 10.4 (br s, IH) , 7.52-7.43 (m, IH) , 7.03-6.99 ( m, IH) , 3.65 (s, 3H) , 1.58-1.49 (m, IH) , 0.97-0.91 (m, 2H) , 0.86-0.80 (m, 2H) ; 19 F NMR (282 MHz, acetone-d 6 ) δ -79, -135, -145; MS (ES + ) calc'd for C 15 H 12 F 5 N 2 OS : m/z 347.064137, found 347.063819; 347 (MH + ). Example 4 Preparation of (+/- ) -6-Chloro-4-cyclopropylethynyl-4- trifluoromethyl-3, 4-dihydro-2-methyl(lH) - quinazolinthione OH Cl COCF 3 XX NHT 13 a. b. Li -≡-cycPr 15 Step 1 . Synthesis of 14 from 13 . 32 To a solution of 13 (0.45 g, 2.0 mmol) in ethanol (20 mL) was added methyl isothiocyanate (0.49 g, 0.46 mL, 6.7 mmol) and the resulting mixture was stirred at room temperature for 4 days. The solvents were removed under reduced pressure, dissolved residue in EtOAc (50 mL) and washed sequentially with 1 M citric acid (30 mL) , saturated aqueous NaHC0 3 (30 mL) and saturated aqueous NaCl (30 mL) . The organic extract was dried over MgS0 , filtered and concentrated. The crude material was purified by flash chromatography (25% EtOAc/hexanes) to afford 14 (0.26 g, 29%): X H NMR (300 MHz, acetone-d 6 ) δ 10.4 (br s, 1), 7.57 (br s, 1), 7.49 (dd, 8.5, 2.2, 1), 7.20 (d, 8.5, 1), 3.47 (d, 1.8, 3); 19 F NMR (282 MHz, acetone-d 6 ) δ -83. Step 2. Synthesis of 15 from 14. A solution of cyclopropylacetylene (1.32 mL of 30 wt% solution in toluene/THF/hexanes, 6.0 mmol) in anhydrous THF (15 mL) was cooled to -78 °C, treated with n-BuLi (3.75 mL of 1.6 M solution in hexanes, 6.0 mmol), warmed to 0 °C in an ice bath, and aged for 40 minutes. To a solution of 14 (0.30 g, 1.0 mmol) in anhydrous THF (15 mL) at 0 °C was sequentially added methanesulfonyl chloride (0.14 g, 93 μL, 1.2 mmol) and triethylamine (0.15 g, 0.21 mL, 1.5 mmol). The resulting mixture was stirred at 0 °C for 0.5 hours. To this solution was added the lithium cyclopropyl acetylide and the resulting mixture was stirred at 0 °C for 2 hours, and then overnight at room temperature. The reaction was quenched by the addition of 1 M citric acid (5 mL) . The THF was removed under reduced pressure, the resulting thick orange solution was diluted with EtOAc (150 mL) , and washed sequentially with saturated aqueous NaHC0 3 (30 mL) and saturated aqueous NaCl (30 mL) . The organic extract was dried over MgS0 4 , filtered and concentrated. The crude material was purified by flash chromatography (13% EtOAc/hexanes) to give 15 as a yellow solid (93 mg, 27%): mp 178.9-179.6 °C; X H NMR (300 MHz, acetone-d 6 ) δ 10.4 (br s, IH) , 7.58 (d, J = 1.4 Hz, IH) , 7.48 (dd, J = 8.6, 2.4 Hz, IH) , 7.18 (d, J = 8.4 Hz, IH) , 3.64 (d, 33 J = 1.1 Hz, 3H) , 1.65-1.56 (m, IH) , 1.02-0.93 (m, 2H) , 0.91- 0.82 (m, 2H) ; 19 F NMR (282 MHz, acetone-d 6 ) δ -79; MS (ES " ) calc'd for C: 5 H 13 C1F 3 N 2 S : m/z 345.044008, found 344.043482; 343 (MH " ) . Table 1* 4 Ex.# R3 Rl R2 R3 m.p. Mass Spec (°C) 1 5,6-diF CF 3 C≡C-cycPr H 241- 243 2 6-C1 CF 3 G≡C-cycPr H 259- 331 (MH + ) 260 3 5,6-diF CF 3 C≡C-cycPr CH 3 178- 347 (MH + ) 180 4 6-C1 CF 3 C≡C-cycPr CH 3 178.9- 343 (MH + ) 179.6 *Unless otherwise indicated, stereochemisty is (+/-). Tables 2 and 3 contain representative examples of the present invention. Table 2* R, 1 R 2 (^ 5 Ex. # R3 Rl R2 RS 1 6-C1 CF 3 C=CCH 2 CH 2 0H H 2 6-C1 CF 3 C≡C-CH(OH)Me H 3 6-C1 CF 3 C≡C-(2-Cl)Ph H 4 6-C1 CF 3 C≡C-(3-Cl)Ph H 5 6-C1 CF 3 C≡C-(4-Cl)Ph H 6 6-C1 CF 3 C≡C-(2-F)Ph H 7 6-C1 CF 3 C≡C-(3-F)Ph H 34 8 6-C1 CF 3 C≡C-(4-F)Ph H 9 6-C1 CF 3 C≡C-(2-OH)Ph H 10 6-C1 CF 3 C≡C-(3-OH)Ph H 11 6-C1 CF 3 C≡C-(4-OH)Ph H 12 6-C1 CF 3 C≡C-(2-0Me)Ph H 13 6-C1 CF 3 C=C-(3-OMe)Ph H 14 6-C1 CF 3 C≡C-(4-0Me)Ph H 15 6-C1 CF 3 C≡C-(2-CN)Ph H 16 6-C1 CF 3 C≡C-(3-CN)Ph H 17 6-C1 CF 3 C≡C-(4-CN)Ph H 18 6-C1 CF 3 C≡C-(2-N0 2 )Ph H 19 6-C1 CF 3 C≡C- ( 3 -N0 2 ) Ph 20 6-C1 CF 3 C≡C-(4-N0 2 )Ph 21 6-C1 CF 3 C≡C-(2-NH 2 )Ph 22 6-C1 CF 3 C≡C-(3-NH 2 )Ph 23 6-C1 CF 3 C≡C-(4-NH 2 )Ph H 24 6-C1 CF 3 C≡C-(2-NMe )Ph H 25 6-C1 CF 3 C≡C-(3-NMe 2 )Ph H 26 6-C1 CF 3 C≡C-(4-NMe 2 )Ph H 27 6-C1 CF 3 C≡C-3 -Pyr idyl 28 6-C1 CF 3 C≡C-4-Pyridyl 29 6-C1 CF 3 C≡C-2-furanyl 30 6-C1 CF 3 C≡C-3-furanyl 31 6-C1 CF 3 C≡C-2-thienyl 32 6-C1 CF 3 C≡C-3-thienyl 33 6-C1 CF 3 C≡C-2-oxazolyl 34 6-C1 CF 3 C≡C-2-thiazolyl 35 6-C1 CF 3 C≡C-4-isoxazolyl 36 6-C1 CF 3 C≡C-2-imidazolyl 37 6-C1 CF 3 C≡C-(l-CH 3 )cycPr 38 6-C1 CF 3 C=CCH 2 CH 2 OH H 39 6-C1 CF 3 C=C-CH(OH)Me H 40 6-C1 CF 3 C=C-(2-Cl)Ph H 41 6-C1 CF 3 C=C-(3-Cl)Ph H 35 6-C1 CF 3 C=C-(4-Cl)Ph H 6-C1 CF 3 C=C-(2-F)Ph H 6-C1 CF 3 C=C-(3-F)Ph H 6-C1 CF 3 C=C-(4-F)Ph H 6-C1 CF 3 C=C-(2-OH)Ph H 6-C1 CF 3 C=C-(3-OH)Ph H 6-C1 CF 3 C=C-(4-OH)Ph H 6-C1 CF 3 C=C-(2-OMe)Ph H 6-C1 CF 3 C=C-(3-OMe)Ph H 6-C1 CF 3 C=C-(4-OMe)Ph H 6-C1 CF 3 C=C-(2-CN)Ph H 6-C1 CF 3 C=C-(3-CN)Ph H 6-C1 CF 3 C=C-(4-CN)Ph H 6-C1 CF 3 C=C-(2-N0 2 )Ph H 6-C1 CF 3 C=C- ( 3 -N0 2 ) Ph H 6-C1 CF 3 C=C-(4-N0 2 )Ph H 6-C1 CF 3 C=C-(2-NH 2 )Ph H 6-C1 CF 3 C=C- ( 3 -NH 2 ) Ph H 6-C1 CF 3 C=C-(4-NH 2 )Ph H 6-C1 CF 3 C=C-(2-NMe 2 )Ph H 6-C1 CF 3 C=C- ( 3 -NMe 2 ) Ph H 6-C1 CF 3 C=C-(4-NMe )Ph H 6-C1 CF 3 C=C-3 -Pyr idyl H 6-C1 CF 3 C=C-4 -Pyr idyl H 6-C1 CF 3 C=C-2- furanyl H 6-C1 CF 3 C=C-3- furanyl H 6-C1 CF 3 C=C-2 -thienyl H 6-C1 CF 3 C=C-3 -thienyl H 6-C1 CF 3 C=C-2-oxazolyl H 6-C1 CF 3 C=C-2-thiazolyl H 6-C1 CF 3 C=C-4-isoxazolyl H 6-C1 CF 3 C=C-2- imidazolyl H 6-C1 CF 3 CH 2 CH 2 -cycPr H 6-C1 CF 3 CH 2 CH 2 CH 2 CH 2 0H H 36 76 6-C1 CF 3 CH 2 CH 2 -CH(OH)Me H 77 6-C1 CF 3 CH 2 CH 2 -Ph H 78 6-C1 CF 3 CH 2 CH 2 -(2-Cl)Ph H 79 6-C1 CF 3 CH 2 CH 2 -(3-Cl)Ph H 80 6-C1 CF 3 CH 2 CH 2 -(4-Cl)Ph H 81 6-C1 CF 3 CH 2 CH 2 -(2-F)Ph H 82 6-C1 CF 3 CH 2 CH 2 -(3-F)Ph H 83 6-C1 CF 3 CH 2 CH 2 -(4-F)Ph H 84 6-C1 CF 3 CH 2 CH 2 -(2-OH)Ph H 85 6-C1 CF 3 CH 2 CH 2 -(3-OH)Ph H 86 6-C1 CF 3 CH 2 CH 2 -(4-OH)Ph H 87 6-C1 CF 3 CH 2 CH 2 -(2-OMe)Ph H 88 6-C1 CF 3 CH 2 CH 2 -(3-OMe)Ph H 89 6-C1 CF 3 CH 2 CH 2 -(4-OMe)Ph H 90 6-C1 CF 3 CH 2 CH 2 -(2-CN)Ph H 91 6-C1 CF 3 CH 2 CH 2 -(3-CN)Ph H 92 6-C1 CF 3 CH 2 CH 2 -(4-CN)Ph H 93 6-C1 CF 3 CH 2 CH 2 -(2-N0 2 )Ph H 94 6-C1 CF 3 CH CH 2 -(3-N0 2 )Ph H 95 6-C1 CF 3 CH 2 CH 2 -(4-N0 2 )Ph H 96 6-C1 CF 3 CH 2 CH 2 -(2-NH 2 )Ph H 97 6-C1 CF 3 CH 2 CH 2 -(3-NH 2 )Ph H 98 6-C1 CF 3 CH 2 CH 2 -(4-NH 2 )Ph H 99 6-C1 CF 3 CH 2 CH 2 -(2-NMe 2 )Ph H 100 6-C1 CF 3 CH 2 CH 2 -(3-NMe 2 )Ph H 101 6-C1 CF 3 CH 2 CH 2 -(4-NMe 2 )Ph H 102 6-C1 CF 3 CH 2 CH 2 -2-Pyridyl H 103 6-C1 CF 3 CH 2 CH 2 -3-Pyridyl H 104 6-C1 CF 3 CH 2 CH 2 -4-Pyridyl H 105 6-C1 CF 3 CH 2 CH 2 -2-furanyl H 106 6-C1 CF 3 CH 2 CH 2 -3-furanyl H 107 6-C1 CF 3 CH 2 CH 2 -4-furanyl H 108 6-C1 CF 3 CH 2 CH 2 -3-thienyl H 109 6-C1 CF 3 CHCH 2 -2-oxazolyl H 37 110 6-C1 CF 3 CH 2 CH -2-thiazolyl H 111 6-C1 CF 3 CH 2 CH 2 -4-isoxazolyl H 112 6-C1 CF 3 CH 2 CH 2 -2 -imidazolyl H 113 6-C1 CF 3 C≡C-cycPr CH 3 114 6-C1 CF 3 C≡C-Ph CH 3 115 6-C1 CF 3 C≡C-2 -Pyridyl CH 3 116 6-C1 CF 3 C≡C-3 -Pyridyl CH 3 117 6-C1 CF 3 C≡C-4 -Pyridyl CH 3 118 6-C1 CF 3 C≡C-2 -furanyl CH 3 119 6-C1 CF 3 C≡C-3 -furanyl CH 3 120 6-C1 CF 3 C≡C-2 -thienyl CH 3 121 6-C1 CF 3 C≡C-3 -thienyl CH 3 122 6-C1 CF 3 C≡C-(l-CH 3 )cycPr CH 3 123 6-C1 CF 3 C=C-cycPr CH 3 124 6-C1 CF 3 C=C-Ph CH 3 125 6-C1 CF 3 C=C-2 -Pyridyl CH 3 126 6-C1 CF 3 C=C-3 -Pyridyl CH 3 127 6-C1 CF 3 C=C-4 -Pyridyl CH 3 128 6-C1 CF 3 C=C-2- furanyl CH 3 129 6-C1 CF 3 C=C-3- furanyl CH 3 130 6-C1 CF 3 C=C-2 -thienyl CH 3 131 6-C1 CF 3 C=C-3 -thienyl CH 3 132 6-C1 CF 3 CH CH 2 -cycPr CH 3 133 6-C1 CF 3 CH 2 CH 2 -Ph CH 3 134 6-C1 CF 3 CH 2 CH 2 -2 -Pyridyl CH 3 135 6-C1 CF 3 CH 2 CH 2 - 3 -Pyridyl CH 3 136 6-C1 CF 3 CH 2 CH 2 -4-Pyridyl CH 3 137 6-C1 CF 3 CH 2 CH 2 -2 -furanyl CH 3 138 6-C1 CF 3 CH 2 CH 2 -3 -furanyl CH 3 139 6-C1 CF 3 CH 2 CH 2 -2 -thienyl CH 3 140 6-C1 CF 3 CH 2 CH 2 -3 -thienyl CH 3 141 6-C1 CF 3 C≡C-cycPr CH 2 CH 3 142 6-C1 CF 3 C≡C-Ph CH 2 CH 3 143 6-C1 CF 3 C≡C-2 -Pyridyl CH 2 CH 3 144 6-C1 CF 3 C≡C-3 -Pyridyl CH 2 CH 3 145 6-C1 CF 3 C≡C-4 -Pyridyl CH 2 CH 3 146 6-C1 CF 3 C≡C-2 -furanyl CH 2 CH 3 147 6-C1 CF 3 C≡C-3 -furanyl CH 2 CH 3 148 6-C1 CF 3 C≡C-2 -thienyl CH2CH3 149 6-C1 CF 3 C≡C-3 -thienyl CH 2 CH 3 150 6-C1 CF 3 C≡C-(l-CH 3 )cycPr CH 2 CH 3 151 6-C1 CF 3 C=C-cycPr CH 2 CH 3 152 6-C1 CF 3 C=C-Ph CH 2 CH 3 153 6-C1 CF 3 C=C-2 -Pyridyl CH 2 CH 3 154 6-C1 CF 3 C=C-3 -Pyridyl CH 2 CH 3 155 6-C1 CF 3 C=C-4 -Pyridyl CH 2 CH 3 156 6-C1 CF 3 C=C-2- furanyl CH 2 CH 3 157 6-C1 CF 3 C=C-3- furanyl CH 2 CH 3 158 6-C1 CF 3 C=C-2 -thienyl CH 2 CH 3 159 6-C1 CF 3 C=C-3 -thienyl CH 2 CH 3 160 6-C1 CF 3 CH 2 CH 2 -cycPr CH2CH3 161 6-C1 CF 3 CH 2 CH 2 -Ph CH 2 CH 3 162 6-C1 CF 3 CH 2 CH 2 -2 -Pyridyl CH 2 CH 3 163 6-C1 CF 3 CH 2 CH 2 -3 -Pyridyl CH 2 CH 3 164 6-C1 CF 3 CH 2 CH 2 -4 -Pyridyl CH 2 CH 3 165 6-C1 CF 3 CH 2 CH 2 -2- furanyl CH 2 CH 3 166 6-C1 CF 3 CH 2 CH -3 -furanyl CH 2 CH 3 167 6-C1 CF 3 CH 2 CH 2 -2 -thienyl CH 2 CH 3 168 6-C1 CF 3 CH 2 CH 2 -3 -thienyl CH 2 CH 3 169 6-MeO CF 3 C≡CCH 2 CH 2 OH H 170 6-MeO CF 3 C≡C-CH(OH)Me H 171 6-MeO CF 3 C≡C-(2-Cl)Ph H 172 6-MeO CF 3 C≡C-(3-Cl)Ph H 173 6-MeO CF 3 C≡C-(4-Cl)Ph H 174 6-MeO CF 3 C≡C-(2-F)Ph H 175 6-MeO CF 3 C≡C-(3-F)Ph H 176 6-MeO CF 3 C≡C-(4-F)Ph H 177 6-MeO CF 3 C≡C- ( 2 -OH )Ph H 39 178 6-MeO CF 3 C≡C-(3-OH)Ph H 179 6-MeO CF 3 C≡C-(4-OH)Ph H 180 6-MeO CF 3 C≡C-(2-OMe)Ph H 181 6-MeO CF 3 C≡C-(3-0Me)Ph H 182 6-MeO CF 3 C≡C-(4-0Me)Ph H 183 6-MeO CF 3 C≡C-(2-CN)Ph H 184 6-MeO CF 3 C=C-(3-CN)Ph H 185 6-MeO CF 3 C≡C-(4-CN)Ph H 186 6-MeO CF 3 C≡C-(2-N0 2 )Ph H 187 6-MeO CF 3 C≡C-(3-N0 2 )Ph H 188 6-MeO CF 3 C≡C-(4-N0 2 )Ph H 189 6-MeO CF 3 C≡C-(2-NH 2 )Ph H 190 6-MeO CF 3 C≡C-(3-NH 2 )Ph H 191 6-MeO CF 3 C≡C-(4-NH 2 )Ph H 192 6-MeO CF 3 C≡C-(2-NMe 2 )Ph H 193 6-MeO CF 3 C≡C- ( 3 -NMe 2 ) Ph H 194 6-MeO CF 3 C≡C-(4-NMe 2 )Ph H 195 6-MeO CF 3 C≡C-3 -Pyridyl H 196 6-MeO CF 3 C≡C-4- Pyridyl H 197 6-MeO CF 3 C≡C-2 -furanyl H 198 6-MeO CF 3 C≡C-3 -furanyl H 199 6-MeO CF 3 C≡C-2 -thienyl H 200 6-MeO CF 3 C≡C-3 -thienyl H 201 6-MeO CF 3 C≡C-2 -oxazolyl H 202 6-MeO CF 3 C≡C-2 -thiazolyl H 203 6-MeO CF 3 C≡C-4 -isoxazolyl H 204 6-MeO CF 3 C≡C-2 -imidazolyl H 205 6-MeO CF 3 C≡C-(l-CH 3 )cycPr H 206 6-MeO CF 3 C=CCH 2 CH 2 0H H 207 6-MeO CF 3 C=C-CH(OH)Me H 208 6-MeO CF 3 C=C-(2-Cl)Ph H 209 6-MeO CF 3 C=C-(3-Cl)Ph H 210 6-MeO CF 3 C=C-(4-Cl)Ph H 211 6-MeO CF 3 C=C-(2-F)Ph H 40 t to t t to t to to to to to t to to to to to to to to t to t to t to to to to to to to to if* It* it* it* it* if* LO LO LO LO LO LO LO LO LO CO t to to to to to t to to to M> H> LΠ it* LO to H* O VO CO ~o cn LΠ it* LO t H» O VO 00 - cn LΠ rf* LO to I- 1 o vo co ^1 cn LΠ it* LO to o t i t in W cn cn cn n cn cn cn cn cn cn cn cn n cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn n cn cn cn cn I I I I I I I I I I I I I I I I I I I I I I I I I I I 3 3 3 3 3 3 3 φ φ 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 φ Φ φ 3 φ φ 3 c! φ φ φ φ φ φ φ Φ φ φ φ φ φ φ Φ Φ φ Φ φ Φ Φ φ Φ φ Φ Φ O O O O O O O O O O O O O O O o O O O O O O O O O O O O O O O O O O o o O o O O O O O O O O O O O O O O O O O O O O O O O O O O O O HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ it* o o o o II II o o o o t a o II o o o o O o o o II II II o o o o II II II II II II II II o o o l J o o II II II o o o O O t a o 1 1 o II o o II I o II O t a to if* o o o o o o to I o o o o o o o o II II II II II o o o 1 1 1 1 1 1 1 I I I I I I o o o o II II t a to a a O 1 1 I to I I LO to LO to LO I o o o l J I I 1 1 1 | I I o o I I O I t H- H- rt I 1 1 1 it* L to tO it* LO t LO O O t ao 3 ω o I LO to it* t t* LO to it* LO to a I H- to a I a Mi Mi 1 1 1 it* LO o tr ft rr I I * 1 I 1 I Ω H- X u tr tr fi X c 3 3 I I 25 I I I 25 25 O 1 I P> P> H- φ φ φ O o 3 O O o I o O 0 ) f t TrJ a n N N to to to t oo O N N Φ to to 5 o o 25 3 φ s Φ a a a HJ to a o φ TJ o o O TJ T ^ ^ TJ TJ TJ TJ TJ TJ 3 o a 3 TJ TJ TJ TJ TJ TJ TJ TJ T H φ K5 * tr tr tr tr s tr tr tr tr tr t tr TJ TJ tr tr tr tr tr tr tr tr o PH PH PH K PH PH PH t-Q PH PH PH HH PH PH P HH H P PH PH *^ PH P^ K PH a a a a x x CΛ vo o o σ\ VO to t to t to to t to to to t to to to to to M to to to to to to to to to to NJ to to to to to to vo -0 -J -0 o -j ~o -j -J -J -O cn cn cn cn n cn cn cn cn cn LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ it* it* if* it* vo oo -o cn LΠ it* LO to h-» O vo CO -j cn LΠ it* O to !- » o vo co -J cn LΠ rf* LO t l- 1 o vo CO -J D cn ©i in 1*1 CΛ cn cn cn CTl cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn n cn cn cn cn cn cn cn cn cn cn t 1 1 1 1 1 1 1 1 1 1 1 1 1 t 1 1 1 1 1 1 1 1 1 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 φ φ φ φ φ φ φ φ Φ φ φ φ φ φ φ φ φ φ φ Φ φ φ Φ φ φ Φ φ φ φ φ φ Φ φ O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O o O O O O O O O O O O HJ o O HJ HJ HJ HJ o HJ o HJ HJ o HJ HJ HJ HJ HJ o O O HJ o HJ HJ HJ o HI HJ HJ o HJ oT) o HJ o HI HJ o HJ o HJ oHJ oHJ oHJ oHJ oHJ oHJ oHJ OJ OJ OJ OJ OJ OJ J OJ OJ OJ OJ 0* t o a o to o t a o o o o o o O O O O o O O O to a O o o o O to a o Ci t ao a X o o o o a to a o O o O t a to a t a t a t a t a to a to a a o O to t a to a a o t a to a O O O O O o o o t a t ao a to a t O o to O O t t t a to a t a to a to a t a a O O O t a t a t a I to to a a it*. I a O o t O I to a to a to t a O O t a to a t ao to a t a a t a t a to a t ao o to a to a to to a t a to a I t to 1 1 t a to a a to a to a O t a I I 1 1 1 I I I t a to I I I I I t ao to LO H- I it* LO to I I I I I to a to a it* LO to I I I I I I I I I I CΛ rr O 1 1 I I if* LO to if* LO f* LO to I I I to i if* LO t it* it* LO tO r if* LO tO I oo to O tr H- X Mi Ml Mi X 0 ) rr 3 I I I I I I I I I I I I I it* C c I I I 25 25 25 I I 0 ) 0 ) N p- i i 3 i-i l o O HJ HJ O O O t- 1 N N Φ pJ OJ H- H- H- φ φ O O O to D § φ φ a a a - to to to to ϋ a o I S a § I O o o l to φ i a t Oi s -i PJ Qi TJ TJ h -. > < ^ • • < TJ TJ TJ TJ TJ TJ TJ TJ TJ TJ TJ TJ T T T TJ TJ tr tr tr tr tr tr tr t TrJ tr ^ * tr rr tr tr tr tr TJ TJ TJ rr tr tr . J rr tr tr tr tr "0 n t-M PH PH PH HH PH H PH PH PH PH PH t^ PH PH PH PH PH PH PH PH a a HH HH PH PH PH HM PH CΛ VO vo © ON 1*1 280 6-MeO CF 3 CH 2 CH 2 -2- imidazolyl H 281 6-MeO CF 3 C≡C-cycPr CH 3 282 6-MeO CF 3 C≡C-Ph CH 3 283 6-MeO CF 3 C≡C-2 -Pyridyl CH 3 284 6-MeO CF 3 C≡C-3 -Pyridyl CH 3 285 6-MeO CF 3 C≡C-4 -Pyridyl CH 3 286 6-MeO CF 3 C≡C-2 -furanyl CH 3 287 6-MeO CF 3 C≡C-3 -furanyl CH 3 288 6-MeO CF 3 C≡C-2 -thienyl CH 3 289 6-MeO CF 3 C≡C-3 -thienyl CH 3 290 6-MeO CF 3 C≡C-(l-CH 3 )cycPr CH 3 291 6-MeO CF 3 C=C-cycPr CH 3 292 6-MeO CF 3 C=C-Ph CH 3 293 6-MeO CF 3 C=C-2 -Pyridyl CH 3 294 6-MeO CF 3 C=C-3 -Pyridyl CH 3 295 6-MeO CF 3 C=C-4 -Pyridyl CH 3 296 6-MeO CF 3 C=C-2- furanyl CH 3 297 6-MeO CF 3 C=C-3- furanyl CH 3 298 6-MeO CF 3 C=C-2 -thienyl CH 3 299 6-MeO CF 3 C=C-3 -thienyl CH 3 300 6-MeO CF 3 CH 2 CH 2 -cycPr CH 3 301 6-MeO CF 3 CH 2 CH 2 -Ph CH 3 302 6-MeO CF 3 CH 2 CH 2 -2 -Pyridyl CH 3 303 6-MeO CF 3 CH 2 CH 2 -3 -Pyridyl CH 3 304 6-MeO CF 3 CH 2 CH -4 -Pyridyl CH 3 305 6-MeO CF 3 CH 2 CH 2 -2- furanyl CH 3 306 6-MeO CF 3 CH 2 CH 2 -3- furanyl CH 3 307 6-MeO CF 3 CH 2 CH -2 -thienyl CH 308 6-MeO CF 3 CH 2 CH 2 -3 -thienyl CH 3 309 6-MeO CF 3 C≡C-cycPr CH 2 CH 3 310 6-MeO CF 3 C≡C-Ph CH2CH3 311 6-MeO CF 3 C≡C-2 -Pyridyl CH2CH3 312 6-MeO CF 3 C≡C-3 -Pyridyl CH2CH3 313 6-MeO CF 3 C≡C-4 -Pyridyl CH2CH3 43 314 6-MeO CF 3 C≡C-2 -furanyl CH 2 CH 3 315 6-MeO CF 3 C≡C-3 -furanyl CH2CH3 316 6-MeO CF 3 C≡C-2 -thienyl CH2CH3 317 6-MeO CF 3 C≡C-3 -thienyl CH2CH3 318 6-MeO CF 3 C≡C-(l-CH 3 )cycPr CH2CH3 319 6-MeO CF 3 C=C-cycPr CH 2 CH 3 320 6-MeO CF 3 C=C-Ph CH2CH3 321 6-MeO CF 3 C=C-2 -Pyridyl CH2CH3 322 6-MeO CF 3 C=C-3 -Pyridyl CH2CH3 323 6-MeO CF 3 C=C-4 -Pyridyl CH2CH3 324 6-MeO CF 3 C=C-2- furanyl CH2CH3 325 6-MeO CF 3 C=C-3- furanyl CH 2 CH 3 326 6-MeO CF 3 C=C-2 -thienyl CH2CH3 327 6-MeO CF 3 C=C-3 -thienyl CH 2 CH 3 328 6-MeO CF 3 CH 2 CH 2 -cycPr CH 2 CH 3 329 6-MeO CF 3 CH 2 CH 2 -Ph CH 2 CH 3 330 6-MeO CF 3 CH 2 CH -2 -Pyridyl CH 2 CH 3 331 6-MeO CF 3 CH 2 CH -3 -Pyridyl CH 2 CH 3 332 6-MeO CF 3 CH CH 2 -4 -Pyridyl CH 2 CH 3 333 6-MeO CF 3 CH 2 CH 2 -2 -furanyl CH 2 CH 3 334 6-MeO CF 3 CH CH 2 -3- furanyl CH 2 CH 3 335 6-MeO CF 3 CH 2 CH 2 -2 -thienyl CH 2 CH 3 336 6-MeO CF CH 2 CH 2 -3 -thienyl CH2CH3 337 5,6-diF CF 3 C≡C-(2-Cl)Ph H 338 5,6-diF CF 3 C≡C-(3-Cl)Ph H 339 5,6-diF CF 3 C≡C-(4-Cl)Ph H 340 5,6-diF CF 3 C≡C-(2-F)Ph H 341 5,6-diF CF 3 C≡C-(3-F)Ph H 342 5,6-diF CF 3 C≡C-(4-F)Ph H 343 5,6-diF CF 3 C≡C-(2-OH)Ph H 344 5,6-diF CF 3 C≡C-(3-OH)Ph H 345 5,6-diF CF 3 C≡C-(4-OH)Ph H 346 5,6-diF CF 3 C≡C-(2-OMe)Ph H 347 5, 6-diF CF 3 C≡C-(3-OMe)Ph H 44 348 5,6-diF CF 3 C≡C-(4-OMe) Ph H 349 5,6-diF CF 3 C≡C-(2-CN)Ph H 350 5,6-diF CF 3 C≡C-(3-CN)Ph H 351 5,6-diF CF 3 C≡C-(4-CN)Ph H 352 5,6-diF CF 3 C≡C-(2-N0 2 )Ph H 353 5,6-diF CF 3 C≡C- ( 3 -N0 2 ) Ph H 354 5,6-diF CF 3 C≡C-(4-N0 2 )Ph H 355 5,6-diF CF 3 C≡C-(2-NH 2 )Ph H 356 5,6-diF CF 3 C≡C- ( 3 -NH 2 ) Ph H 357 5,6-diF CF 3 C≡C-(4-NH 2 )Ph H 358 5,6-diF CF 3 C≡C-(2-NMe 2 )Ph H 359 5,6-diF CF 3 C≡C-(3-NMe 2 )Ph H 360 5,6-diF CF 3 C≡C-(4-NMe 2 )Ph H 361 5,6-diF CF 3 C≡C-3 -Pyridyl H 362 5,6-diF CF 3 C≡C-4 -Pyridyl H 363 5,6-diF CF 3 C≡C-2 -furanyl H 364 5,6-diF CF 3 C≡C-3 -furanyl H 365 5,6-diF CF 3 C≡C-2 -thienyl H 366 5,6-diF CF 3 C≡C-3 -thienyl H 367 5,6-diF CF 3 C≡C-2 -oxazolyl H 368 5,6-diF CF 3 C≡C-2 -thiazolyl H 369 5,6-diF CF 3 C≡C-4 -isoxazolyl H 370 5,6-diF CF 3 C≡C-2 - imidazolyl H 371 5,6-diF CF 3 C≡C-(l-CH 3 )cycPr H 372 5,6-diF CF 3 C=C-(2-Cl)Ph H 373 5,6-diF CF 3 C=C-(3-Cl)Ph H 374 5,6-diF CF 3 C=C-(4-Cl)Ph H 375 5,6-diF CF 3 C=C-(2-F)Ph H 376 5,6-diF CF 3 C=C-(3-F)Ph H 377 5,6-diF CF 3 C=C-(4-F)Ph H 378 5,6-diF CF 3 C=C-(2-OH)Ph H 379 5,6-diF CF 3 C=C-(3-OH)Ph H 380 5,6-diF CF 3 C=C-(4-OH)Ph H 381 5,6-diF CF 3 C=C-(2-OMe)Ph H 45 OJ OJ h- > h- 1 H* o o o o o o o vo vo vo vo vo vo vo vo oo LΠ t h-> co cn LΠ to l~» o vo en LΠ to o co cn LΠ to in o t-> in 1*1 LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ Lπ Lπ Ln Lπ Lπ Lπ Lπ Lπ Lπ π Lπ Lπ LΠ LΠ LΠ LΠ cn en cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn Oi Oi J Oi Oi OJ Oi 0J J Oi Oi i Oi Oi OJ i Oi Oi J Oi Oi Oi Oi OJ Oi H- H- H- p- H- H- M- H- H- H- I- i - H- H- H- H 1 - W- H- H- H- H- HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ o O o o o O O o O o O o O O O H] HJ HJ HJ HJ HJ HJ HJ HJ o o o o o o o o o o o o o o o o o HI HI HJ if* cn O o o o O o O l O a X o II O II o o o o o o to t a t ao t a o o o o o o t to a to a o II o o o o o O t a o o o II I o II II II II II II II II II II II II o o O o o II II I II o O O O O O to a o o II I to ^ t I o O o o o o o I I 1 1 1 o o o o o O o o o o a a I I I I I I o I I to to a to a t to to a t ao to a t a to LO to 1 1 I I I to a I H- to I I I O I O O to a o I I it* LO t it* t LO it* to It* if* OJ I 3 rt H- o tr rf* to t t a I I I a to a X rt rt Mi Mi I I I I I I I I I O X H- tr tr c c 25 25 25 I I I O P> H- Hi H( Hi 3 Hi y j PJ O O O o O o HJ HJ HJ O O o TJ tr o H- Φ φ φ 25 25 25 3" a N N N Φ Φ to to t to t to φ Φ to a n TJ o o 3 3 TJ TJ TJ TJ TJ TJ o o o Hi ^ s 1 • < • Q< 1 Tl Tl Tl TJ TJ TJ TJ TJ TJ tr tr tr TJ TJ TJ tr tr tr 3 φ a tr tr tr tr tr tr tr tr tr tr tr tr TJ TJ tr tr n PH t^ PH PH PH PH PH HH PH PH PH PH a PH t^- PH PH PH a a CΛ VO vo O o\ 1*1 416 5,6-diF CF 3 CH 2 CH 2 -(2-OH)Ph H 417 5, 6-diF CF 3 CH 2 CH 2 -(3-OH)Ph H 418 5, 6-diF CF 3 CH 2 CH 2 -(4-OH)Ph H 419 5, 6-diF CF 3 CH 2 CH 2 -(2-OMe)Ph H 420 5, 6-diF CF 3 CH 2 CH 2 -(3-OMe)Ph H 421 5, 6-diF CF 3 CH 2 CH 2 -(4-OMe)Ph H 422 5, , 6-diF CF 3 CH 2 CH 2 -(2-CN)Ph H 423 5, , 6-diF CF 3 CH 2 CH 2 -(3-CN)Ph H 424 5, , 6-diF CF 3 CH 2 CH 2 -(4-CN)Ph H 425 5, .6-diF CF 3 CH 2 CH 2 -(2-N0 2 )Ph H 426 5, , 6-diF CF 3 CH 2 CH 2 -(3-N0 2 )Ph H 427 5, , 6-diF CF 3 CH 2 CH 2 -(4-N0 2 )Ph H 428 5, , 6-diF CF 3 CH 2 CH 2 -(2-NH 2) Ph H 429 5, , 6-diF CF 3 CH 2 CH 2 -(3-NH 2 )Ph H 430 5, , 6-diF CF 3 CH 2 CH 2 -(4-NH 2 )Ph H 431 5, , 6-diF CF 3 CH 2 CH 2 -(2-NMe2)Ph H 432 5, , 6-diF CF 3 CH 2 CH 2 -(3-NMe 2 )Ph H 433 5, , 6-diF CF 3 CH 2 CH 2 - ( 4-NMe 2 ) Ph H 434 5, , 6-diF CF 3 CH CH 2 -2 -Pyridyl H 435 5, , 6-diF CF 3 CH 2 CH 2 -3 -Pyridyl H 436 5, , 6-diF CF 3 CH 2 CH 2 -4 -Pyridyl H 437 5, , 6-diF CF 3 CH2CH2 -2 -furanyl H 438 5, , 6-diF CF 3 CH CH 2 -3 -furanyl H 439 5, , 6-diF CF 3 CH 2 CH 2 -2- thienyl H 440 5, , 6-diF CF 3 CH 2 CH 2 -3 -thienyl H 441 5. , 6-diF CF 3 CH 2 CH -2-oxazolyl H 442 5. , 6-diF CF 3 CH 2 CH 2 -2-thiazolyl H 443 5 , 6-diF CF 3 CH2CH2~4-isoxazolyl H 444 5 , 6-diF CF 3 CH2CH2 -2 -imidazolyl H 445 5 , 6-diF CF 3 C≡C-cycPr CH 3 446 5 , 6-diF CF 3 C≡C-2 -Pyridyl CH3 447 5 , 6-diF CF 3 C≡C-3 -Pyridyl CH3 448 5 , 6-diF CF 3 C≡C-4 -Pyridyl CH3 449 5 , 6-diF CF 3 C≡C-2 -furanyl CH3 47 450 5, 6-diF CF 3 C≡C-3 -furanyl CH 3 451 5, 6-diF CF 3 C≡C-2 -thienyl CH 3 452 5, 6-diF CF 3 C≡C-3 -thienyl CH 3 453 5, 6-diF CF 3 C≡C-(l-CH3)cycPr CH 3 454 5, 6-diF CF 3 C=C-cycPr CH 3 455 5, 6-diF CF 3 C=C-2 -Pyridyl CH 3 456 5, 6-diF CF 3 C=C-3 -Pyridyl CH 3 457 5, 6-diF CF 3 C=C-4 -Pyridyl CH 3 458 5, 6-diF CF 3 C=C-2- furanyl CH 3 459 5 6-diF CF 3 C=C-3 -furanyl CH 3 460 5 6-diF CF 3 C=C-2 -thienyl CH 3 461 5 6-diF CF 3 C=C-3 -thienyl CH 3 462 5 6-diF CF 3 CH 2 CH 2 -cycPr CH 3 463 5 6-diF CF 3 CH 2 CH 2 -Ph CH 3 464 5 6-diF CF 3 CH 2 CH 2 -2 -Pyridyl CH 3 465 5 6-diF CF 3 CH 2 CH 2 -3 -Pyridyl CH3 466 5 6-diF CF 3 CH 2 CH 2 -4 -Pyridyl CH 3 467 5 6-diF CF 3 CH CH 2 -2- furanyl CH 3 468 5 , 6-diF CF 3 CH 2 CH 2 -3 -furanyl CH 3 469 5 6-diF CF 3 CH 2 CH 2 -2 -thienyl CH 3 470 5 , 6-diF CF 3 CH 2 CH -3 -thienyl CH 3 471 5 , 6-diF CF 3 C≡C-cycPr CH 2 CH 3 472 5 , 6-diF CF 3 C≡C-Ph CH 2 CH 3 473 5 , 6-diF CF 3 C≡C-2 -Pyridyl CH CH 3 474 5 , 6-diF CF 3 C≡C-3 -Pyridyl CH 2 CH 3 475 5 , 6-diF CF 3 C≡C-4 -Pyridyl CH 2 CH 3 476 5 , 6-diF CF 3 C≡C-2 -furanyl CH2CH3 477 5 , 6-diF CF 3 C≡C-3 -furanyl CH2CH3 478 5 , 6-diF CF 3 C≡C-2 -thienyl CH 2 CH 3 479 5 , 6-diF CF 3 C≡C-3 -thienyl CH 2 CH 3 480 5 , 6-diF CF 3 C≡C-(l-CH 3 )cycPr CH2CH3 481 5 , 6-diF CF 3 C=C-cycPr CH 2 CH 3 482 5 , 6-diF CF 3 C=C-Ph CH 2 CH 3 483 5 , 6-diF CF 3 C=C-2 -Pyridyl CH2CH3 48 484 5,6-diF CF 3 C=C-3 -Pyridyl CH 2 CH 3 485 5 , 6-diF CF 3 C=C-4-Pyridyl CH 2 CH 3 486 5 6-diF CF 3 C=C-2- furanyl CH 2 CH 3 487 5 , 6-diF CF 3 C=C-3- furanyl CH 2 CH 3 488 5 , 6-diF CF 3 C=C-2- thienyl CH 2 CH 3 489 5 , 6-diF CF 3 C=C-3 -thienyl CH 2 CH 3 490 5 , 6-diF CF 3 CH 2 CH 2 -cycPr CH2CH3 491 5 , 6-diF CF 3 CH 2 CH 2 -Ph CH 2 CH 3 492 5 , 6-diF CF 3 CH 2 CH 2 -2 -Pyridyl CH2CH3 493 5 , 6-diF CF 3 CH 2 CH 2 -3 -Pyridyl CH2CH3 494 5 , 6-diF CF 3 CH 2 CH 2 -4 -Pyridyl CH2CH3 495 5 , 6-diF CF 3 CH 2 CH 2 -2 -furanyl CH 2 CH 3 496 5 , 6-diF CF 3 CH 2 CH 2 -3- furanyl CH2CH3 497 5 , 6-diF CF 3 CH 2 CH 2 -2- thienyl CH2CH3 498 5 , 6-diF CF 3 CH 2 CH 2 -3 -thienyl CH 2 CH 3 499 5, 6-diCl CF 3 C≡C-(2-Cl)Ph H 500 5, 6-diCl CF 3 C≡C-(3-Cl)Ph H 501 5, 6-diCl CF 3 C≡C-(4-Cl)Ph H 502 5, 6-diCl CF 3 C≡C-(2-F)Ph H 503 5, 6-diCl CF 3 C≡C-(3-F)Ph H 504 5, 6-diCl CF C≡C-(4-F)Ph H 505 5, 6-diCl CF 3 C≡C-(2-OH)Ph H 506 5, 6-diCl CF 3 C≡C-(3-OH)Ph H 507 5, 6-diCl CF 3 C≡C-(4-OH)Ph H 508 5, 6-diCl CF 3 C≡C-(2-OMe)Ph H 509 5, 6-diCl CF 3 C≡C-(3-OMe)Ph H 510 5, 6-diCl CF 3 C≡C-(4-OMe)Ph H 511 5, 6-diCl CF 3 C≡C-(2-CN)Ph H 512 5, 6-diCl CF 3 C≡C-(3-CN)Ph H 513 5, 6-diCl CF 3 C≡C-(4-CN)Ph H 514 5, 6-diCl CF 3 C≡C-(2-N0 2 )Ph H 515 5, 6-diCl CF 3 C≡C-(3-N0 2 )Ph H 516 5 6-diCl CF 3 C≡C-(4-N0 2 )Ph H 517 5 6-diCl CF 3 C≡C-(2-NH 2 )Ph H 49 518 5, 6-diCl CF 3 C≡C- ( 3 -NH 2 ) Ph H 519 5, 6-diCl CF 3 C≡C-(4-NH 2 )Ph H 520 5, 6-diCl CF 3 C≡C-(2-NMe 2 )Ph H 521 5, 6-diCl CF 3 C≡C-(3-NMe 2 )Ph H 522 5, 6-diCl CF 3 C≡C-(4-NMe 2 )Ph H 523 5, 6-diCl CF 3 C≡C-3 -Pyridyl H 524 5, 6-diCl CF 3 C≡C-4 -Pyridyl H 525 5 6-diCl CF 3 C≡C-2 -furanyl H 526 5 6-diCl CF 3 C≡C-3 -furanyl H 527 5 6-diCl CF 3 C≡C-2 -thienyl H 528 5 6-diCl CF 3 C≡C-3 -thienyl H 529 5 6-diCl CF 3 C≡C-2 -oxazolyl H 530 5 6-diCl CF 3 C≡C-2 -thiazolyl H 531 5 6-diCl CF 3 C≡C-4 -isoxazolyl H 532 5 6-diCl CF 3 C≡C-2 -imidazolyl H 533 5 6-diCl CF 3 C≡C-(l-CH 3 )cycPr H 534 5 6-diCl CF 3 C=C-(2-Cl)Ph H 535 5 6-diCl CF 3 C=C-(3-Cl)Ph H 536 5 6-diCl CF 3 C=C-(4-Cl)Ph H 537 5 f 6-diCl CF 3 C=C-(2-F)Ph H 538 5 , 6-diCl CF 3 C=C-(3-F)Ph H 539 5 , 6-diCl CF 3 C=C-(4-F)Ph H 540 5 , 6-diCl CF 3 C=C-(2-OH)Ph H 541 5 , 6-diCl CF 3 C=C-(3-OH)Ph H 542 5 , 6.-diCl CF 3 C=C-(4-OH)Ph H 543 5 , 6-diCl CF 3 C=C-(2-OMe)Ph H 544 5 , 6-diCl CF 3 C=C-(3-OMe)Ph H 545 5 ,6-diCl CF 3 C=C-(4-OMe)Ph H 546 5 ,6-diCl CF 3 C=C-(2-CN)Ph H 547 5 , 6-diCl CF 3 C=C-(3-CN)Ph H 548 5 , 6-diCl CF 3 C=C-(4-CN)Ph H 549 5 , 6-diCl CF 3 C=C-(2-N0 2 )Ph H 550 5 , 6-diCl CF 3 C=C-(3-N0 2 )Ph H 551 5 , 6-diCl CF 3 C=C-(4-N0 2 )Ph H 50 552 5, 6-diCl CF 3 C=C-(2-NH 2 )Ph H 553 5,6-diCl CF 3 C=C-(3-NH 2 )Ph H 554 5,6-diCl CF 3 C=C-(4-NH 2 )Ph H 555 5,6-diCl CF 3 C=C-(2-NMe 2 )Ph H 556 5,6-diCl CF 3 C=C-(3-NMe 2 )Ph H 557 5,6-diCl CF 3 C=C-(4-NMe 2 )Ph H 558 5,6-diCl CF 3 C=C-3 -Pyridyl H 559 5,6-diCl CF 3 C=C-4- Pyridyl H 560 5,6-diCl CF 3 C=C-2- furanyl H 561 5,6-diCl CF 3 C=C-3- furanyl H 562 5,6-diCl CF 3 C=C-2 -thienyl H 563 5,6-diCl CF 3 C=C-3 -thienyl H 564 5,6-diCl CF 3 C=C-2-oxazolyl H 565 5,6-diCl CF 3 C=C-2-thiazolyl H 566 5,6-diCl CF 3 C=C-4-isoxazolyl H 567 5,6-diCl CF 3 C=C-2 -imidazolyl H 568 5,6-diCl CF 3 CH 2 CH 2 -cycPr H 569 5,6-diCl CF 3 CH 2 CH 2 CH 2 CH 2 OH H 570 5,6-diCl CF 3 CH 2 CH 2 -CH(OH)Me H 571 5,6-diCl CF 3 CH 2 CH 2 -Ph H 572 5,6-diCl CF 3 CH 2 CH 2 -(2-Cl)Ph H 573 5,6-diCl CF 3 CH 2 CH 2 -(3-Cl)Ph H 574 5,6-diCl CF 3 CH 2 CH 2 -(4-Cl)Ph H 575 5,6-diCl CF 3 CH 2 CH 2 -(2-F)Ph H 576 5,6-diCl CF 3 CH 2 CH 2 -(3-F)Ph H 577 5,6-diCl CF 3 CH 2 CH 2 -(4-F)Ph H 578 5,6-diCl CF 3 CH 2 CH 2 -(2-OH)Ph H 579 5,6-diCl CF 3 CH 2 CH 2 -(3-OH)Ph H 580 5,6-diCl CF 3 CH 2 CH -(4-OH)Ph H 581 5,6-diCl CF 3 CH 2 CH 2 -(2-OMe)Ph H 582 5,6-diCl CF 3 CH 2 CH 2 -(3-OMe)Ph H 583 5,6-diCl CF 3 CH 2 CH 2 -(4-OMe)Ph H 584 5,6-diCl CF 3 CH 2 CH 2 -(2-CN)Ph H 585 5,6-diCl CF 3 CH 2 CH 2 -(3-CN)Ph H 51 cn cn cn cn cn cn cn cn cn cn cn cn cn cn n cn LΠ LΠ LΠ LΠ LΠ LΠ Ln LΠ LΠ on LΠ LΠ LΠ Ul vo vo H> H> H> H 1 H 1 o o o o o o o o o o vo vo LO LO O vo LO vo vo vo co co 00 co -o cn LΠ if* OJ to O oo -o cn LΠ it* 00 t H > o o oo cn LΠ it* OJ to H 1 o vo oo -o cn in 1*1 LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 t 1 1 I 1 1 1 1 1 t 1 1 1 1 Oi Oi Oi i i Oi o. Oi Oi i Oi Oi i Oi Oi Oi Oi i Oi i Oi Oi Oi Oi Oi Oi Oi i H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- H- o O o o o O o O o o o o O o o O o o O o o o o o o O o o O o o O H 1 H 1 H 1 H 1 H 1 H 1 H" H 1 H 1 H 1 H 1 H 1 H 1 O O O o o o O O O O O O O O O O O O O O O O O o O O O HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ H] HJ HJ HJ HJ HJ HJ HJ HJ HJ H] HJ HJ HJ HJ LΠ t o o o o to a to a a o o o o Cl Cl o Cl o o o O Cl o O o o o o o o o o O O to to a to a to o II II II O to a to a X t ao X t ao to a to a t a to x to a to a o o o o o t ao to a to a to X o t ao to a O o O O Ci o O O O O O O O O I V A I A I A I A I A I A to a X O I to t ao t ao to a t a it* LO to o H> I A I LO to LO tO if* LO tO to to a to a t ao t ao to a t a to a to a A I to a I to a to a t a it* o I t ao I I I I t i l l I I I t to I I 1 1 I I I I I I I I O rt rt if* LO Mi to I 3 o tr t o H- H- I LO to LO to •<: a rt 0 1 it* LO to it* OJ K5 B W 1 I I to OJ to 4* H- Hr- c Hj hj I I I I Hi % Hi •< t?i Hi 2 Hi Hj I I μ. μ. μ. o n H- o tr X rt rt Ml Ml T) φ φ 01 H- H- H- TJ Oi X Oi tr tr 25 25 25 I N H- H( H( Hi Hj Hi OJ i Oi Hi o 0 ) tJ tl Hi Oi 1 0 ) H- O O O O to t to 25 • <: Φ φ 01 0 ) μ. μ. N N H- φ Φ φ o N P tJ tl tl t to t OJ OI TJ H 1 o o o O ^ * X5 ^ ^ T TJ Hi h- i J T TJ T H 1 tr tr tr tr tr T trJ T trJ tr tr " n a O a o a o o o o o o o o o o a a CΛ vo © l*> cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn vo vo LΠ LΠ LΠ Lπ if* it* if* if* rf* it* tf* it* it* it* LO J 00 LO OJ 0J OJ J 00 to to to to to to to to to to J to H> o vo co -j cn t_n if* t H» o vo 00 -o cn LΠ if* LO t H> σ o oo -0 cn LΠ it* to H> o o L to in 1*1 LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ LΠ Ch en cn cn cn cn cn <_n cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I i i i i i I I I I I I I I I i Oi i i i Oi 0i i C Oi Oi Oi OJ Oi OJ J Oi Oi Oi i i Oi i Oi Oi Oi i l i H- H- H- H- H- H- H- H- H- H- H- H- H- H- μ. H- H- H- H- μ. μ. μ. μ. μ. μ. μ. μ. μ. μ. μ. μ. μ. o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o H H 1 M H 1 H H 1 H 1 H 1 o o O o O o O O o O O O O o O o O O O O O O o O O O O O O O O O O O HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ HJ O o o Ci o o o O o o O o Cl o o o o II II II II II II II jll o o o o o o o t a to a to a t ao to a to a to a o o o II II II II O O O o O to a o o o o o o o 1 o ' A o O O O O I A I A I A I A I A I A o to a o o o o t a O a to a to a to a to a t a t a DO to it* to o LO to LO to it* LO to O o to I I I I I I I I t a t t to a 1 1 t t II o rr rt o I o I I I I ( J n • OJ t J to it* LO t Ml Mi o 1 1 1 t a I tr tr I o a rt rt Mi tr I I I I TJ "< to a t a I rt rt Ml Ml tr tr C I o c H- H- Hi Hi 3 Hi 3 Hi 3 H- t Hr- Hi H 2i 3 Hj 33 A TJ H n5 rr rt Mi t r C I O • <: H- H- Hi Hi tr O Φ Φ t TrJ o o φ φ Oi 0> μ. μ. μ. tr TJ t Hr- H- c T Hi Hi Hj Hi Hj O φ Φ 0 ) 0 ) T i ι Oi Hi Φ φ 0> 0 ) H- H- H- trJ TJ tl tJ tl P Hi s H- B H- H- TJ tl tl 0? Oi Oi Hi *5 "< *<5 K O ■ 3 tJ Hi • *< * TJ s O H 1 H 1 Hi H i o o o o o O o O o o o o o o o o o o o o o n to a to a to a to a to a t a to a to a to a to a tao toa toa toa toa tao tao tao to a to a to a o o o o o o o o o o o o o o o O O O a O O O O O a a a a a o o o o o o o o a a a a a a O a a CΛ vo © 1*1 654 5,6-diCl CF 3 CH 2 CH 2 -2-Pyridyl CH 2 CH 3 655 5,6-diCl CF 3 CH 2 CH 2 -3-Pyridyl CH 2 CH 3 656 5,6-diCl CF 3 CH 2 CH 2 -4-Pyridyl CH 2 CH 3 657 5,6-diCl CF 3 CH 2 CH 2 -2-furanyl CH 2 CH 3 658 5,6-diCl CF 3 CHCH 2 -3-furanyl CH 2 CH 3 659 5,6-diCl CF 3 CHCH 2 -2-thienyl CH 2 CH 3 660 5,6-diCl CF 3 CH 2 CH 2 -3 -thienyl CH 2 CH 3 661 6-F CF 3 C≡CCH 2 CH 2 OH H 662 6-F CF 3 C≡C-CH(OH)Me H 663 6-F CF 3 C≡C-(2-Cl)Ph H 664 6-F CF 3 C≡C-(3-Cl)Ph H 665 6-F CF 3 C≡C-(4-Cl)Ph H 666 6-F CF 3 C≡C-(2-F)Ph H 667 6-F CF 3 C≡C-(3-F)Ph H 668 6-F CF 3 C≡C-(4-F)Ph H 669 6-F CF 3 C≡C-(2-OH)Ph H 670 6-F CF 3 C≡C-(3-OH)Ph H 671 6-F CF 3 C≡C-(4-OH)Ph H 672 6-F CF 3 C≡C-(2-OMe)Ph H 673 6-F CF 3 C≡C-(3-OMe)Ph H 674 6-F CF 3 C≡C-(4-OMe)Ph H 675 6-F CF 3 C≡C-(2-CN)Ph H 676 6-F CF 3 C≡C-(3-CN)Ph H 677 6-F CF 3 C≡C-(4-CN)Ph H 678 6-F CF 3 C≡C-(2-N0 2 )Ph H 679 6-F CF 3 C≡C-(3-N0 2 )Ph H 680 6-F CF 3 C≡C-(4-N0 2 )Ph H 681 6-F CF 3 C≡C-(2-NH 2 )Ph H 682 6-F CF 3 C≡C- ( 3 -NH 2 ) Ph H 683 6-F CF 3 C≡C-(4-NH 2 )Ph H 684 6-F CF 3 C≡C-(2-NMe 2 )Ph H 685 6-F CF 3 C≡C- ( 3 -NMe 2 ) Ph H 686 6-F CF 3 C≡C- ( 4-NMe 2 )Ph H 687 6-F CF 3 C≡C-3 -Pyridyl H 54 688 6-F CF 3 C≡C-4 -Pyridyl H 689 6-F CF 3 C≡C-2 -furanyl H 690 6-F CF 3 C≡C-3 -furanyl H 691 6-F CF 3 C≡C-2 -thienyl H 692 6-F CF 3 C≡C-3 -thienyl H 693 6-F CF 3 C≡C-2 -oxazolyl H 694 6-F CF 3 C≡C-2 -thiazolyl H 695 6-F CF 3 C≡C-4 -isoxazolyl H 696 6-F CF 3 C≡C-2 -imidazolyl H 697 6-F CF 3 C≡C-(l-CH 3 )cycPr H 698 6-F CF 3 C=CCH 2 CH 2 0H H 699 6-F CF 3 C=C-CH(0H)Me H 700 6-F CF 3 C=C-(2-Cl)Ph H 701 6-F CF 3 C=C-(3-Cl)Ph H 702 6-F CF 3 C=C-(4-Cl)Ph H 703 6-F CF 3 C=C-(2-F)Ph H 704 6-F CF 3 C=C-(3-F)Ph H 705 6-F CF 3 C=C-(4-F)Ph H 706 6-F CF 3 C=C-(2-OH)Ph H 707 6-F CF 3 C=C-(3-OH)Ph H 708 6-F CF 3 C=C-(4-OH)Ph H 709 6-F CF 3 C=C-(2-OMe)Ph H 710 6-F CF 3 C=C-(3-OMe)Ph H 711 6-F CF 3 C=C-(4-OMe)Ph H 712 6-F CF 3 C=C-(2-CN)Ph H 713 6-F CF 3 C=C-(3-CN)Ph H 714 6-F CF 3 C=C-(4-CN)Ph H 715 6-F CF 3 C=C- ( 2 -N0 2 ) Ph H 716 6-F CF 3 C=C- ( 3 -N0 2 ) Ph H 717 6-F CF 3 C=C-(4-N0 2 )Ph H 718 6-F CF 3 C=C-(2-NH )Ph H 719 6-F CF 3 C=C-(3-NH 2 )Ph H 720 6-F CF 3 C=C-(4-NH 2 )Ph H 721 6-F CF 3 C=C-(2-NMe 2 ) Ph H 55 722 6-F CF 3 C=C- ( 3 -NMe ) Ph H 723 6-F CF 3 C=C-(4-NMe 2 )Ph H 724 6-F CF 3 C=C-3 -Pyridyl H 725 6-F CF 3 C=C- 4 -Pyridyl H 726 6-F CF 3 C=C -2 -furanyl H 727 6-F CF 3 C=C-3- furanyl H 728 6-F CF 3 C=C-2 -thienyl H 729 6-F CF 3 C=C-3 -thienyl H 730 6-F CF 3 C=C-2-oxazolyl H 731 6-F CF 3 C=C-2-thiazolyl H 732 6-F CF 3 C=C-4-isoxazolyl H 733 6-F CF 3 C=C-2- imidazolyl H 734 6-F CF 3 CH 2 CH 2 -cycPr H 735 6-F CF 3 CH 2 CH 2 CH 2 CH 2 0H H 736 6-F CF 3 CH 2 CH 2 -CH(0H)Me H 737 6-F CF 3 CH 2 CH 2 -(2-Cl)Ph H 738 6-F CF 3 CH 2 CH 2 -(3-Cl)Ph H 739 6-F CF 3 CH 2 CH 2 -(4-Cl)Ph H 740 6-F CF 3 CH 2 CH 2 -(2-F)Ph H 741 6-F CF 3 CH 2 CH 2 -(3-F)Ph H 742 6-F CF 3 CH 2 CH 2 -(4-F)Ph H 743 6-F CF 3 CH 2 CH 2 -(2-0H)Ph H 744 6-F CF 3 CH 2 CH 2 -(3-0H)Ph H 745 6-F CF 3 CH 2 CH 2 -(4-0H)Ph H 746 6-F CF 3 CH 2 CH 2 -(2-OMe)Ph H 747 6-F CF 3 CH 2 CH 2 -(3-OMe)Ph H 748 6-F CF 3 CH 2 CH 2 -(4-OMe)Ph H 749 6-F CF 3 CH 2 CH 2 -(2-CN)Ph H 750 6-F CF 3 CH 2 CH 2 -(3-CN)Ph H 751 6-F CF 3 CH 2 CH 2 -(4-CN)Ph H 752 6-F CF 3 CH 2 CH 2 -(2-N0 2 )Ph H 753 6-F CF 3 CH 2 CH 2 -(3-N0 2 )Ph H 754 6-F CF 3 CH 2 CH 2 -(4-N0 2 )Ph H 755 6-F CF 3 CH 2 CH 2 -(2-NH 2 )Ph H 56 756 6-F CF 3 CH 2 CH 2 -(3-NH 2 )Ph H 757 6-F CF 3 CH 2 CH 2 -(4-NH 2 )Ph H 758 6-F CF 3 CH 2 CH 2 -(2-NMe 2 )Ph H 759 6-F CF 3 CH 2 CH 2 -(3-NMe2)Ph H 760 6-F CF 3 CH 2 CH2-(4-NMe 2 )Ph H 761 6-F CF 3 CH 2 CH2-3 -Pyridyl H 762 6-F CF 3 CH 2 CH 2 -4-Pyridyl H 763 6-F CF 3 CH 2 CH 2 -2- furanyl H 764 6-F CF 3 CH 2 CH 2 -3 -furanyl H 765 6-F CF 3 CH 2 CH 2 -2 -thienyl H 766 6-F CF 3 CH 2 CH 2 -3 -thienyl H 767 6-F CF 3 CH 2 CH 2 -2-oxazolyl H 768 6-F CF 3 CH 2 CH -2-thiazolyl H 769 6-F CF 3 CH 2 CH 2 -4-isoxazolyl H 770 6-F CF 3 CH CH 2 -2 -imidazolyl H 771 6-F CF 3 C≡C-cycPr CH3 772 6-F CF 3 C≡C-iPr CH3 773 6-F CF 3 C≡C-Pr CH3 774 6-F CF 3 C≡C-Bu CH3 775 6-F CF 3 C≡C-iBu CH3 776 6-F CF 3 C≡C-tBu CH3 777 6-F CF 3 C≡C-Et CH3 778 6-F CF 3 C≡C -Me CH3 779 6-F CF 3 C≡C-Ph CH3 780 6-F CF 3 C≡C-2 -Pyridyl CH3 781 6-F CF 3 C≡C-3 -Pyridyl CH3 782 6-F CF 3 C≡C-4 -Pyridyl CH3 783 6-F CF 3 C≡C-2 -furanyl CH3 784 6-F CF 3 C≡C-3 -furanyl CH3 785 6-F CF 3 C≡C-2 -thienyl CH3 786 6-F CF 3 C≡C-3 -thienyl CH3 787 6-F CF 3 C≡C-(l-CH 3 )cycPr CH 3 788 6-F CF 3 C=C-cycPr CH3 789 6-F CF 3 C=C-iPr CH3 57 790 6-F CF 3 C=C-Pr CH 3 791 6-F CF 3 C=C-Bu CH 3 792 6-F CF 3 C=C-iBu CH 3 793 6-F CF 3 C=C-tBu CH 3 794 6-F CF 3 C=C-Et CH 3 795 6-F CF 3 C=C-Me CH 3 796 6-F CF 3 C=C-Ph CH 3 797 6-F CF 3 C=C-2 -Pyridyl CH 3 798 6-F CF 3 C=C- 3 -Pyridyl CH 3 799 6-F CF 3 C=C-4 -Pyridyl CH 3 800 6-F CF 3 C=C-2- furanyl CH 3 801 6-F CF 3 C=C-3- furanyl CH 3 802 6-F CF 3 C=C-2 -thienyl CH 3 803 6-F CF 3 C=C-3 -thienyl CH 3 804 6-F CF 3 CH 2 CH 2 -cycPr CH 3 805 6-F CF 3 CH 2 CH -Ph CH 3 806 6-F CF 3 CH 2 CH 2 -2 -Pyridyl CH 3 807 6-F CF 3 CH 2 CH 2 -3 -Pyridyl CH 3 808 6-F CF 3 CH 2 CH 2 -4 -Pyridyl CH 3 809 6-F CF 3 CH 2 CH 2 -2- furanyl CH 3 810 6-F CF 3 CH 2 CH 2 -3- furanyl CH 3 811 6-F CF 3 CH 2 CH 2 -2 -thienyl CH 3 812 6-F CF 3 CH 2 CH 2 -3 -thienyl CH 3 813 6-F CF 3 C≡C-cycPr CH 2 CH 3 814 6-F CF 3 C≡C-Ph CH 2 CH 3 815 6-F CF 3 C≡C-2 -Pyridyl CH 2 CH 3 816 6-F CF 3 C≡C-3 -Pyridyl CH 2 CH 3 817 6-F CF 3 C≡C-4 -Pyridyl CH2CH3 818 6-F CF 3 C≡C-2 -furanyl CH 2 CH 3 819 6-F CF 3 C≡C-3 -furanyl CH2CH3 820 6-F CF 3 C≡C-2 -thienyl CH2CH3 821 6-F CF 3 C≡C-3 -thienyl CH 2 CH 3 822 6-F CF 3 C≡C-(l-CH3)cycPr CH2CH3 823 6-F CF 3 C=C-cycPr CH2CH3 58 824 6-F CF 3 C=C-Ph CH 2 CH 3 825 6-F CF 3 C=C-2 -Pyridyl CH 2 CH 3 826 6-F CF 3 C=C-3 -Pyridyl CH 2 CH 3 827 6-F CF 3 C=C-4-Pyridyl CH 2 CH 3 828 6-F CF3 C=C-2-furanyl CH2CH3 829 6-F CF3 C=C-3-furanyl CH2CH3 830 6-F CF3 C=C-2-thienyl CH2CH3 831 6-F CF 3 C=C-3 -thienyl CH2CH3 832 6-F CF 3 CH 2 CH 2 -cycPr CH2CH3 833 6-F CF3 CH 2 CH 2 -Ph CH2CH3 834 6-F CF 3 CH 2 CH 2 -2-Pyridyl CH2CH3 835 6-F CF 3 CH 2 CH 2 -3 -Pyridyl CH2CH3 836 6-F CF3 CH 2 CH 2 -4-Pyridyl CH2CH3 837 6-F CF 3 CH 2 CH 2 -2-furanyl CH2CH3 838 6-F CF3 CH 2 CH 2 -3-furanyl CH2CH3 839 6-F CF 3 CH 2 CH 2 -2-thienyl CH2CH3 840 6-F CF 3 CH 2 CH 2 -3 -thienyl CH2CH3 841 5-C1 CF3 C≡C-cycPr H 842 5-C1 CF 3 C≡CCH 2 CH 2 OH H 843 5-C1 CF3 C≡C-CH(OH)Me H 844 5-C1 CF3 C≡C-Ph H 845 5-C1 CF 3 C≡C-(2-Cl)Ph H 846 5-C1 CF3 C≡C-(3-Cl)Ph H 847 5-C1 CF3 C≡C-(4-Cl)Ph H 848 5-C1 CF 3 C≡C-(2-F)Ph H 849 5-C1 CF3 C≡C-(3-F)Ph H 850 5-C1 CF3 C≡C-(4-F)Ph H 851 5-C1 CF3 C≡C-(2-OH)Ph H 852 5-C1 CF3 C≡C-(3-OH)Ph H 853 5-C1 CF3 C≡C-(4-OH)Ph H 854 5-C1 CF3 C≡C-(2-OMe)Ph H 855 5-C1 CF3 C≡C-(3-OMe)Ph H 856 5-C1 CF3 C≡C-(4-OMe)Ph H 857 5-C1 CF 3 C≡C-(2-CN)Ph H 59 858 5-C1 CF 3 C≡C-(3-CN)Ph H 859 5-C1 CF 3 C≡C-(4-CN)Ph H 860 5-C1 CF 3 C≡C-(2-N0 2 )Ph H 861 5-C1 CF 3 C≡C- ( 3 -N0 2 ) Ph H 862 5-C1 CF 3 C≡C-(4-N0 2 )Ph H 863 5-C1 CF 3 C≡C-(2-NH 2 )Ph H 864 5-C1 CF 3 C≡C- ( 3 -NH 2 ) Ph H 865 5-C1 CF 3 C≡C-(4-NH 2 )Ph H 866 5-C1 CF 3 C≡C-(2-NMe 2 )Ph H 867 5-C1 CF 3 C≡C- ( 3 -NMe 2 ) Ph H 868 5-C1 CF 3 C≡C-(4-NMe 2 )Ph H 869 5-C1 CF 3 C≡C-2 -Pyridyl H 870 5-C1 CF 3 C≡C-2 -Pyridyl H 871 5-C1 CF 3 C≡C-3 -Pyridyl H 872 5-C1 CF 3 C≡C -4 -Pyr idyl H 873 5-C1 CF 3 C≡C-2 -furanyl H 874 5-C1 CF 3 C≡C-3 -furanyl H 875 5-C1 CF 3 C≡C-2 -thienyl H 876 5-C1 CF 3 C≡C-3 -thienyl H 877 5-C1 CF 3 C≡C-2 -oxazolyl H 878 5-C1 CF 3 C≡C-2 -thiazolyl H 879 5-C1 CF 3 C≡C-4 -isoxazolyl H 880 5-C1 CF 3 C≡C-2 -imidazolyl H 881 5-C1 CF 3 C≡C-(l-CH 3 )cycPr H 882 5-C1 CF 3 C=C-cycPr H 883 5-C1 CF 3 C=CCH CH 2 0H H 884 5-C1 CF 3 C=C-CH(0H)Me H 885 5-C1 CF 3 C=C-Ph H 886 5-C1 CF 3 C=C-(2-Cl)Ph H 887 5-C1 CF 3 C=C-(3-Cl)Ph H 888 5-C1 CF 3 C=C-(4-Cl)Ph H 889 5-C1 CF 3 C=C-(2-F)Ph H 890 5-C1 CF 3 C=C-(3-F)Ph H 891 5-C1 CF 3 C=C-(4-F)Ph H 60 892 5-C1 CF 3 C=C-(2-0H)Ph H 893 5-C1 CF 3 C=C-(3-OH)Ph H 894 5-C1 CF 3 C=C-(4-OH)Ph H 895 5-C1 ' CF 3 C=C-(2-OMe)Ph H 896 5-C1 CF 3 C=C-(3-OMe)Ph H 897 5-C1 CF 3 C=C-(4-OMe)Ph H 898 5-C1 CF 3 C=C-(2-CN)Ph H 899 5-C1 CF 3 C=C-(3-CN)Ph H 900 5-C1 CF 3 C=C-(4-CN)Ph H 901 5-C1 CF 3 C=C-(2-N0 2 )Ph H 902 5-C1 CF 3 C=C-(3-N0 2 )Ph H 903 5-C1 CF 3 C=C-(4-N0 2 )Ph H 904 5-C1 CF 3 C=C-(2-NH 2 )Ph H 905 5-C1 CF 3 C=C- ( 3 -NH 2 ) Ph H 906 5-C1 CF 3 C=C-(4-NH 2 )Ph H 907 5-C1 CF 3 C=C-(2-NMe )Ph H 908 5-C1 CF 3 C=C-(3-NMe 2 )Ph H 909 5-C1 CF 3 C=C-(4-NMe 2 )Ph H 910 5-C1 CF 3 C=C-2-Pyridyl H 911 5-C1 CF 3 C=C-2 -Pyridyl H 912 5-C1 CF 3 C=C-3 -Pyridyl H 913 5-C1 CF 3 C=C-4-Pyridyl H 914 5-C1 CF 3 C=C-2-furanyl H 915 5-C1 CF 3 C=C-3-furanyl H 916 5-C1 CF 3 C=C-2 -thienyl H 917 5-C1 CF 3 C=C-3 -thienyl H 918 5-C1 CF 3 C=C-2-oxazolyl H 919 5-C1 CF 3 C=C-2-thiazolyl H 920 5-C1 CF 3 C=C-4-isoxazolyl H 921 5-C1 CF 3 C=C-2 -imidazolyl H 922 5-C1 CF 3 CH 2 CH 2 -cycPr H 923 5-C1 CF 3 CH 2 CH 2 CH 2 CH 2 OH H 924 5-C1 CF 3 CH 2 CH 2 -CH(OH)Me H 925 5-C1 CF 3 CH 2 CH 2 Ph H 61 926 5-C1 CF 3 CH 2 CH 2 -(2-Cl)Ph H 927 5-C1 CF 3 CH 2 CH 2 -(3-Cl)Ph H 928 5-C1 CF 3 CH 2 CH 2 -(4-Cl)Ph H 929 5-C1 CF 3 CH 2 CH 2 -(2-F)Ph H 930 5-C1 CF 3 CH 2 CH 2 -(3-F)Ph H 931 5-C1 CF 3 CH 2 CH 2 -(4-F)Ph H 932 5-C1 CF 3 CH 2 CH 2 -(2-OH)Ph H 933 5-C1 CF 3 CH 2 CH 2 -(3-OH)Ph H 934 5-C1 CF 3 CH 2 CH 2 -(4-OH)Ph H 935 5-C1 CF 3 CH 2 CH 2 -(2-OMe)Ph H 936 5-C1 CF 3 CH 2 CH 2 -(3-OMe)Ph H 937 5-C1 CF 3 CH 2 CH 2 -(4-OMe)Ph H 938 5-C1 CF 3 CH 2 CH 2 -(2-CN)Ph H 939 5-C1 CF 3 CH 2 CH 2 -(3-CN)Ph H 940 5-C1 CF 3 CH 2 CH 2 -(4-CN)Ph H 941 5-C1 CF 3 CH 2 CH 2 -(2-N0 2 )Ph H 942 5-C1 CF 3 CH 2 CH 2 -(3-N0 2 )Ph H 943 5-C1 CF 3 CH 2 CH 2 -(4-N0 2 )Ph H 944 5-C1 CF 3 CH 2 CH 2 -(2-NH 2 )Ph H 945 5-C1 CF 3 CH 2 CH 2 -(3-NH 2 )Ph H 946 5-C1 CF 3 CH 2 CH 2 -(4-NH 2 )Ph H 947 5-C1 CF 3 CH 2 CH 2 -(2-NMe )Ph H 948 5-C1 CF 3 CH 2 CH 2 -(3-NMe 2 )Ph H 949 5-C1 CF 3 CH 2 CH 2 -(4-NMe 2 )Ph H 950 5-C1 CF 3 CH 2 CH 2 - 2 -Pyridyl H 951 5-C1 CF 3 CH 2 CH 2 -3 -Pyridyl H 952 5-C1 CF 3 CH 2 CH 2 -4 -Pyridyl H 953 5-C1 CF 3 CH 2 CH 2 -2-furanyl H 954 5-C1 CF 3 CH 2 CH -3- furanyl H 955 5-C1 CF 3 CH 2 CH 2 -2 -thienyl H 956 5-C1 CF 3 CH 2 CH 2 -3 -thienyl H 957 5-C1 CF 3 CH 2 CH 2 -2 -oxazolyl H 958 5-C1 CF 3 CH 2 CH 2 -2 -thiazolyl H 959 5-Cl CF 3 CH 2 CH 2 -4 -isoxazolyl H 62 960 5-C1 CF 3 CH 2 CH 2 -2-imidazolyl H 961 5-C1 CF 3 C≡C-cycPr CH3 962 5-C1 CF 3 C≡C-Ph CH3 963 5-C1 CF 3 C≡C-2 -Pyridyl CH3 964 5-C1 CF 3 C≡C-3-Pyridyl CH3 965 5-C1 CF 3 C≡C-4-Pyridyl CH3 966 5-C1 CF 3 C≡C-2-furanyl CH3 967 5-C1 CF 3 C≡C-3 -furanyl CH3 968 5-C1 CF 3 C≡C-2-thienyl CH3 969 5-C1 CF 3 C≡C-3 -thienyl CH 3 970 5-C1 CF 3 C≡C-(l-CH 3 )cycPr CH3 971 5-C1 CF 3 C=C-cycPr CH3 972 5-C1 CF 3 C=C-Ph CH3 973 5-C1 CF 3 C=C-2-Pyridyl CH3 974 5-C1 CF 3 C=C-3 -Pyridyl CH3 975 5-C1 CF 3 C=C-4-Pyridyl CH3 976 5-C1 CF 3 C=C-2-furanyl CH3 977 5-C1 CF 3 C=C-3-furanyl CH3 978 5-C1 CF 3 C=C-2-thienyl CH3 979 5-C1 CF 3 C=C-3-thienyl CH3 980 5-C1 CF 3 CH 2 CH -cycPr CH3 981 5-C1 CF 3 CH 2 CH 2 -Ph CH3 982 5-C1 CF 3 CH 2 CH 2 -2-Pyridyl CH3 983 5-C1 CF 3 CH 2 CH 2 -3-Pyridyl CH3 984 5-C1 CF 3 CH 2 CH 2 -4-Pyridyl CH3 985 5-C1 CF 3 CH 2 CH 2 -2-furanyl CH3 986 5-C1 CF 3 CH 2 CH 2 -3-furanyl CH 3 987 5-C1 CF 3 CH2CH 2 -2-thienyl CH3 988 5-C1 CF 3 CH 2 CH 2 -3-thienyl CH3 989 5-C1 CF 3 C≡C-cycPr CH 2 CH 3 990 5-C1 CF 3 C≡C-Ph CH 2 CH 3 991 5-C1 CF 3 C≡C-2 -Pyridyl CH 2 CH 3 992 5-C1 CF 3 C≡C-3 -Pyridyl CH2CH3 993 5-C1 CF 3 C≡C-4-Pyridyl CH2CH3 994 5-C1 CF 3 C≡C-2 -furanyl CH 2 CH 3 995 5-C1 CF 3 C≡C-3 -furanyl CH 2 CH 3 996 5-C1 CF 3 C≡C-2 -thienyl CH 2 CH 3 997 5-C1 CF 3 C≡C-3 -thienyl CH 2 CH 3 998 5-C1 CF 3 C≡C-(l-CH 3 )cycPr CH2CH3 999 5-C1 CF 3 C=C-cycPr CH 2 CH 3 1000 5-C1 CF 3 C=C-Ph CH2CH 3 1001 5-C1 CF 3 C=C-2 -Pyridyl CH2CH3 1002 5-C1 CF 3 C=C-3 -Pyridyl CH2CH3 1003 5-C1 CF 3 C=C-4-Pyridyl CH2CH3 1004 5-C1 CF 3 C=C-2-furanyl CH2CH3 1005 5-C1 CF 3 C=C-3-furanyl CH 2 CH 1006 5-C1 CF 3 C=C-2 -thienyl CH CH 3 1007 5-C1 CF 3 C=C-3 -thienyl CH 2 CH 3 1008 5-C1 CF 3 CH 2 CH 2 -cycPr CH 2 CH 3 1009 5-C1 CF 3 CH 2 CH 2 -Ph CH 2 CH 3 1010 5-C1 CF 3 CH 2 CH -2-Pyridyl CH 2 CH 3 1011 5-C1 CF 3 CH CH -3 -Pyridyl CH 2 CH 3 1012 5-C1 CF 3 CH 2 CH 2 -4-Pyridyl CH 2 CH 3 1013 5-C1 CF 3 CH 2 CH 2 -2-furanyl CH 2 CH 3 1014 5-C1 CF 3 CH 2 CH -3-furanyl CH 2 CH 3 1015 5-C1 CF 3 CHCH 2 -2-thienyl CH 2 CH 1016 5-C1 CF 3 CH 2 CH 2 -3 -thienyl CH 2 CH 3 1017 5-F CF 3 C≡C-cycPr H 1018 5-F CF 3 C≡CCH 2 CH 2 0H H 1019 5-F CF 3 C≡C-CH(OH)Me H 1020 5-F CF 3 C≡C-Ph H 1021 5-F CF 3 C≡C-(2-Cl)Ph H 1022 5-F CF 3 C≡C-(3-Cl)Ph H 1023 5-F CF 3 C≡C-(4-Cl)Ph H 1024 5-F CF 3 C≡C-(2-F)Ph H 1025 5-F CF 3 C≡C-(3-F)Ph H 1026 5-F CF 3 C≡C-(4-F)Ph H 1027 5-F CF 3 C≡C-(2-OH)Ph H 64 1028 5-F CF 3 C≡C- (3 -OH) Ph H 1029 5-F CF 3 C≡C-(4-OH)Ph H 1030 5-F CF 3 C≡C-(2-OMe) Ph H 1031 5-F CF 3 C≡C-(3-OMe)Ph H 1032 5-F CF 3 C≡C-(4-OMe) Ph H 1033 5-F CF 3 C≡C-(2-CN)Ph H 1034 5-F CF 3 C≡C-(3-CN)Ph H 1035 5-F CF 3 C≡C-(4-CN)Ph H 1036 5-F CF 3 C≡C-(2-N0 2 )Ph H 1037 5-F CF 3 C≡C- ( 3 -N0 2 ) Ph H 1038 5-F CF 3 C≡C-(4-N0 2 )Ph H 1039 5-F CF 3 C≡C-(2-NH 2 )Ph H 1040 5-F CF 3 C≡C-(3-NH 2 )Ph H 1041 5-F CF 3 C≡C-(4-NH 2 )Ph H 1042 5-F CF 3 C≡C-(2-NMe 2 )Ph H 1043 5-F CF 3 C≡C-(3-NMe2)Ph H 1044 5-F CF 3 C≡C-(4-NMe 2 )Ph H 1045 5-F CF 3 C≡C-2 -Pyridyl H 1046 5-F CF 3 C≡C-2 -Pyridyl H 1047 5-F CF 3 C≡C-3 -Pyridyl H 1048 5-F CF 3 C≡C-4 -Pyridyl H 1049 5-F CF 3 C≡C-2 -furanyl H 1050 5-F CF 3 C≡C-3 -furanyl H 1051 5-F CF 3 C≡C-2 -thienyl H 1052 5-F CF 3 C≡C-3 -thienyl H 1053 5-F CF 3 C≡C-2 -oxazolyl H 1054 5-F CF 3 C≡C-2 -thiazolyl H 1055 5-F CF 3 C≡C-4 -isoxazolyl H 1056 5-F CF 3 C≡C-2 -imidazolyl H 1057 5-F CF 3 C≡C-(l-CH3)cycPr H 1058 5-F CF 3 C=C-cycPr H 1059 5-F CF 3 C=CCH 2 CH 2 OH H 1060 5-F CF 3 C=C-CH(OH)Me H 1061 5-F CF 3 C=C-Ph H 65 1062 5-F CF 3 C=C-(2-Cl)Ph H 1063 5-F CF 3 C=C-(3-Cl)Ph H 1064 5-F CF 3 C=C-(4-Cl)Ph H 1065 5-F CF 3 C=C-(2-F)Ph H 1066 5-F CF 3 C=C-(3-F)Ph H 1067 5-F CF 3 C=C-(4-F)Ph H 1068 5-F CF 3 C=C-(2-0H)Ph H 1069 5-F CF 3 C=C-(3-OH)Ph H 1070 5-F CF 3 C=C-(4-OH)Ph H 1071 5-F CF 3 C=C-(2-OMe)Ph H 1072 5-F CF 3 C=C-(3-0Me)Ph H 1073 5-F CF 3 C=C-(4-OMe)Ph H 1074 5-F CF 3 C=C-(2-CN)Ph H 1075 5-F CF 3 C=C-(3-CN)Ph H 1076 5-F CF 3 C=C-(4-CN)Ph H 1077 5-F CF 3 C=C-(2-N0 2 )Ph H 1078 5-F CF 3 C=C-(3-N0 2 )Ph H 1079 5-F CF 3 C=C-(4-N0 2 )Ph H 1080 5-F CF 3 C=C-(2-NH 2 )Ph H 1081 5-F CF 3 C=C-(3-NH 2 )Ph H 1082 5-F CF 3 C=C-(4-NH 2 )Ph H 1083 5-F CF 3 C=C-(2-NMe 2 )Ph H 1084 5-F CF 3 C=C-(3-NMe 2 )Ph H 1085 5-F CF 3 C=C-(4-NMe 2 )Ph H 1086 5-F CF 3 C=C-2-Pyridyl H 1087 5-F CF 3 C=C-2-Pyridyl H 1088 5-F CF 3 C=C-3 -Pyridyl H 1089 5-F CF 3 C=C-4-Pyridyl H 1090 5-F CF 3 C=C-2-furanyl H 1091 5-F CF 3 C=C-3-furanyl H 1092 5-F CF 3 C=C-2-thienyl H 1093 5-F CF 3 C=C-3 -thienyl H 1094 5-F CF 3 C=C-2-oxazolyl H 1095 5-F CF 3 C=C-2-thiazolyl H 66 1096 5-F CF 3 C=C-4-isoxazolyl H 1097 5-F CF 3 C=C-2-imidazolyl H 1098 5-F CF 3 CH 2 CH 2 -cycPr H 1099 5-F CF 3 CH CH 2 CH 2 CH 2 OH H 1100 5-F CF 3 CH 2 CH 2 -CH(OH)Me H 1101 5-F CF 3 CHCH 2 Ph H 1102 5-F CF 3 CH 2 CH 2 -(2-Cl)Ph H 1103 5-F CF 3 CH 2 CH 2 -(3-Cl)Ph H 1104 5-F CF 3 CH 2 CH 2 -(4-Cl)Ph H 1105 5-F CF 3 CH 2 CH 2 -(2-F)Ph H 1106 5-F CF 3 CH 2 CH 2 -(3-F)Ph H 1107 5-F CF 3 CH 2 CH 2 -(4-F)Ph H 1108 5-F CF 3 CH 2 CH 2 -(2-OH)Ph H 1109 5-F CF 3 CH 2 CH 2 -(3-OH)Ph H 1110 5-F CF 3 CH 2 CH 2 -(4-OH)Ph H 1111 5-F CF 3 CH 2 CH 2 -(2-OMe)Ph H 1112 5-F CF 3 CH 2 CH 2 -(3-OMe)Ph H 1113 5-F CF 3 CH 2 CH 2 -(4-OMe)Ph H 1114 5-F CF 3 CH 2 CH 2 -(2-CN)Ph H 1115 5-F CF 3 CH 2 CH -(3-CN)Ph H 1116 5-F CF 3 CH 2 CH 2 -(4-CN)Ph H 1117 5-F CF 3 CH 2 CH 2 -(2-N0 2 )Ph H 1118 5-F CF 3 CH 2 CH 2 -(3-N0 2 )Ph H 1119 5-F CF 3 CH 2 CH 2 -(4-N0 2 )Ph H 1120 5-F CF 3 CH 2 CH 2 -(2-NH 2 )Ph H 1121 5-F CF 3 CH 2 CH 2 -(3-NH2)Ph H 1122 5-F CF 3 CH 2 CH 2 -(4-NH 2 )Ph H 1123 5-F CF 3 CH 2 CH 2 -(2-NMe 2 )Ph H 1124 5-F CF 3 CH 2 CH 2 -(3-NMe 2 )Ph H 1125 5-F CF 3 CH 2 CH 2 -(4-NMe 2 )Ph H 1126 5-F CF 3 CH 2 CH 2 -2-Pyridyl H 1127 5-F CF 3 CH 2 CH 2 -3 -Pyridyl H 1128 5-F CF 3 CH 2 CH 2 -4-Pyridyl H 1129 5-F CF 3 CH 2 CH 2 -2-furanyl H 67 1130 5-F CF 3 CH 2 CH 2 -3 -furanyl H 1131 5-F CF 3 CH 2 CH 2 -2 -thienyl H 1132 5-F CF 3 CH 2 CH 2 -3 -thienyl H 1133 5-F CF 3 CH 2 CH 2 -2 -oxazolyl H 1134 5-F CF 3 CH 2 CH 2 -2 -thiazolyl H 1135 5-F CF 3 CH2CH2-4-isoxazolyl H 1136 5-F CF 3 CH2CH2-2-imidazolyl H 1137 5-F CF 3 C≡C-cycPr CH 3 1138 5-F CF 3 C≡C-Ph CH 3 1139 5-F CF 3 C≡C-2 -Pyridyl CH 3 1140 5-F CF 3 C≡C-3 -Pyridyl CH3 1141 5-F CF 3 C≡C-4-Pyridyl CH3 1142 5-F CF 3 C≡C-2 -furanyl CH3 1143 5-F CF 3 C≡C-3 -furanyl CH3 1144 5-F CF 3 C≡C-2 -thienyl CH3 1145 5-F CF 3 C≡C-3 -thienyl CH3 1146 5-F CF 3 C≡C-(l-CH 3 )cycPr CH3 1147 5-F CF 3 C=C-cycPr CH 3 1148 5-F CF 3 C=C-Ph CH3 1149 5-F CF 3 C=C-2-Pyridyl CH 3 1150 5-F CF 3 C=C-3 -Pyridyl CH 3 1151 5-F CF 3 C=C-4-Pyridyl CH3 1152 5-F CF 3 C=C-2-furanyl CH3 1153 5-F CF 3 C=C-3-furanyl CH 3 1154 5-F CF 3 C=C-2-thienyl CH3 1155 5-F CF 3 C=C-3-thienyl CH3 1156 5-F CF 3 CH 2 CH 2 -cycPr CH 3 1157 5-F CF 3 CH 2 CH 2 -Ph CH 3 1158 5-F CF 3 CH CH 2 -2-Pyridyl CH 3 1159 5-F CF 3 CH 2 CH 2 -3-Pyridyl CH 3 1160 5-F CF 3 CH 2 CH 2 -4-Pyridyl CH3 1161 5-F CF 3 CH2CH2-2-furanyl CH3 1162 5-F CF 3 CH 2 CH 2 -3-furanyl CH 3 1163 5-F CF 3 CH 2 CH 2 -2-thienyl CH 3 68 1164 5-F CF 3 CH 2 CH 2 -3-thienyl CH 3 1165 5-F CF 3 C≡C-cycPr CH 2 CH 3 1166 5-F CF 3 C≡C-Ph CH2CH3 1167 5-F CF 3 C≡C-2 -Pyridyl CH2CH3 1168 5-F CF 3 C≡C-3-Pyridyl CH2CH3 1169 5-F CF 3 C≡C-4-Pyridyl CH 2 CH 3 1170 5-F CF 3 C≡C-2 -furanyl CH2CH 3 1171 5-F CF 3 C≡C-3 -furanyl CH2CH3 1172 5-F CF 3 C≡C-2 -thienyl CH2CH 3 1173 5-F CF 3 C≡C-3 -thienyl CH2CH3 1174 5-F CF 3 C≡C-(l-CH 3 )cycPr CH 2 CH 3 1175 5-F CF 3 C=C-cycPr CH 2 CH 3 1176 5-F CF 3 C=C-Ph CH 2 CH 3 1177 5-F CF 3 C=C-2-Pyridyl CH 2 CH 3 1178 5-F CF 3 C=C-3-Pyridyl CH 2 CH 3 1179 5-F CF 3 C=C-4-Pyridyl CH 2 CH 3 1180 5-F CF 3 C=C-2-furanyl CH 2 CH 3 1181 5-F CF 3 C=C-3-furanyl CH 2 CH 3 1182 5-F CF 3 C=C-2-thienyl CH2CH3 1183 5-F CF 3 C=C-3 -thienyl CH2CH3 1184 5-F CF 3 CH 2 CH 2 -cycPr CH 2 CH 3 1185 5-F CF 3 CH 2 CH 2 -Ph CH2CH 3 1186 5-F CF 3 CH 2 CH 2 -2-Pyridyl CH 2 CH 3 1187 5-F CF 3 CH 2 CH 2 -3-Pyridyl CH 2 CH 3 1188 5-F CF 3 CH 2 CH 2 -4-Pyridyl CH2CH 3 1189 5-F CF 3 CH CH 2 -2-furanyl CH2CH3 1190 5-F CF 3 CH 2 CH 2 -3 -furanyl CH 2 CH 3 1191 5-F CF 3 CH 2 CH 2 -2-thienyl CH 2 CH 3 1192 5-F CF 3 CH 2 CH 2 -3 -thienyl CH 2 CH 3 1193 5-Cl,6-F CF 3 C≡C-cycPr H 1194 5-Cl,6-F CF 3 C≡C-Ph H 1195 5-Cl,6-F CF 3 C≡C-2 -Pyridyl H 1196 5-Cl,6-F CF 3 C≡C-3 -Pyridyl H 1197 5-Cl,6-F CF 3 C≡C-4-Pyridyl H 69 1198 5-Cl,6-F CF 3 C≡C-2-furanyl H 1199 5-Cl,6-F CF 3 C≡C-3 -furanyl H 1200 5-Cl,6-F CF 3 C≡C-2 -thienyl H 1201 5-Cl,6-F CF 3 C≡C-3 -thienyl H 1202 5-Cl,6-F CF 3 C≡C-(l-CH 3 )cycPr H 1203 5-Cl,6-F CF 3 C=C-cycPr H 1204 5-Cl,6-F CF 3 C=C-Ph H 1205 5-Cl,6-F CF 3 C=C-2-Pyridyl H 1206 5-Cl,6-F CF 3 C=C-3-Pyridyl H 1207 5-Cl,6-F CF 3 C=C-4-Pyridyl H 1208 5-Cl,6-F CF 3 C=C-2-furanyl H 1209 5-Cl,6-F CF 3 C=C-3- uranyl H 1210 5-Cl,6-F CF 3 C=C-2-thienyl H 1211 5-C1.6-F CF 3 C=C-3-thienyl H 1212 5-Cl,6-F CF 3 CH 2 CH 2 -cycPr H 1213 5-Cl,6-F CF 3 CH 2 CH 2 -Ph H 1214 5-Cl,6-F CF 3 CH 2 CH 2 -2-Pyridyl H 1215 5-Cl,6-F CF 3 CH 2 CH 2 -3 -Pyridyl H 1216 5-Cl,6-F CF 3 CHCH 2 -4-Pyridyl H 1217 5-Cl,6-F CF 3 CH 2 CH 2 -2-furanyl H 1218 5-Cl,6-F CF 3 CH 2 CH 2 -3-furanyl H 1219 5-Cl,6-F CF 3 CH 2 CH 2 -2-thienyl H 1220 5-Cl,6-F CF 3 CH 2 CH 2 -3-thienyl H 1221 5-Cl,6-F CF 3 C≡C-cycPr CH 3 1222 5-Cl,6-F CF 3 C≡C-Ph CH 3 1223 5-C1.6-F CF 3 C≡C-2-Pyridyl CH 3 1224 5-C1, 6-F CF 3 C≡C-3 -Pyridyl CH 3 1225 5-Cl,6-F CF 3 C≡C-4-Pyridyl CH 3 1226 5-Cl,6-F CF 3 C≡C-2-furanyl CH 3 1227 5-Cl,6-F CF 3 C≡C-3 -furanyl CH 3 1228 5-Cl,6-F CF 3 C≡C-2 -thienyl CH 3 1229 5-Cl,6-F CF 3 C≡C-3 -thienyl CH 3 1230 5-Cl,6-F CF 3 C≡C-(l-CH 3 )cycPr CH 3 1231 5-Cl,6-F CF 3 C=C-cycPr CH 3 70 1232 5-Cl,6-F CF 3 C=C-Ph CH 3 1233 5-Cl,6-F CF 3 C=C-2 -Pyridyl CH 3 1234 5-Cl,6-F CF 3 C=C-3 -Pyridyl CH 3 1235 5-C1.6-F CF 3 C=C-4-Pyridyl CH 3 1236 5-Cl,6-F CF 3 C=C-2- furanyl CH 3 1237 5-Cl,6-F CF 3 C=C-3- furanyl CH 3 1238 5-Cl,6-F CF 3 C=C-2 -thienyl CH 3 1239 5-Cl,6-F CF 3 C=C-3 -thienyl CH 3 1240 5-C1, 6-F CF 3 CH 2 CH 2 -cycPr CH 3 1241 5-Cl,6-F CF 3 CH 2 CH 2 -Ph CH 3 1242 5-Cl,6-F CF 3 CH CH 2 -2-Pyridyl CH 3 1243 5-Cl,6-F CF 3 CH 2 CH -3 -Pyridyl CH 3 1244 5-Cl,6-F CF 3 CH CH -4-Pyridyl CH 3 1245 5-Cl,6-F CF 3 CH 2 CH 2 -2- furanyl CH 3 1246 5-Cl,6-F CF 3 CH 2 CH 2 -3 -furanyl CH 3 1247 5-Cl,6-F CF 3 CH 2 CH 2 -2- thienyl CH 3 1248 5-Cl,6-F CF 3 CH 2 CH 2 -3 -thienyl CH 1249 5-F,6-Cl CF 3 C≡C-cycPr H 1250 5-F,6-Cl CF 3 C≡C-Ph H 1251 5-F,6-Cl CF 3 C≡C-2 -Pyridyl H 1252 5-F,6-Cl CF 3 C≡C-3 -Pyridyl H 1253 5-F, 6-C1 CF 3 C≡C-4 -Pyridyl H 1254 5-F,6-Cl CF 3 C≡C-2 -furanyl H 1255 5-F, 6-C1 CF 3 C≡C-3 -furanyl H 1256 5-F,6-Cl CF 3 C≡C-2 -thienyl H 1257 5-F,6-Cl CF 3 C≡C-3 -thienyl H 1258 5-F,6-Cl CF 3 C≡C-(l-CH 3 )cycPr H 1259 5-F,6-Cl CF 3 C=C-cycPr H 1260 5-F,6-Cl CF 3 C=C-Ph H 1261 5-F,6-Cl CF 3 C=C-2 -Pyridyl H 1262 5-F,6-Cl CF 3 C=C-3 -Pyridyl H 1263 5-F,6-Cl CF 3 C=C-4 -Pyridyl H 1264 5-F.6-C1 CF 3 C=C-2- furanyl H 1265 5-F,6-Cl CF 3 C=C-3- furanyl H 71 1266 5-F,6-Cl CF 3 C=C-2 -thienyl H 1267 5-F,6-Cl CF 3 C=C-3 -thienyl H 1268 5-F,6-Cl CF 3 CH 2 CH 2 -cycPr H 1269 5-F,6-Cl CF 3 CH 2 CH 2 -Ph H 1270 5-F,6-Cl CF 3 CH 2 CH 2 -2 -Pyridyl H 1271 5-F,6-Cl CF 3 CH 2 CH 2 -3 -Pyridyl H 1272 5-F,6-Cl CF 3 CH 2 CH 2 -4 -Pyridyl H 1273 5-F,6-Cl CF 3 CH CH 2 -2 -furanyl H 1274 5-F,6-Cl CF 3 CH 2 CH 2 -3 -furanyl H 1275 5-F,6-Cl CF 3 CH 2 CH 2 -2 -thienyl H 1276 5-F,6-Cl CF 3 CH 2 CH 2 -3 -thienyl H 1277 5-F,6-Cl CF 3 C≡C-cycPr CH 3 1278 5-F,6-Cl CF 3 C≡C-Ph CH 3 1279 5-F,6-Cl CF 3 C≡C-2 -Pyridyl CH 3 1280 5-F,6-Cl CF 3 C≡C-3 -Pyridyl CH 3 1281 5-F,6-Cl CF 3 C≡C-4-Pyridyl CH 3 1282 5-F,6-Cl CF 3 C≡C-2 -furanyl CH 3 1283 5-F,6-Cl CF 3 C≡C-3 -furanyl CH 3 1284 5-F,6-Cl CF 3 C≡C-2 -thienyl CH 3 1285 5-F,6-Cl CF 3 C≡C-3 -thienyl CH 3 1286 5-F,6-Cl CF 3 C≡C-(l-CH 3 )cycPr CH 3 1287 5-F,6-Cl CF 3 C=C-cycPr CH 3 1288 5-F,6-Cl CF 3 C=C-Ph CH 3 1289 5-F,6-Cl CF 3 C=C-2-Pyridyl CH 3 1290 5-F,6-Cl CF 3 C=C-3 -Pyridyl CH 3 1291 5-F,6-Cl CF 3 C=C-4 -Pyridyl CH 3 1292 5-F,6-Cl CF 3 C=C-2- furanyl CH 3 1293 5-F,6-Cl CF 3 C=C-3- furanyl CH 1294 5-F,6-Cl CF 3 C=C-2- thienyl CH 3 1295 5-F,6-Cl CF 3 C=C-3 -thienyl CH 3 1296 5-F,6-Cl CF 3 CH CH 2 -cycPr CH 3 1297 5-F,6-Cl CF 3 CH 2 CH 2 -Ph CH 3 1298 5-F,6-Cl CF 3 CH 2 CH 2 -2 -Pyridyl CH 3 1299 5-F,6-Cl CF 3 CH 2 CH 2 -3 -Pyridyl CH 3 72 1300 5-F,6-Cl CF 3 CH 2 CH 2 -4-Pyridyl CH 3 1301 5-F,6-Cl CF 3 CH 2 CH 2 -2- furanyl CH 3 1302 5-F,6-Cl CF 3 CH CH 2 -3- furanyl CH 3 1303 5-F,6-Cl CF 3 CH 2 CH 2 -2-thienyl CH 3 1304 5-F,6-Cl CF 3 CH 2 CH 2 -3 -thienyl CH 3 1305 6-C1, 8-F CF 3 C≡C-cycPr H 1306 6-C1, 8-F CF 3 C≡C-Ph H 1307 6-C1, 8-F CF 3 C≡C-2 -Pyridyl H 1308 6-C1, 8-F CF 3 C≡C-3 -Pyridyl H 1309 6-C1, 8-F CF 3 C≡C-4 -Pyridyl H 1310 6-C1, 8-F CF 3 C≡C-2 -furanyl H 1311 6-C1, 8-F CF 3 C≡C-3 -furanyl H 1312 6-C1, 8-F CF 3 C≡C-2 -thienyl H 1313 6-C1 8-F CF 3 C≡C-3 -thienyl H 1314 6-C1 8-F CF 3 C≡C-(l-CH 3 )cycPr H 1315 6-C1 8-F CF 3 C=C-cycPr H 1316 6-C1 8-F CF 3 C=C-Ph H 1317 6-C1 8-F CF 3 C=C-2 -Pyridyl H 1318 6-C1 8-F CF 3 C=C-3 -Pyridyl H 1319 6-C1 8-F CF 3 C=C- 4 -Pyridyl H 1320 6-C1 8-F CF 3 C=C-2- furanyl H 1321 6-C1 8-F CF 3 C=C-3- furanyl H 1322 6-C1 8-F CF 3 C=C-2- thienyl H 1323 6-C1 8-F CF 3 C=C-3 -thienyl H 1324 6-C1 ,8-F CF 3 CH 2 CH 2 -cycPr H 1325 6-C1 8-F CF 3 CH 2 CH 2 -Ph H 1326 6-C1 ,8-F CF 3 CH CH 2 -2-Pyridyl H 1327 6-C1 ,8-F CF 3 CH 2 CH 2 -3 -Pyridyl H 1328 6-C1 ,8-F CF 3 CH 2 CH -4 -Pyridyl H 1329 6-C1 ,8-F CF 3 CH 2 CH 2 -2 -furanyl H 1330 6-C1 ,8-F CF 3 CH CH 2 -3 -furanyl H 1331 6-C1 ,8-F CF 3 CH 2 CH 2 -2 -thienyl H 1332 6-C1 ,8-F CF 3 CH 2 CH 2 -3 -thienyl H 1333 6-C1 ,8-F CF 3 C≡C-cycPr CH 3 73 1334 6-Cl,8-F CF 3 C≡C-Ph CH3 1335 6-C1, 8-F CF 3 C≡C-2 -Pyridyl CH3 1336 6-C1, 8-F CF 3 C≡C-3 -Pyridyl CH3 1337 6-C1, 8-F CF3 C≡C-4-Pyridyl CH3 1338 6-C1, 8-F CF 3 C≡C-2 -furanyl CH3 1339 6-C1, 8-F CF 3 C≡C-3 -furanyl CH 3 1340 6-C1 8-F CF3 C≡C-2 -thienyl CH3 1341 6-C1 8-F CF 3 C≡C-3 -thienyl CH3 1342 6-C1 8-F CF 3 C≡C-(l-CH 3 )cycPr CH3 1343 6-C1 8-F CF 3 C=C-cycPr CH3 1344 6-C1 8-F CF 3 C=C-Ph CH3 1345 6-C1 8-F CF 3 C=C-2-Pyridyl CH3 1346 6-C1 8-F CF 3 C=C-3 -Pyridyl CH3 1347 6-C1 8-F CF 3 C=C-4-Pyridyl CH3 1348 6-C1 8-F CF 3 C=C-2-furanyl CH3 1349 6-C1 8-F CF 3 C=C-3-furanyl CH3 1350 6-C1 ,8-F CF 3 C=C-2-thienyl CH3 1351 6-C1 ,8-F CF 3 C=C-3 -thienyl CH3 1352 6-C1 ,8-F CF 3 CH 2 CH 2 -cycPr CH3 1353 6-C1 ,8-F CF3 CH 2 CH 2 -Ph CH3 1354 6-C1 ,8-F CF 3 CH 2 CH 2 -2-Pyridyl CH3 1355 6-C1 ,8-F CF3 CH 2 CH 2 -3-Pyridyl CH3 1356 6-C1 ,8-F CF 3 CH 2 CH 2 -4-Pyridyl CH3 1357 6-C1 ,8-F CF 3 CH 2 CH -2-furanyl CH3 1358 6-C1 ,8-F CF 3 CH 2 CH -3-furanyl CH3 1359 6-C1 ,8-F CF 3 CH 2 CH 2 -2-thienyl CH3 1360 6-C1 ,8-F CF 3 CHCH 2 -3-thienyl CH3 1361 6-CH 3 CF 3 C≡C-cycPr H 1362 6-CH 3 CF 3 C≡C-Ph H 1363 6-CH 3 CF 3 C≡C-2-Pyridyl H 1364 6-CH3 CF3 C≡C-3 -Pyridyl H 1365 6-CH 3 CF 3 C≡C-4-Pyridyl H 1366 6-CH 3 CF3 C≡C-2 -furanyl H 1367 6-CH 3 CF3 C≡C-3 -furanyl H 74 1368 6-CH3 CF 3 C≡C-2 -thienyl H 1369 6-CH3 CF3 C≡C-3 -thienyl H 1370 6-CH3 CF 3 C≡C-(l-CH 3 )cycPr H 1371 6-CH3 CF 3 C=C-cycPr H 1372 6-CH3 CF 3 C=C-Ph H 1373 6-CH3 CF 3 C=C-2 -Pyridyl H 1374 6-CH3 CF3 C=C-3 -Pyridyl H 1375 6-CH3 CF 3 C=C-4 -Pyridyl H 1376 6-CH3 CF 3 C=C-2- furanyl H 1377 6-CH3 CF 3 C=C-3- furanyl H 1378 6-CH3 CF3 C=C-2- thienyl H 1379 6-CH3 CF3 C=C-3 -thienyl H 1380 6-CH3 CF3 CH 2 CH 2 -cycPr H 1381 6-CH3 CF 3 CH 2 CH -Ph H 1382 6-CH3 CF3 CH 2 CH 2 -2 -Pyridyl H 1383 6-CH3 CF 3 CH 2 CH 2 -3 -Pyridyl H 1384 6-CH3 CF 3 CH 2 CH 2 -4 -Pyridyl H 1385 6-CH3 CF3 CH 2 CH 2 -2- furanyl H 1386 6-CH3 CF3 CH 2 CH 2 -3- furanyl H 1387 6-CH3 CF3 CH 2 CH 2 -2 -thienyl H 1388 6-CH3 CF 3 CH 2 CH 2 -3 -thienyl H 1389 6-CH3 CF 3 C≡C-cycPr CH3 1390 6-CH3 CF 3 C≡C-Ph CH3 1391 6-CH3 CF 3 C≡C-2 -Pyridyl CH3 1392 6-CH3 CF 3 C≡C-3 -Pyridyl CH3 1393 6-CH3 CF 3 C≡C-4 -Pyridyl CH 3 1394 6-CH3 CF 3 C≡C-2 -furanyl CH3 1395 6-CH3 CF 3 C≡C-3 -furanyl CH3 1396 6-CH3 CF 3 C≡C-2 -thienyl CH3 1397 6-CH3 CF 3 C≡C-3 -thienyl CH3 1398 6-CH3 CF 3 C≡C-(l-CH 3 )cycPr CH3 1399 6-CH3 CF 3 C=C-cycPr CH3 1400 6-CH3 CF 3 C=C-Ph CH3 1401 6-CH3 CF3 C=C-2 -Pyridyl CH3 75 1402 6-CH3 CF3 C=C-3-Pyridyl CH3 1403 6-CH3 CF 3 C=C-4-Pyridyl CH 3 1404 6-CH3 CF 3 C=C-2-furanyl CH 3 1405 6-CH3 CF 3 C=C-3-furanyl CH 3 1406 6-CH3 CF 3 C=C-2-thienyl CH 3 1407 6-CH3 CF 3 C=C-3 -thienyl CH 3 1408 6-CH3 CF 3 CH CH 2 -cycPr CH 3 1409 6-CH3 CF 3 CH 2 CH 2 -Ph CH 3 1410 6-CH3 CF 3 CH2CH2-2 -Pyridyl CH 3 1411 6-CH3 CF 3 CH 2 CH 2 -3 -Pyridyl CH 3 1412 6-CH3 CF 3 CH 2 CH 2 -4 -Pyridyl CH 3 1413 6-CH3 CF3 CH 2 CH 2 -2- furanyl CH 3 1414 6-CH3 CF 3 CH 2 CH 2 -3-furanyl CH 3 1415 6-CH3 CF 3 CH 2 CH 2 -2-thienyl CH 3 1416 6-CH3 CF 3 CH 2 CH 2 -3-thienyl CH 3 1417 6-COCH3 CF3 C≡C-cycPr H 1418 6-COCH3 CF 3 C≡C-Ph H 1419 6-COCH3 CF3 C≡C-2-Pyridyl H 1420 6-COCH3 CF3 C≡C-3-Pyridyl H 1421 6-COCH3 CF 3 C≡C-4-Pyridyl H 1422 6-COCH3 CF 3 C≡C-2-furanyl H 1423 6-COCH3 CF3 C≡C-3 -furanyl H 1424 6-COCH3 CF 3 C≡C-2-thienyl H 1425 6-COCH3 CF 3 C≡C-3-thienyl H 1426 6-COCH3 CF 3 C≡C-(l-CH 3 )cycPr H 1427 6-NH 2 CF 3 C≡C-cycPr H 1428 6-NH 2 CF 3 C≡C-Ph H 1429 6- H2 CF 3 C≡C-2-Pyridyl H 1430 6-NH 2 CF 3 C≡C-3 -Pyridyl H 1431 6-NH 2 CF 3 C≡C-4-Pyridyl H 1432 6-NH 2 CF3 C≡C-2-furanyl H 1433 6-NH 2 CF 3 C≡C-3 -furanyl H 1434 6-NH 2 CF 3 C≡C-2-thienyl H 1435 6- H2 CF3 C≡C-3 -thienyl H 76 1436 6-NH CF 3 C≡C-(l-CH 3 )cycPr H 1437 6-NMe 2 CF 3 C≡C-cycPr H 1438 6-NMe 2 CF 3 C≡C-Ph H 1439 6-N e 2 CF 3 C≡C-2 -Pyridyl H 1440 6- Me 2 CF 3 C≡C-3 -Pyridyl H 1441 6-NMe 2 CF 3 C≡C-4 -Pyridyl H 1442 6-NMe 2 CF 3 C≡C-2 -furanyl H 1443 6-NMe CF 3 C≡C-3 -furanyl H 1444 6-NMe CF 3 C≡C-2 -thienyl H 1445 6-NMe 2 CF 3 C≡C-3 -thienyl H 1446 6-NMe 2 CF 3 C≡C-(l-CH 3 )cycPr H 1447 7-C1 CF 3 C≡C-cycPr H 1448 7-C1 CF 3 C≡C-Ph H 1449 7-C1 CF 3 C≡C-2 -Pyridyl H 1450 7-C1 CF 3 C≡C-3 -Pyridyl H 1451 7-C1 CF 3 C≡C-4 -Pyridyl H 1452 7-C1 CF 3 C≡C-2 -furanyl H 1453 7-C1 CF 3 C≡C -3 -furanyl H 1454 7-C1 CF 3 C≡C-2 -thienyl H 1455 7-C1 CF 3 C≡C-3 -thienyl H 1456 7-C1 CF 3 C≡C-(l-CH 3 )cycPr H 1457 5,6-OCH 2 0- CF 3 C≡C-cycPr H 1458 5,6-OCH 2 0- CF 3 C≡CCH 2 CH 2 OH H 1459 5,6-OCH 2 0- CF 3 C≡C-CH(OH)Me H 1460 5,6-OCH 2 0- CF 3 C≡C-Ph H 1461 5,6-OCH 2 0- CF 3 C≡C-(2-Cl)Ph H 1462 5,6-OCH 2 0- CF 3 C≡C-(3-Cl)Ph H 1463 5,6-OCH 2 0- CF 3 C≡C-(4-Cl)Ph H 1464 5,6-0CH 2 O- CF 3 C≡C-(2-F)Ph H 1465 5,6-OCH 2 0- CF 3 C≡C-(3-F)Ph H 1466 5,6-OCH 2 0- CF 3 C≡C-(4-F)Ph H 1467 5,6-OCH 2 0- CF 3 C≡C-(2-OH)Ph H 1468 5, 6-OCH 2 0- CF 3 C≡C- (3 -OH) Ph H 1469 5,6-OCH 2 0- CF 3 C≡C-(4-OH)Ph H 77 1470 5, 6-OCH 2 0- CF3 C≡C-(2-OMe)Ph H 1471 5, 6-OCH 0- CF 3 C≡C-(3-OMe) Ph H 1472 5,6-OCH 2 0- CF 3 C≡C-(4-OMe)Ph H 1473 5, 6-OCH 2 0- CF3 C≡C-(2-CN)Ph H 1474 5, 6-OCH 2 0- CF 3 C≡C-(3-CN)Ph H 1475 5, 6-OCH 2 0- CF 3 C≡C-(4-CN)Ph H 1476 5,6-OCH 2 0- CF 3 C≡C-(2-N0 2 )Ph H 1477 5, 6-OCH 2 0- CF 3 C≡C- ( 3 -N0 2 ) Ph H 1478 5, 6-OCH 2 0- CF 3 C≡C-(4-N0 2 )Ph H 1479 5,6-OCH 2 0- CF 3 C≡C-(2-NH 2 )Ph H 1480 5,6-OCH 2 0- CF3 C≡C- ( 3 -NH 2 ) Ph H 1481 5,6-OCH 2 0- CF 3 C≡C-(4- H 2 )Ph H 1482 5,6-OCH 2 0- CF 3 C≡C-(2-NMe 2 )Ph H 1483 5,6-OCH 2 0- CF3 C≡C- ( 3 - Me 2 ) Ph H 1484 5,6-OCH 2 0- CF 3 C≡C-(4-NMe 2 )Ph H 1485 5,6-OCH 2 0- CF 3 C≡C-2 -Pyridyl H 1486 5,6-OCH 2 0- CF 3 C≡C-2 -Pyridyl H 1487 5,6-OCH 2 0- CF 3 C≡C-3 -Pyridyl H 1488 5,6-OCH 2 0- CF3 C≡C-4 -Pyridyl H 1489 5,6-OCH 2 0- CF 3 C≡C-2 -furanyl H 14-90 5,6-OCH 2 0- CF 3 C≡C-3 -furanyl H 1491 5,6-OCH 2 0- CF 3 C≡C-2 -thienyl H 1492 5,6-OCH 2 0- CF 3 C≡C-3 -thienyl H 1493 5,6-OCH 2 0- CF 3 C≡C-2 -oxazolyl H 1494 5,6-OCH 2 0- CF3 C≡C-2 -thiazolyl H 1495 5,6-OCH 2 0- CF 3 C≡C-4 - isoxazolyl H 1496 5,6-OCH 2 0- CF 3 C≡C-2 -imidazolyl H 1497 5,6-OCH 2 0- CF 3 C≡C-(l-CH3)cycPr H 1498 6-COCH3 CF 3 C=C-cycPr H 1499 6-COCH3 CF 3 C=C-Ph H 1500 6-COCH3 CF 3 C=C-2 -Pyridyl H 1501 6-COCH3 CF 3 C=C- 3 -Pyridyl H 1502 6-COCH3 CF 3 C=C-4 -Pyridyl H 1503 6-COCH3 CF 3 C=C-2- furanyl H 78 1504 6-COCH3 CF 3 C=C-3- furanyl H 1505 6-COCH3 CF 3 C=C-2 -thienyl H 1506 6-COCH3 CF 3 C=C-3 -thienyl H 1507 6-NH 2 CF 3 C=C-cycPr H 1508 6-NH 2 CF 3 C=C-Ph H 1509 6-NH 2 CF 3 C=C-2 -Pyridyl H 1510 6-NH CF 3 C=C-3 -Pyridyl H 1511 6-NH 2 CF 3 C=C-4 -Pyridyl H 1512 6-NH 2 CF 3 C=C-2- furanyl H 1513 6- H 2 CF 3 C=C-3- furanyl H 1514 6-NH 2 CF 3 C=C-2 -thienyl H 1515 6-NH 2 CF 3 C=C-3 -thienyl H 1516 6-NMe 2 CF 3 C=C-cycPr H 1517 6-NMe 2 CF 3 C=C-Ph H 1518 6-NMe 2 CF 3 C=C-2 -Pyridyl H 1519 6- Me 2 CF3 C=C-3 -Pyridyl H 1520 6-3SIMe 2 CF 3 C=C-4-Pyridyl H 1521 6-NMe 2 CF 3 C=C-2- furanyl H 1522 6-NMe 2 CF 3 C=C-3- furanyl H 1523 6-NMe 2 CF 3 C=C-2 -thienyl H 1524 6- Me 2 CF 3 C=C-3 -thienyl H 1525 7-C1 CF 3 C=C-cycPr H 1526 7-C1 CF 3 C=C-Ph H 1527 7-C1 CF 3 C=C-2 -Pyridyl H 1528 7-C1 CF 3 C=C-3 -Pyridyl H 1529 7-C1 CF 3 C=C-4-Pyridyl H 1530 7-C1 CF 3 C=C-2- furanyl H 1531 7-C1 CF 3 C=C-3- furanyl H 1532 7-C1 CF3 C=C-2 -thienyl H 1533 7-C1 CF 3 C=C-3 -thienyl H 1534 5,6-OCH 2 0- CF 3 C=C-cycPr H 1535 5,6-OCH 2 0- CF 3 C=CCH 2 CH 2 OH H 1536 5,6-OCH 2 0- CF 3 C=C-CH(OH)Me H 1537 5,6-OCH 2 0- CF 3 C=C-Ph H 79 1538 5, 6-OCH 0- CF 3 C=C-(2-Cl)Ph H 1539 5,6-OCH 2 0- CF 3 C=C-(3-Cl)Ph H 1540 5,6-OCH 2 0- CF 3 C=C-(4-Cl)Ph H 1541 5, 6-OCH 2 0- CF3 C=C-(2-F)Ph H 1542 5,6-OCH 2 0- CF 3 C=C-(3-F)Ph H 1543 5, 6-OCH 2 0- CF 3 C=C-(4-F)Ph H 1544 5,6-OCH 2 0- CF 3 C=C-(2-OH)Ph H 1545 5,6-OCH 0- CF 3 C=C-(3-OH)Ph H 1546 5,6-OCH 2 0- CF 3 C=C-(4-OH)Ph H 1547 5,6-OCH 2 0- CF 3 C=C-(2-OMe)Ph H 1548 5,6-OCH 2 0- CF 3 C=C-(3-OMe)Ph H 1549 5,6-OCH 2 0- CF 3 C=C-(4-OMe)Ph H 1550 5,6-OCH 2 0- CF 3 C=C-(2-CN)Ph H 1551 5,6-OCH 2 0- CF 3 C=C-(3-CN)Ph H 1552 5,6-OCH 2 0- CF 3 C=C-(4-CN)Ph H 1553 5,6-OCH 2 0- CF 3 C=C-(2-N0 2 )Ph H 1554 5,6-OCH 2 0- CF 3 C=C-(3-N0 2 )Ph H 1555 5,6-OCH 2 0- CF 3 C=C-(4-N0 2 )Ph H 1556 5,6-OCH 2 0- CF 3 C=C-(2- H 2 )Ph H 1557 5,6-OCH 2 0- CF 3 C=C-(3- H 2 )Ph H 1558 5,6-OCH 2 0- CF 3 C=C-(4-NH 2 )Ph H 1559 5,6-OCH 2 0- CF 3 C=C-(2-NMe 2 )Ph H 1560 5,6-OCH 2 0- CF 3 C=C-(3-NMe 2 )Ph H 1561 5,6-OCH 2 0- CF 3 C=C-(4-NMe )Ph H 1562 5,6-OCH 2 0- CF 3 C=C-2-Pyridyl H 1563 5,6-OCH 2 0- CF3 C=C-2-Pyridyl H 1564 5,6-OCH 2 0- CF 3 C=C-3-Pyridyl H 1565 5,6-OCH 2 0- CF3 C=C-4-Pyridyl H 1566 5,6-OCH 2 0- CF 3 C=C-2-furanyl H 1567 5,6-OCH 2 0- CF3 C=C-3-furanyl H 1568 5,6-OCH 2 0- CF3 C=C-2-thienyl H 1569 5,6-OCH 2 0- CF 3 C=C-3 -thienyl H 1570 5,6-OCH 2 0- CF 3 C=C-2-oxazolyl H 1571 5,6-OCH 2 0- CF 3 C=C-2-thiazolyl H 80 1572 5, 6-OCH 2 0- CF3 C=C-4- isoxazolyl H 1573 5,6-OCH 2 0- CF 3 C=C-2 -imidazolyl H 1574 5,6-OCH 2 0- CF 3 CH CH 2 -cycPr H 1575 5,6-OCH 2 0- CF 3 CH 2 CH 2 CH 2 CH 2 OH H 1576 5,6-OCH 2 0- CF 3 CH 2 CH 2 -CH(OH)Me H 1577 5,6-OCH 2 0- CF 3 CH 2 CH 2 Ph H 1578 5,6-OCH 2 0- CF 3 CH 2 CH -(2-Cl)Ph H 1579 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(3-Cl)Ph H 1580 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(4-Cl)Ph H 1581 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(2-F)Ph H 1582 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(3-F)Ph H 1583 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(4-F)Ph H 1584 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(2-OH)Ph H 1585 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(3-OH)Ph H 1586 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(4-OH)Ph H 1587 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(2-OMe)Ph H 1588 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(3-OMe)Ph H 1589 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(4-OMe)Ph H 1590 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(2-CN)Ph H 1591 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(3-CN)Ph H 1592 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(4-CN)Ph H 1593 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(2-N0 2 )Ph H 1594 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(3-N0 2 )Ph H 1595 5,6-OCH 2 0- CF 3 CH CH 2 -(4-N0 2 )Ph H 1596 5, 6-OCH 2 0- CF 3 CH 2 CH 2 -(2-NH 2 )Ph H 1597 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(3-NH 2 )Ph H 1598 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(4-NH 2 )Ph H 1599 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(2-NMe 2 )Ph H 1600 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(3-NMe 2 )Ph H 1601 5,6-OCH 2 0- CF 3 CH 2 CH 2 -(4-NMe 2 )Ph H 1602 5,6-OCH 2 0- CF 3 CH 2 CH 2 -2-Pyridyl H 1603 5,6-OCH 2 0- CF 3 CH 2 CH 2 -3 -Pyridyl H 1604 5,6-OCH 2 0- CF 3 CH 2 CH 2 -4-Pyridyl H 1605 5, 6-OCH2O- CF 3 CH 2 CH 2 -2 -furanyl H 1606 5,6-OCH 2 0- CF 3 CH 2 CH 2 -3-furanyl H 1607 5,6-OCH 2 0- CF 3 CH 2 CH 2 -2-thienyl H 1608 5,6-OCH 2 0- CF 3 CH 2 CH 2 -3-thienyl H 1609 5,6-0CH 2 O- CF 3 CH 2 CH2-2 -oxazolyl H 1610 5,6-OCH 2 0- CF 3 CH 2 CH 2 -2-thiazolyl H 1611 5,6-0CH 2 O- CF 3 CH 2 CH -4-isoxazolyl H 1612 5,6-OCH 2 0- CF 3 CH 2 CH 2 -2-imidazolyl H 1613 5, 6-OCH 2 0- CF 3 C≡C-cycPr CH 3 1614 5,6-OCH 2 0- CF 3 C≡C-Ph CH3 1615 5,6-OCH 2 0- CF 3 C≡C-2-Pyridyl CH3 1616 5,6-OCH 2 0- CF 3 C≡C-3 -Pyridyl CH 3 1617 5,6-OCH 2 0- CF 3 C≡C-4-Pyridyl CH3 1618 5,6-OCH 2 0- CF 3 C≡C-2-furanyl CH 3 1619 5,6-OCH 2 0- CF 3 C≡C-3-furanyl CH 3 1620 5,6-OCH 2 0- CF 3 C≡C-2-thienyl CH 3 1621 5,6-OCH 2 0- CF 3 C≡C-3-thienyl CH3 1622 5,6-OCH 2 0- CF 3 C≡C-(l-CH 3 )cycPr CH3 1623 5,6-OCH 2 0- CF 3 C=C-cycPr CH3 1624 5,6-OCH 2 0- CF3 C=C-Ph CH3 1625 5,6-0CH 2 O- CF 3 C=C-2-Pyridyl CH3 1626 5,6-OCH 2 0- CF 3 C=C-3 -Pyridyl CH3 1627 5,6-OCH0- CF 3 C=C-4-Pyridyl CH 3 1628 5,6-OCH 2 0- CF 3 C=C-2-furanyl CH 3 1629 5,6-OCH 2 0- CF 3 C=C-3-furanyl CH3 1630 5,6-0CH 2 O- CF 3 C=C-2-thienyl CH3 1631 5,6-0CH 2 O- CF 3 C=C-3 -thienyl CH3 1632 5,6-OCH 2 0- CF 3 CH 2 CH 2 -cycPr CH3 1633 5,6-OCH 2 0- CF 3 CHCH 2 -Ph CH3 1634 5,6-OCH 2 0- CF 3 CH 2 CH 2 -2-Pyridyl CH 3 1635 5,6-OCH 2 0- CF 3 CH 2 CH 2 -3 -Pyridyl CH3 1636 5,6-OCH 2 0- CF 3 CH 2 CH 2 -4-Pyridyl CH3 1637 5,6-OCH 2 0- CF 3 CH 2 CH -2-furanyl CH3 1638 5,6-OCH 2 0- CF 3 CH 2 CH 2 -3-furanyl CH 3 1639 5,6-OCH 2 0- CF 3 CH 2 CH 2 -2 -thienyl CH3 82 1640 5,6-OCH 2 0- CF 3 CH 2 CH 2 -3 -thienyl CH 3 1641 5,6-OCH 2 0- CF 3 C≡C-cycPr CH 2 CH 3 1642 5,6-OCH 2 0- CF 3 C≡C-Ph CH 2 CH 3 1643 5,6-OCH 2 0- CF 3 C≡C-2 -Pyridyl CH 2 CH 3 1644 5,6-OCH 2 0- CF 3 C≡C-3 -Pyridyl CH2CH3 1645 5,6-OCH 2 0- CF 3 C≡C-4 -Pyridyl CH 2 CH 3 1646 5,6-OCH 2 0- CF 3 C≡C-2 -furanyl CH2CH3 1647 5,6-OCH 2 0- CF C≡C-3 -furanyl CH 2 CH 3 1648 5,6-OCH 2 0- CF 3 C≡C-2 -thienyl CH2CH3 1649 5,6-OCH 2 0- CF 3 C≡C-3 -thienyl CH2CH3 1650 5,6-OCH 2 0- CF C≡C-(l-CH 3 )cycPr CH 2 CH 3 1651 5,6-OCH 2 0- CF 3 C=C-cycPr CH 2 CH 3 1652 5,6-OCH 2 0- CF 3 C=C-Ph CH 2 CH 3 1653 5, 6-OCH 2 0- CF 3 C=C-2 -Pyridyl CH2CH3 1654 5,6-OCH 2 0- CF 3 C=C-3 -Pyridyl CH 2 CH 3 1655 5,6-OCH 2 0- CF 3 C=C-4 -Pyridyl CH2CH3 1656 5,6-OCH 2 0- CF 3 C=C-2- furanyl CH2CH3 1657 5,6-OCH 2 0- CF 3 C=C-3 - furanyl CH2CH3 1658 5,6-OCH 2 0- CF 3 C=C-2-thienyl CH 2 CH 3 1659 5,6-OCH 2 0- CF 3 C=C-3 -thienyl CH2CH3 1660 5,6-OCH 2 0- CF 3 CH 2 CH -cycPr CH2CH3 1661 5,6-OCH 2 0- CF CH 2 CH 2 -Ph CH2CH3 1662 5,6-OCH 2 0- CF 3 CH 2 CH 2 -2 -Pyridyl CH2CH3 1663 5,6-OCH 2 0- CF 3 CH 2 CH 2 -3 -Pyridyl CH 2 CH 3 1664 5,6-OCH 2 0- CF 3 CH 2 CH 2 -4 -Pyridyl CH2CH3 1665 5,6-OCH 2 0- CF 3 CH 2 CH 2 -2- furanyl CH2CH3 1666 5,6-OCH 2 0- CF 3 CH 2 CH 2 -3 -furanyl CH2CH3 1667 5,6-OCH 2 0- CF 3 CH CH 2 -2 -thienyl CH2CH3 1668 5,6-OCH 2 0- CF 3 CH 2 CH 2 -3 -thienyl CH 2 CH 3 *Unless otherwise indicated, stereochemisty is (+/- ) Table 3* H Ex. # R3 R l R2 R8 1 6-C1 CF 3 C≡C-Pr H 2 6-C1 CF 3 C≡C-Bu H 3 6-C1 CF 3 C≡C-iBu H 4 6-C1 CF 3 C≡C-tBu H 5 6-C1 CF 3 C≡C-Me H 6 6-C1 CF 3 CH 2 CH 2 CH 2 CH 2 CH 3 H 7 6-C1 CF 3 CH 2 CH 2 CH(CH 3 ) 2 H 8 6-C1 CF 3 CH 2 CH 2 CH 2 CH 3 H 9 6-C1 CF 3 CH 2 CH 2 CH 3 H 10 6-C1 CF 3 CH 2 CH 2 -tBu H 11 6-C1 CF 3 CH 2 C≡C-CH 3 H 12 6-C1 CF 3 CH 2 C≡C-CH 2 CH3 H 13 6-C1 CF 3 C≡C-iPr CH 3 14 6-C1 CF 3 C≡C-Pr CH 3 15 6-C1 CF 3 C≡C-Bu CH 3 16 6-C1 CF 3 C≡C-iBu CH 3 17 6-C1 CF 3 C≡C-tBu CH 3 18 6-C1 CF 3 C≡C-Et CH 3 19 6-C1 CF 3 C≡C-Me CH 3 20 6-C1 CF 3 CH 2 C≡C-CH 3 CH 3 21 6-C1 CF 3 CH 2 C≡C-CH 2 CH 3 CH 3 22 6-C1 CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH 3 23 6-C1 CF 3 CH 2 CH 2 CH 2 CH 3 CH 3 24 6-C1 CF 3 CH 2 CH 2 CH 3 CH 3 25 6-C1 CF 3 CH 2 CH 2 -tBu CH 3 26 6-C1 CF 3 C≡C-iPr CH 2 CH 3 27 6-C1 CF 3 C≡C-Pr CH 2 CH 3 28 6-C1 CF 3 C≡C-Bu CH 2 CH 3 84 6-C1 CF 3 C≡C-iBu CH 2 CH 3 6-C1 CF 3 C≡C-tBu CH 2 CH 3 6-C1 CF 3 C≡C-Et CH 2 CH 3 6-C1 CF 3 C≡C -Me CH2CH3 6-C1 CF 3 CH 2 C≡C-CH CH 2 CH 3 6-C1 CF 3 CH 2 C≡C-CH 2 CH 3 CH 2 CH 3 6-C1 CF 3 CH 2 CH 2 CH(CH3) 2 CH 2 CH 3 6-C1 CF 3 CH2CH2CH2CH3 CH 2 CH 3 6-C1 CF 3 CH 2 CH 2 CH 3 CH 2 CH 3 6-C1 CF 3 CH 2 CH 2 -tBu CH 2 CH 3 6-MeO CF 3 C≡C-Pr H 6-MeO CF 3 C≡C-Bu H 6-MeO CF 3 C≡C-iBu H 6-MeO CF 3 C≡C-tBu H 6-MeO CF 3 C≡C-Et H 6-MeO CF 3 C≡C-Me H 6-MeO CF 3 CH 2 C≡C-CH 3 H 6-MeO CF 3 CH 2 C≡C-CH 2 CH 3 H 6-MeO CF 3 CH 2 CH 2 CH 2 CH 2 CH 3 H 6-MeO CF 3 CH 2 CH 2 CH(CH 3 ) 2 H 6-MeO CF 3 CH 2 CH 2 CH 2 CH 3 H 6-MeO CF 3 CH 2 CH 2 CH 3 H 6-MeO CF 3 CH 2 CH 2 -tBu H 6-MeO CF 3 CH 2 C≡C-CH 3 H 6-MeO CF 3 CH 2 C≡C-CH 2 CH3 H 6-MeO CF 3 C≡C-iPr CH3 6-MeO CF 3 C≡C-Pr CH 3 6-MeO CF 3 C≡C-Bu CH3 6-MeO CF 3 C≡C-iBu CH3 6-MeO CF 3 C≡C-tBu CH 3 6-MeO CF 3 C≡C-Et CH3 6-MeO CF 3 C≡C-Me CH3 6-MeO CF 3 CH 2 C≡C-CH 3 CH3 6-MeO CF 3 CH 2 C≡C-CH 2 CH3 CH3 6-MeO CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH 3 6-MeO CF 3 CH 2 CH 2 CH 2 CH 3 CH 3 6-MeO CF 3 CH 2 CH CH 3 CH 3 6-MeO CF 3 CH CH 2 -tBu CH 3 6-MeO CF 3 C≡C-iPr CH 2 CH 3 6-MeO CF 3 C≡C-Pr CH 2 CH 3 6-MeO CF 3 C≡C-Bu CH CH 3 6-MeO CF 3 C≡C-iBu CH 2 CH 3 6-MeO CF 3 C≡C-tBu CH 2 CH 3 6-MeO CF 3 C≡C-Et CH 2 CH 3 6-MeO CF 3 C≡C-Me CH2CH3 6-MeO CF 3 CH 2 C≡C-CH 3 CH 2 CH 3 6-MeO CF 3 CH 2 C≡C-CH 2 CH 3 CH 2 CH 3 6-MeO CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH 2 CH 3 6-MeO CF 3 CH 2 CH 2 CH 2 CH 3 CH 2 CH 3 6-MeO CF 3 CH 2 CH 2 CH 3 CH 2 CH 3 6-MeO CF 3 CH CH 2 -tBu CH CH 3 5,6-diF CF 3 C≡C-Pr H 5,6-diF CF 3 C≡C-Bu H 5,6-diF CF 3 C≡C-iBu H 5,6-diF CF 3 C≡C-tBu H 5,6-diF CF 3 C≡C-Me H 5,6-diF CF 3 CH 2 C≡C-CH 3 H 5,6-diF CF 3 CH 2 C≡C-CH 2 CH 3 H 5,6-diF CF 3 CH 2 CH 2 CH 2 CH 2 CH 3 H 5,6-diF CF 3 CH 2 CH 2 CH 3 H 5,6-diF CF 3 CH 2 CH 2 -tBu H 5,6-diF CF 3 C≡C-iPr CH3 5,6-diF CF 3 C≡C-Pr CH3 5,6-diF CF 3 C≡C-Bu CH3 5,6-diF CF 3 C≡C-iBu CH3 5,6-diF CF 3 C≡C-tBu CH 3 5,6-diF CF 3 C≡C-Et CH3 5,6-diF CF 3 C≡C-Me CH3 86 97 5,6-diF CF 3 C≡C-Ph CH3 98 5,6-diF CF 3 CH 2 C≡C-CH 3 CH3 99 5,6-diF CF 3 CH2C≡C-CH CH CH3 100 5,6-diF CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH3 101 5,6-diF CF 3 CH 2 CH 2 CH CH 3 CH3 102 5,6-diF CF 3 CH 2 CH 2 CH 3 CH3 103 5,6-diF CF 3 CH 2 CH 2 -tBu CH3 104 5,6-diF CF 3 C≡C-iPr CH2CH3 105 5,6-diF CF 3 C≡C-Pr CH 2 CH 3 106 5,6-diF CF 3 C≡C-Bu CH CH 3 107 5,6-diF CF 3 C≡C-iBu CH 2 CH 3 108 5,6-diF CF 3 C≡C-tBu CH 2 CH 3 109 5,6-diF CF 3 C≡C-Et CH 2 CH 3 110 5,6-diF CF 3 C≡C-Me CH 2 CH 3 111 5,6-diF CF 3 CH 2 C≡C-CH 3 CH 2 CH 3 112 5,6-diF CF 3 CH 2 C≡C-CH 2 CH 3 CH 2 CH 3 113 5,6-diF CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH 2 CH 3 114 5,6-diF CF 3 CH 2 CH 2 CH 2 CH 3 CH 2 CH 3 115 5,6-diF CF 3 CH 2 CH 2 CH 3 CH 2 CH 3 116 5,6-diF CF 3 CH 2 CH 2 -tBu CH 2 CH 3 117 6-F CF 3 C≡C-Pr H 118 6-F CF 3 C≡C-Bu H 119 6-F CF 3 C≡C-iBu H 120 6-F CF 3 C≡C-tBu H 121 6-F CF 3 C≡C-Me H 122 6-F CF 3 CH 2 C≡C-CH 2 CH3 H 123 6-F CF 3 CH2CH2CH2CH2CH3 H 124 6-F CF 3 CH 2 CH 2 CH 3 H 125 6-F CF 3 CH 2 CH 2 -tBu H 126 6-F CF 3 C≡C-iPr CH3 127 6-F CF 3 C≡C-Pr CH3 128 6-F CF 3 C≡C-Bu CH3 129 6-F CF 3 C≡C-iBu CH3 130 6-F CF 3 C≡C-tBu CH3 87 131 6-F CF 3 C≡C-Et CH3 132 6-F CF 3 C≡C-Me CH3 133 6-F CF 3 CH C≡C-CH 3 CH3 134 6-F CF 3 CH 2 C≡C-CH 2 CH 3 CH3 135 6-F CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH3 136 6-F CF 3 CH 2 CH 2 CH 2 CH 3 CH3 137 6-F CF 3 CH 2 CH 2 CH 3 CH3 138 6-F CF 3 CH 2 CH 2 -tBu CH3 139 6-F CF 3 C≡C-iPr CH2CH3 140 6-F CF 3 C≡C-Pr CH2CH3 141 6-F CF 3 C≡C-Bu CH 2 CH 3 142 6-F CF 3 C≡C-iBu CH 2 CH 3 143 6-F CF 3 C≡C-tBu CH 2 CH 3 144 6-F CF 3 C≡C-Et CH 2 CH 3 145 6-F CF 3 C≡C-Me CH2CH3 146 6-F CF 3 CH C≡C-CH 3 CH2CH3 147 6-F CF 3 CH 2 C≡C-CH 2 CH3 CH2CH3 148 6-F CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH2CH3 149 6-F CF 3 CH 2 CH 2 CH 2 CH 3 CH2CH3 150 6-F CF 3 CH 2 CH 2 CH 3 CH2CH3 151 6-F CF 3 CH 2 CH 2 -tBu CH 2 CH 3 152 5-C1 CF 3 C≡C-iPr H 153 5-C1 CF 3 C≡C-Pr H 154 5-C1 CF 3 C≡C-Bu H 155 5-C1 CF 3 C≡C-iBu H 156 5-C1 CF 3 C≡C-tBu H 157 5-C1 CF 3 C≡C-Et H 158 5-C1 CF 3 C≡C-Me H 159 5-C1 CF 3 CH 2 C≡C-CH 3 H 160 5-C1 CF 3 CH 2 C≡C-CH 2 CH 3 H 161 5-C1 CF 3 CH 2 CH CH CH 2 CH 3 H 162 5-C1 CF 3 CH 2 CH 2 CH(CH 3 ) 2 H 163 5-C1 CF 3 CH 2 CH 2 CH 2 CH 3 H 164 5-C1 CF 3 CH 2 CH 2 CH 3 H 88 165 5-C1 CF 3 CH 2 CH 2 -tBu H 166 5-C1 CF 3 C≡C-iPr CH3 167 5-C1 CF 3 C≡C-Pr CH3 168 5-C1 CF 3 C≡C-Bu CH3 169 5-C1 CF 3 C≡C-iBu CH3 170 5-C1 CF 3 C≡C-tBu CH 3 171 5-C1 CF 3 C≡C-Et CH3 172 5-C1 CF 3 C≡C-Me CH3 173 5-C1 CF 3 CH C≡C-CH 3 CH3 174 5-C1 CF 3 CH 2 C≡C-CH 2 CH 3 CH3 175 5-C1 CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH3 176 5-C1 CF 3 CH 2 CH 2 CH 2 CH 3 CH3 177 5-C1 CF 3 CH 2 CH 2 CH 3 CH3 178 5-C1 CF 3 CH 2 CH 2 -tBu CH3 179 5-C1 CF 3 C≡C-iPr CH 2 CH 3 180 5-C1 CF 3 C≡C-Pr CH 2 CH 3 181 5-C1 CF 3 C≡C-Bu CH 2 CH 3 182 5-C1 CF 3 C≡C-iBu CH2CH3 183 5-C1 CF 3 C≡C-tBu CH2CH3 184 5-C1 CF 3 C≡C-Et CH2CH3 185 5-C1 CF 3 C≡C-Me CH 2 CH 3 186 5-C1 CF 3 CH 2 C≡C-CH 3 CH 2 CH 3 187 5-C1 CF 3 CH 2 C≡C-CH 2 CH 3 CH 2 CH 3 188 5-C1 CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH 2 CH 3 189 5-C1 CF 3 CH2CH2CH2CH3 CH 2 CH 3 190 5-C1 CF 3 CH 2 CH 2 CH 3 CH 2 CH 3 191 5-C1 CF 3 CH 2 CH 2 -tBu CH 2 CH 3 192 5-F CF 3 C≡C-iPr H 193 5-F CF 3 C≡C-Pr H 194 5-F CF 3 C≡C-Bu H 195 5-F CF 3 C≡C-iBu H 196 5-F CF 3 C≡C-tBu H 197 5-F CF 3 C≡C-Et H 198 5-F CF 3 C≡C-Me H 89 199 5-F CF 3 CH 2 C≡C-CH 3 H 200 5-F CF 3 CH 2 C≡C-CH 2 CH 3 H 201 5-F CF 3 CH 2 CH 2 CH 2 CH 2 CH 3 H 202 5-F CF 3 CH 2 CH 2 CH(CH 3 ) 2 H 203 5-F CF 3 CH 2 CH 2 CH 2 CH3 H 204 5-F CF 3 CH 2 CH 2 CH 3 H 205 5-F CF 3 CH 2 CH 2 -tBu H 206 5-F CF 3 C≡C-iPr CH 3 207 5-F CF 3 C≡C-Pr CH 3 208 5-F CF 3 C≡C-Bu CH 3 209 5-F CF 3 C≡C-iBu CH 3 210 5-F CF 3 C≡C-tBu CH 3 211 5-F CF 3 C≡C-Et CH 3 212 5-F CF 3 C≡C-Me CH 3 213 5-F CF 3 CH 2 C≡C-CH 3 CH 3 214 5-F CF 3 CH 2 C≡C-CH 2 CH 3 CH 3 215 5-F CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH 3 216 5-F CF 3 CH 2 CH 2 CH 2 CH 3 CH 3 217 5-F CF 3 CH 2 CH 2 CH 3 CH 3 218 5-F CF 3 CH 2 CH 2 -tBu CH 3 219 5-F CF 3 C≡C-iPr CH 2 CH 3 220 5-F CF 3 C≡C-Pr CH 2 CH 3 221 5-F CF 3 C≡C-Bu CH2CH3 222 5-F CF 3 C≡C-iBu CH 2 CH 3 223 5-F CF 3 C≡C-tBu CH 2 CH 3 224 5-F CF 3 C≡C-Et CH 2 CH 3 225 5-F CF 3 C≡C-Me CH 2 CH 3 226 5-F CF 3 CH 2 C≡C-CH 3 CH CH 3 227 5-F CF 3 CH 2 C≡C-CH 2 CH 3 CH 2 CH 3 228 5-F CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH 2 CH 3 229 5-F CF 3 CH 2 CH 2 CH 2 CH 3 CH2CH3 230 5-F CF 3 CH 2 CH 2 CH 3 CH2CH3 231 5-F CF 3 CH 2 CH 2 -tBu CH2CH3 232 5-Cl,6-F CF 3 C≡C-iPr H 90 ro vo o\ H υ 0. a a u a U U U U U U U U U U u a u a ro a ro ro u β ro a a ro β H a a ro u a β β u u CN a a u a CM a 40 Φ a u CN a a u 40 β aβ 40 Φ u a a υ a u 40 β a u 40 Φ u I a I a I £i u a I a a £ 1 a u I ua u CM I CM CN I a I £ I u a a a u •H a PQ • a 40 1 1 u CN a I x X CN u (N u u a u a I I I H a a I I y I u Xu x u C.J u u u Xu & CN x a u u CN £ U U u u trj Uu u V u V III u iii au CN ua u u CN ua a u u a u a a u u u u u a u au ua au a u u a a u u u a u ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro a a a a a a a a a a a CH a a a U U U U u U u U u u u u U u U U u a a a a a υ u u u U U U U u u u u u u u u U | CH 1 1 f 1 | 1 1 1 1 1 | 1 1 1 | 1 a | | C 1 | H a | | | VD VD VD VD VD VD VD vo vo vo VD o VO VD VD vo VD vo vo vo vo VD VD D VD 00 00 CO 00 00 00 00 00 CO rH rH rH rH rH rH rH rH rH rH rH rH rH rH rH rH rH rH rH H rH rH rH rH rH rH rH rH rH rH rH rH rH rH u u u u u U υ u U U U U U | U u u U u U U U u 1 u 1 u u U u υ u u u u u υ L0 in LO in in LO LO LO in LO LO LO LO LO in in LO in in in in in LO LO LO vo vo vo vo vo o VO vo VO ro «Λ © «Λ ro in VD r- 00 cn o rH CN ro >* in VO 00 en o rH CN ro • < LO vo r oo <Tl o rH CN ro LO VO CO ro ro ro ro •<* LO LO in in LO in LO in in in VO VO VO vo vo vo vo CN CN CN CN CN CN CM CN CN CN CN CN CN CN CN N CN CN CN N CN CN CN CN CN CN CN CN CN CN CN CN CN CN O 267 6- -Cl,8-F CF 3 CH 2 CH 2 CH(CH 3 )2 H 268 6- -Cl,8-F CF 3 CH 2 CH 2 CH 2 CH 3 H 269 6- -Cl,8-F CF 3 CH 2 CH 2 CH 3 H 270 6- -Cl, 8-F CF 3 CH 2 CH -tBu H 271 6- -Cl, 8-F CF 3 C≡C-iPr CH3 272 6- -Cl,8-F CF 3 C≡C-Pr CH3 273 6- -Cl,8-F CF 3 C≡C-Bu CH3 274 6- -Cl,8-F CF 3 C≡C-iBu CH3 275 6- -Cl,8-F CF 3 C≡C-tBu CH3 276 6- -Cl,8-F CF 3 C≡C-Et CH3 277 6- -Cl,8-F CF 3 C≡C-Me CH3 278 6- -Cl,8-F CF 3 CH 2 C≡C-CH 3 CH3 279 6 -Cl, 8-F CF 3 CH 2 C≡C-CH 2 CH 3 CH3 280 6 -Cl,8-F CF 3 CH 2 CH 2 CH(CH3)2 CH3 281 6 -Cl,8-F CF 3 CH 2 CH 2 CH 2 CH3 CH3 282 6 -Cl,8-F CF 3 CH 2 CH 2 CH 3 CH3 283 6 -Cl,8-F CF 3 CH CH 2 -tBu CH3 284 6-CH3 CF 3 C≡C-iPr H 285 6-CH3 CF 3 C≡C-Pr H 286 6-CH3 CF 3 C≡C-Bu H 287 6-CH3 CF 3 C≡C-iBu H 288 6-CH3 CF 3 C≡C-tBu H 289 6-CH3 CF 3 C≡C-Et H 290 6-CH3 CF 3 C≡C-Me H 291 6-CH3 CF 3 CH 2 C≡C-CH3 H 292 6-CH3 CF 3 CH 2 C≡C-CH 2 CH 3 H 293 6-CH3 CF 3 CH 2 CH 2 CH(CH3)2 H 294 6-CH3 CF 3 CH 2 CH 2 CH 2 CH 3 H 295 6-CH3 CF 3 CH CH 2 CH 3 H 296 6-CH3 CF 3 CH 2 CH 2 -tBu H 297 6-CH3 CF 3 C≡C-iPr CH3 298 6-CH3 CF3 C≡C-Pr CH3 299 6-CH3 CF 3 C≡C-Bu CH3 300 6-CH3 CF3 C≡C-iBu CH 3 92 301 6-CH3 CF 3 C≡C-tBu CH 3 302 6-CH3 CF 3 C≡C-Et CH 3 303 6-CH3 CF 3 C≡C-Me CH 3 304 6-CH3 CF 3 CH 2 C≡C-CH 3 CH3 305 6-CH3 CF 3 CH 2 C≡C-CH 2 CH 3 CH 3 306 6-CH3 CF 3 CH 2 CH 2 CH(CH 3 ) 2 CH 3 307 6-CH3 CF 3 CH 2 CH 2 CH CH 3 CH 3 308 6-CH3 CF 3 CH 2 CH 2 CH 3 CH 3 309 6-CH3 CF 3 CH 2 CH -tBu CH 3 310 6-COCH3 CF 3 C≡C-iPr H 311 6-COCH3 CF 3 C≡C-Pr H 312 6-COCH3 CF 3 C≡C-Bu H 313 6-COCH3 CF 3 C≡C-iBu H 314 6-COCH3 CF 3 C≡C-tBu H 315 6-COCH3 CF 3 C≡C-Et H 316 6-COCH3 CF 3 C≡C-Me H 317 6-NH 2 CF3 C≡C-iPr H 318 6-NH CF 3 C≡C-Pr H 319 6-NH 2 CF3 C≡C-Bu H 320 6-NH 2 CF 3 C≡C-iBu H 321 6-NH 2 CF 3 C≡C-tBu H 322 6-NH 2 CF3 C≡C-Et H 323 6-NH 2 CF 3 C≡C-Me H 324 6-NMe 2 CF 3 C≡C-iPr H 325 6- Me CF 3 C≡C-Pr H 326 6- Me 2 CF 3 C≡C-Bu H 327 6-NMe 2 CF 3 C≡C-iBu H 328 6- Me 2 CF3 C≡C-tBu H 329 6-NMe 2 CF 3 C≡C-Et H 330 6-NMe 2 CF 3 C≡C-Me H 331 7-C1 CF 3 C≡C-iPr H 332 7-C1 CF 3 C≡C-Pr H 333 7-C1 CF 3 C≡C-Bu H 334 7-C1 CF 3 C≡C-iBu H 93 335 7-C1 CF 3 C≡C-tBu H 336 7-C1 CF 3 C≡C-Et H 337 7-C1 CF 3 C≡C-Me H *Unless otherwise indicated, stereochemisty is (+/-) 94 Utility The compounds of this invention possess reverse transcriptase inhibitory activity, in particular, HIV inhibitory efficacy. The compounds of formula (I) possess HIV reverse transcriptase inhibitory activity and are therefore useful as antiviral agents for the treatment of HIV infection and associated diseases. The compounds of formula (I) possess HIV reverse transcriptase inhibitory activity and are effective as inhibitors of HIV growth. The ability of the compounds of the present invention to inhibit viral growth or infectivity is demonstrated in standard assay of viral growth or infectivity, for example, using the assay described below. The compounds of formula (I) of the present invention are also useful for the inhibition of HIV in an ex vivo sample containing HIV or expected to be exposed to HIV. Thus, the compounds of the present invention may be used to inhibit HIV present in a body fluid sample (for example, a serum or semen sample) which contains or is suspected to contain or be exposed to HIV. The compounds provided by this invention are also useful as standard or reference compounds for use in tests or assays for determining the ability of an agent to inhibit viral clone replication and/or HIV reverse transcriptase, for example in a pharmaceutical research program. Thus, the compounds of the present invention may be used as a control or reference compound in such assays and as a quality control standard. The compounds of the present invention may be provided in a commercial kit or container for use as such standard or reference compound. Since the compounds of the present invention exhibit specificity for HIV reverse transcriptase, the compounds of the present invention may also be useful as diagnostic reagents in diagnostic assays for the detection of HIV reverse transcriptase. Thus, inhibition of the reverse transcriptase activity in an assay (such as the assays described herein) by a compound of the present invention would be indicative of the presence of HIV reverse transcriptase and HIV virus . 95 As used herein "μg" denotes microgram, "mg" denotes milligram, "g" denotes gram, "μL" denotes microliter, "mL" denotes milliliter, "L" denotes liter, "nM" denotes nanomolar, "μM" denotes micromolar, "mM" denotes millimolar, "M" denotes molar and "nm" denotes nanometer. "Sigma" stands for the Sigma-Aldrich Corp. of St. Louis, MO. HIV RNA Assay DNA Plasmids and in vi tro RNA transcripts; Plasmid pDAB 72 containing both gag and pol sequences of BH10 (bp 113-1816) cloned into PTZ 19R was prepared according to Erickson-Viitanen et al . AIDS Research and Human Retroviruses 1989, 5, 577. The plasmid was linearized with Bam HI prior to the generation of in vi tro RNA transcripts using the Riboprobe Gemini system II kit (Promega) with T7 RNA polymerase. Synthesized RNA was purified by treatment with RNase free DNAse (Promega) , phenol-chloroform extraction, and ethanol precipitation. RNA transcripts were dissolved in water, and stored at -70°C. The concentration of RNA was determined from the A260- Probes ; Biotinylated capture probes were purified by HPLC after synthesis on an Applied Biosystems (Foster City, CA) DNA synthesizer by addition of biotin to the 5' terminal end of the oligonucleotide, using the biotin-phosphoramidite reagent of Cocuzza, Tet. Lett. 1989, 30, 6287. The gag biotinylated capture probe (5-biotin-CTAGCTCCCTGCTTGCCCATACTA 3') was complementary to nucleotides 889-912 of HXB2 and the pol biotinylated capture probe (5 '-biotin -CCCTATCATTTTTGGTTTCCAT 3' ) was complementary to nucleotides 2374-2395 of HXB2. Alkaline phosphatase conjugated oligonucleotides used as reporter probes were prepared by Syngene (San Diego, CA. ) . The pol reporter probe (5' CTGTCTTACTTTGATAAAACCTC 3') was complementary to nucleotides 2403-2425 of HXB2. The gag reporter probe ( 5 ' CCCAGTATTTGTCTACAGCCTTCT 3 ' ) was complementary to nucleotides 950-973 of HXB2. All nucleotide positions are those of the GenBank Genetic Sequence Data Bank 96 as accessed through the Genetics Computer Group Sequence Analysis Software Package (Devereau Nucleic Acids Research 1984, 12 , 387) . The reporter probes were prepared as 0.5 μM stocks in 2 x SSC (0.3 M NaCl, 0.03 M sodium citrate), 0.05 M Tris pH 8.8, 1 mg/mL BSA. The biotinylated capture probes were prepared as 100 μM stocks in water. Streptavidin coated plates: Streptavidin coated plates were obtained from Du Pont Biotechnology Systems (Boston, MA) . Cells and virus stocks; MT-2 and MT-4 cells were maintained in RPMI 1640 supplemented with 5% fetal calf serum (FCS) for MT-2 cells or 10% FCS for MT-4 cells, 2 mM -glutamine and 50 μg/mL gentamycin, all from Gibco. HIV-1 RF was propagated in MT-4 cells in the same medium. Virus stocks were prepared approximately 10 days after acute infection of MT-4 cells and stored as aliquots at -70°C. Infectious titers of HIV-1 (RF) stocks were 1-3 x 10 " ? PFU (plaque forming units) /mL as measured by plaque assay on MT-2 cells (see below) . Each aliquot of virus stock used for infection was thawed only once. For evaluation of antiviral efficacy, cells to be infected were subcultured one day prior to infection. On the day of infection, cells were resuspended at 5 x 10^ cells/mL in RPMI 1640, 5% FCS for bulk infections or at 2 x 10 6 /mL in Dulbecco ' s modified Eagles medium with 5% FCS for infection in microtiter plates . Virus was added and culture continued for 3 days at 37°C. HIV RNA assay; Cell lysates or purified RNA in 3 M or 5 M GED were mixed with 5 M GED and capture probe to a final guanidinium isothiocyanate concentration of 3 M and a final biotin oligonucleotide concentration of 30 hM. Hybridization was carried out in sealed U bottom 96 well tissue culture plates (Nunc or Costar) for 16-20 hours at 37°C. RNA hybridization 97 reactions were diluted three-fold with deionized water to a final guanidinium isothiocyanate concentration of 1 M and aliquots (150 μL) were transferred to streptavidin coated microtiter plates wells. Binding of capture probe and capture probe-RNA hybrid to the immobilized streptavidin was allowed to proceed for 2 hours at room temperature, after which the plates were washed 6 times with DuPont ELISA plate wash buffer (phosphate buffered saline(PBS), 0.05% Tween 20.) A second hybridization of reporter probe to the immobilized complex of capture probe and hybridized target RNA was carried out in the washed streptavidin coated well by addition of 120 μl of a hybridization cocktail containing 4 X SSC, 0.66% Triton X 100, 6.66% deionized formamide, 1 mg/mL BSA and 5 nM reporter probe. After hybridization for one hour at 37 C, the plate was again washed 6 times. Immobilized alkaline phosphatase activity was detected by addition of 100 μL of 0.2 mM 4- methylumbelliferyl phosphate (MUBP, JBL Scientific) in buffer δ (2.5 M diethanola ine pH 8.9 (JBL Scientific), 10 mM MgCl2, 5 mM zinc acetate dihydrate and 5 mM W-hydroxyethyl-ethylene- diamine-triacetic acid). The plates were incubated at 37°C. Fluorescence at 450 hM was measured using a microplate fluorometer (Dynateck) exciting at 365 nM. Microplate based compound evaluation in HIV-1 infected MT-2 cells; Compounds to be evaluated were dissolved in DMSO and diluted in culture medium to twice the highest concentration to be tested and a maximum DMSO concentration of 2%. Further three-fold serial dilutions of the compound in culture medium were performed directly in U bottom microtiter plates (Nunc) . After compound dilution, MT-2 cells (50 μL) were added to a final concentration of 5 x 10^ per mL (1 x 10^ per well) . Cells were incubated with compounds for 30 minutes at 37°C in a Cθ2 incubator. For evaluation of antiviral potency, an appropriate dilution of HIV-1 (RF) virus stock (50 μL) was added to culture wells containing cells and dilutions of the test compounds. The final volume in each well was 200 μL. Eight wells per plate were left uninfected with 50 μL of 98 medium added in place of virus, while eight wells were infected in the absence of any antiviral compound. For evaluation of compound toxicity, parallel plates were cultured without virus infection. After 3 days of culture at 37°C in a humidified chamber inside a CO2 incubator, all but 25 μL of medium/well was removed from the HIV infected plates. Thirty seven μL of 5 M GED containing biotinylated capture probe was added to the settled cells and remaining medium in each well to a final concentration of 3 M GED and 30 nM capture probe. Hybridization of the capture probe to HIV RNA in the cell lysate was carried out in the same microplate well used for virus culture by sealing the plate with a plate sealer (Costar) , and incubating for 16-20 hrs in a 37°C incubator. Distilled water was then added to each well to dilute the hybridization reaction three-fold and 150 μL of this diluted mixture was transferred to a streptavidin coated microtiter plate. HIV RNA was quantitated as described above. A standard curve, prepared by adding known amounts of pDAB 72 in vitro RNA transcript to wells containing lysed uninfected cells, was run on each microtiter plate in order to determine the amount of viral RNA made during the infection. In order to standardize the virus inoculum used in the evaluation of compounds for antiviral activity, dilutions of virus were selected which resulted in an IC90 value (concentration of compound required to reduce the HIV RNA level by 90%) for dideoxycytidine (ddC) of 0.2 μg/mL. IC90 values of other antiviral compounds, both more and less potent than ddC, were reproducible using several stocks of HIV-1 (RF) when this procedure was followed. This concentration of virus corresponded to ~3 x 10^ PFU (measured by plaque assay on MT-2 cells) per assay well and typically produced approximately 75% of the maximum viral RNA level achievable at any virus inoculum. For the HIV RNA assay, IC90 values were determined from the percent reduction of net signal (signal from infected cell samples minus signal from uninfected cell samples) in the RNA assay relative to the net signal from infected, untreated cells on the same culture plate (average of eight wells) . 99 Valid performance of individual infection and RNA assay tests was judged according to three criteria. It was required that the virus infection should result in an RNA assay signal equal to or greater than the signal generated from 2 ng of pDAB 72 in vi tro RNA transcript. The IC90 for ddC, determined in each assay run, should be between 0.1 and 0.3 μg/mL. Finally, the plateau level of viral RNA produced by an effective reverse transcriptase inhibitor should be less than 10% of the level achieved in an uninhibited infection. A compound was considered active if its IC 90 was found to be less than 20μM. For antiviral potency tests, all manipulations in microtiter plates, following the initial addition of 2X concentrated compound solution to a single row of wells, were performed using a Perkin Elmer/Cetus ProPette. Protein Binding and Mutant Resistance In order to characterize NNRTI analogs for their clinical efficacy potential the effect of plasma proteins on antiviral potency and measurements of antiviral potency against wild type and mutant variants of HIV which carry amino acid changes in the known binding site for NNRTIs were examined. The rationale for this testing strategy is two fold: 1. Many drugs are extensively bound to plasma proteins. Although the binding affinity for most drugs for the major components of human plasma, namely, human serum albumin (HSA) or alpha-1-acid glycoprotein (AAG) , is low, these major components are present in high concentration in the blood. Only free or unbound drug is available to cross the infected cell membrane for interaction with the target site (i.e., HIV- 1 reverse transcriptase, HIV-1 RT) . Therefore, the effect of added HSA+AAG on the antiviral potency in tissue culture more closely reflects the potency of a given compound in the clinical setting. The concentration of compound required for 90% inhibition of virus replication as measured in a sensitive viral RNA-based detection method is designated the IC90. The fold increase in apparent IC90 for test compounds in the presence or added levels of HSA and AAG that reflect in vivo concentrations (45 mg/ml HSA, 1 mg/ml AAG) was then 100 calculated. The lower the fold increase, the more compound will be available to interact with the target site. 2. The combination of the high rate of virus replication in the infected individual and the poor fidelity of the viral RT results in the production of a quasi-species or mixtures of HIV species in the infected individual. These species will include a majority wild type species, but also mutant variants of HIV and the proportion of a given mutant will reflect its relative fitness and replication rate. Because mutant variants including mutants with changes in the amino acid sequence of the viral RT likely pre-exist in the infected individual's quasi-species, the overall potency observed in the clinical setting will reflect the ability of a drug to inhibit not only wild type HIV-1, but mutant variants as well. We thus have constructed, in a known genetic background, mutant variants of HIV-1 which carry amino acid substitutions at positions thought to be involved in NNRTI binding, and measured the ability of test compounds to inhibit replication of these mutant viruses . The concentration of compound required for 90% inhibition of virus replication as measured in a sensitive viral RNA-based detection method is designated the IC90. It is desirable to have a compound which has high activity against a variety of mutants. Dosaσe and Formulation The antiviral compounds of this invention can be administered as treatment for viral infections by any means that produces contact of the active agent with the agent's site of action, i.e., the viral reverse transcriptase, in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents . They can be administered alone, but preferably are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic 101 characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired. A daily dosage of active ingredient can be expected to be about 0.001 to about 1000 milligrams per kilogram of body weight, with the preferred dose being about 0.1 to about 30 g/kg. Dosage forms of compositions suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition. The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets and powders, or in liquid dosage forms, such as elixirs, syrups and suspensions. It can also be administered parenterally, in sterile liquid dosage forms. Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets . Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either 102 alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts, and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkoniu chloride, methyl- or propyl-paraben and chlorobutanol . Suitable pharmaceutical carriers are described in Remington ' s Pharmaceutical Sciences , supra , a standard reference text in this field. Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows : Capsules A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose, and 6 mg magnesium stearic. Soft Gelatin Capsules A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil can be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules should then be washed and dried. Tablets A large number of tablets can be prepared by conventional procedures so that the dosage unit is 100 mg of active ingredient, 0.2 mg of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of lactose. Appropriate coatings may be applied to increase palatability or delay absorption. Suspension An aqueous suspension can be prepared for oral administration so that each 5 mL contain 25 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S. P., and 0.025 mg of vanillin. 103 In ectable A parenteral composition suitable for administration by injection can be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is sterilized by commonly used techniques. Combination of components (a) and (b) Each therapeutic agent component of this invention can independently be in any dosage form, such as those described above, and can also be administered in various ways, as described above. In the following description component (b) is to be understood to represent one or more agents as described previously. Thus, if components (a) and (b) are to be treated the same or independently, each agent of component (b) may also be treated the same or independently. Components (a) and (b) of the present invention may be formulated together, in a single dosage unit (that is, combined together in one capsule, tablet, powder, or liquid, etc.) as a combination product. When component (a) and (b) are not formulated together in a single dosage unit, the component (a) may be administered at the same time as component (b) or in any order; for example component (a) of this invention may be administered first, followed by administration of component (b) , or they may be administered in the revserse order. If component (b) contains more that one agent, e.g., one RT inhibitor and one protease inhibitor, these agents may be administered together or in any order. When not administered at the same time, preferably the administration of component (a) and (b) occurs less than about one hour apart. Preferably, the route of administration of component (a) and (b) is oral. The terms oral agent, oral inhibitor, oral compound, or the like, as used herein, denote compounds which may be orally administered. Although it is preferable that component (a) and component (b) both be administered by the same route (that is, for example, both orally) or dosage form, if desired, they may each be administered by different, routes (that; is, for example, one 104 component of the combination product may be administered orally, and another component may be administered intravenously) or dosage forms. As is appreciated by a medical practitioner skilled in the art, the dosage of the combination therapy of the invention may vary depending upon various factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, and the effect desired, as described above. The proper dosage of components (a) and (b) of the present invention will be readily ascertainable by a medical practitioner skilled in the art, based upon the present disclosure. By way of general guidance, typically a daily dosage may be about 100 milligrams to about 1.5 grams of each component. If component (b) represents more than one compound, then typically a daily dosage may be about 100 milligrams to about 1.5 grams of each agent of component (b) . By way of general guidance, when the compounds of component (a) and component (b) are administered in combination, the dosage amount of each component may be reduced by about 70-80% relative to the usual dosage of the component when it is administered alone as a single agent for the treatment of HIV infection, in view of the synergistic effect of the combination. The combination products of this invention may be formulated such that, although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized. In order to minimize contact, for example, where the product is orally administered, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. Another embodiment 105 of this invention where oral administration is desired provides for a combination product wherein one of the active ingredients is coated with a sustained-release material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained- released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose or other appropriate materials as known in the art, in order to further separate the active components . The polymer coating serves to form an additional barrier to interaction with the other component . In each formulation wherein contact is prevented between components (a) and (b) via a coating or some other material, contact may also be prevented between the individual agents of component (b) . Dosage forms of the combination products of the present invention wherein one active ingredient is enteric coated can be in the form of tablets such that the enteric coated component and the other active ingredient are blended together and then compressed into a tablet or such that the enteric coated component is compressed into one tablet layer and the other active ingredient is compressed into an additional layer. Optionally, in order to further separate the two layers, one or more placebo layers may be present such that the placebo layer is between the layers of active ingredients. In addition, dosage forms of the present invention can be in the form of capsules wherein one active ingredient is compressed into a tablet or in the form of a plurality of microtablets, particles, granules or non-perils, which are then enteric coated. These enteric coated microtablets, particles, granules or non-perils are then placed into a capsule or compressed into a capsule along with a granulation of the other active ingredient. 106 These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time or concurrently by the same manner, will be readily apparent to those skilled in the art, based on the present disclosure. Pharmaceutical kits useful for the treatment of HIV infection, which comprise a therapeutically effective amount of a pharmaceutical composition comprising a compound of component (a) and one or more compounds of component (b) , in one or more sterile containers, are also within the ambit of the present invention. Sterilization of the container may be carried out using conventional sterilization methodology well known to those skilled in the art. Component (a) and component (b) may be in the same sterile container or in separate sterile containers. The sterile containers of materials may comprise separate containers, or one or more multi-part containers, as desired. Component (a) and component (b) , may be separate, or physically combined into a single dosage form or unit as described above. Such kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit . Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein. 107

Claims: WHAT IS CLAIMED IS; 1. A compound of formula (I) : I or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: R 1 is Cι_ 3 alkyl substituted with 1-7 halogen; R 2 is selected from C 1 - 5 alkyl substituted with 1-2 R 4 , C 2 _ 5 alkenyl substituted with 1-2 R 4 , and C _ 5 alkynyl substituted with 1 R 4 ; R 3 , at each occurrence, is independently selected from C 1 -. 4 alkyl, OH, C 1 - 4 alkoxy, F, Cl, Br, I, NR 5 R 5 , N0 2 , CN, C(0)R 6 , NHC(0)R 7 , and NHC (0)NR 5 R 5a ; alternatively, if two R 3 ' s are present and are attached to adjacent carbons, then they may combine to form -0CH 2 0-; R 4 is selected from 0 3 - 5 cycloalkyl substituted with 0-2 R 3 , phenyl substituted with 0-5 R 3 , and a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from 0, N, and S, substituted with 0-2 R 3 ; R 5 and R a are independently selected from H and C 1 - 3 alkyl; R 6 is selected from H, OH, C 1 - 4 alkyl, Cι_ 4 alkoxy, and NR 5 R 5a ; R 7 is selected from C 1 - 3 alkyl and C 1 -. 3 alkoxy; R 8 is selected from H, C 3 - 5 cycloalkyl, and C 1 - 3 alkyl; and, n is selected from 0, 1, 2, 3, and 4. 108 2. A compound according to Claim 1, wherein: R 1 is Cι_ 3 alkyl substituted with 1-7 halogen; R 2 is selected from C 1 -. 5 alkyl substituted with 1 R 4 , C 2 _ 5 alkenyl substituted with 1 R 4 , and C 2 _ 5 alkynyl substituted with 1 R 4 ; R , at each occurrence, is independently selected from C 1 -. 4 alkyl, OH, C 1 - 4 alkoxy, F, Cl, Br, I, NR 5 R 5a , N0 2 , CN, C(0)R 6 , NHC(0)R 7 , and NHC (0) NR 5 R 5a ; alternatively, if two R 3 ' s are present and are attached to adjacent carbons, then they may combine to form -OCH 2 0-; R 4 is selected from C 3 -. 5 cycloalkyl substituted with 0-2 R 3 , phenyl substituted with 0-2 R 3 , and a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from 0, N, and S, substituted with 0-1 R 3 ; R 5 and R 5a are independently selected from H, CH 3 and C 2 Hs; R 6 is selected from H, OH, CH 3 , C 2 H 5 , OCH 3 , 0C 2 H 5 , and NR 5 R 5a ; R 7 is selected from CH 3 , CHs, OCH 3 , and 0CHs; R 8 is selected from H, cyclopropyl, CH 3 and C 2 Hs; and, n is selected from 0, 1, 2, and 3. 3. A compound according to Claim 2, wherein: R 1 is selected from CF 3 , and CFs; 109 R 2 is selected from C 1 -. 3 alkyl substituted with 1 R 4 , C 2 _ 3 alkenyl substituted with 1 R , and C 2 _ 3 alkynyl substituted with 1 R 4 ; R 3 , at each occurrence, is independently selected from C 1 -. 3 alkyl, OH, C 1 - 3 alkoxy, F, Cl, Br, I, NR 5 R 5a , N0 2 , CN, C(0)R δ , NHC(0)R 7 , and NHC (0)NR 5 R 5a ; alternatively, if two R 3 ' s are present and are attached to adjacent carbons, then they may combine to form -OCH 2 0-; R 4 is selected from C 3 - 5 cycloalkyl substituted with 0-2 R 3 , phenyl substituted with 0-2 R 3 , and a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from 0, N, and S, substituted with 0-1 R 3 ; R 5 and R 5a are independently selected from H, CH 3 and C 2 Hs; R 6 is selected from H, OH, CH 3 , C 2 H 5 , OCH 3 , OC 2 H 5 , and NR 5 R5 a ; R 7 is selected from CH 3 , C 2 H 5 , OCH 3 , and OC 2 H 5 ; R 8 is selected from H, CH 3 and C 2 H 5 ; and, n is selected from 0, 1, and 2. 4. A compound according to Claim 3, wherein: R 1 is CF 3 ; R 2 is selected from Cι_ 3 alkyl substituted with 1 R 4 , C 2 - 3 alkenyl substituted with 1 R 4 , and C _ 3 alkynyl substituted with 1 R 4 ; R 3 , at each occurrence, is independently selected from C 1 -. 3 alkyl, OH, Cι_ alkoxy, F, Cl, NR 5 R 5a , N0 2 , CN, C(0)R 6 , NHC(0)R 7 , and NHC (0)NR 5 R 5a ; 110 alternatively, if two R 3 ' s are present and are attached to adjacent carbons, then they may combine to form -OCH 2 0-; R 4 is selected from cyclopropyl substituted with 0-1 R 3 , phenyl substituted with 0-2 R 3 , and a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from 0, N, and S, substituted with 0-1 R 3 , wherein the heterocyclic system is selected from 2-pyridyl, 3- pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, 3- thienyl, 2-oxazolyl, 2-thiazolyl, 4-isoxazolyl , and 2- imidazolyl; R 5 and R 5a are independently selected from H, CH 3 and C 2 Hs; R 6 is selected from H, OH, CH 3 , C 2 H 5 , OCH 3 , OC 2 H 5 , and NR 5 R 5a ; R 7 is selected from CH 3 , CHs, OCH 3 , and OCH 5 ; R 8 is selected from H, CH 3 and C 2 Hs; and, n is selected from 1 and 2. 5. A compound according to Claim 4, wherein the compound is of formula la: la. 6. A compound according to Claim 4, wherein the compound is of formula la: 111 R, 1 2 H (T " NT N H Λ lb. 7. A compound according to Claim 1, wherein the compound is selected from: ( +/-) -4-Cyclopropylethynyl-5, 6-difluoro-4-trifluoromethyl-3 , 4- dihydro-2 (IH) -quinazolinthione; (+/-) -6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-3 , 4- dihydro-2 (IH) -quinazolinthione; (+/-) -4-Cyclopropylethynyl-5 , 6-difluoro-4-trifluoromethyl-3 , 4- dihydro-2-methyl (IH) -quinazolinthione; and, (+/-) -6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-3 , 4- dihydro-2-methyl (IH) -quinazolinthione; or a pharmaceutically acceptable salt thereof. 8. A compound according of formula II: II or a stereoisomer or pharmaceutically acceptable salt thereof, wherein : R 2 is C≡C-R 4a ; 11. R 3 is selected from C 1 - 4 alkyl, OH, C 1 -. 4 alkoxy, F, Cl, Br, I, NR 5 R 5a , N0 , CN, C(0)R 6 , NHC(0)R 7 , and NHC (0)NR 5 R 5a ; R a is selected from methyl, ethyl, n-propyl, i-propyl, i-butyl, t-butyl, and i-pentyl; R 5 and R 5a are independently selected from H and C 1 - 3 alkyl; R δ is selected from H, OH, C 1 - 4 alkyl, C 1 - 4 alkoxy, and NR 5 R 5a ; R 7 is selected from C 1 - 3 alkyl and C 1 - 3 alkoxy; R 8 is selected from H, C 3 _ 5 cycloalkyl, and C 1 - 3 alkyl; and, n is selected from 0, 1, 2, 3, and 4. 9. A compound according to Claim 8, wherein: R 2 is C≡C-R 4a ; R 3 is selected from Cι_ 4 alkyl, OH, C 1 -. 4 alkoxy, F, Cl, Br, I, NR 5 R 5a , N0 2 , CN, C(0)R 6 , and NHC(0)R 7 ; R a is selected from methyl, ethyl, n-propyl, i-propyl, i-butyl, t-butyl, and i-pentyl; R 5 and R 5a are independently selected from H, CH 3 and C 2 H 5 ; R 5 is selected from H, OH, CH 3 , C 2 Hs, OCH 3 , OC 2 H 5 , and NR 5 R 5a ; R 7 is selected from CH 3 , C 2 H 5 , OCH 3 , and OC H 5 ; R 8 is selected from H, cyclopropyl, CH 3 and C 2 H 5 ; and, n is selected from 0, 1, and 2. 113 10. A compound according to Claim 9, wherein the compound is of formula Ila: CF 3 H Ila. 11. A compound according to Claim 9, wherein the compound is of formula lib: CF 3 R 2 lib. 12. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of one of Claims 1-11. 13. A method for treating HIV infection, comprising: administering to a host in need of such treatment a therapeutically effective amount of a compound of one of Claims 1-11, or a pharmaceutically acceptable salt form thereof . 14. A method of treating HIV infection which comprises administering, in combination, to a host in need thereof a therapeutically effective amount of: (a) a compound of one of Claims 1-11 or a pharmaceutically acceptable salt thereof; and, (b) at least one compound selected from the group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors . 114

Inventors: CORBETT JEFFREY W, CORBETT, JEFFREY, W.
Applicants: DU PONT PHARM CO, DU PONT PHARMACEUTICALS COMPANY
Application year: 1999
Main classification: C07D239
IPC codes: A61K31, A61P31, A61P37, A61P43, C07D239, C07D401, C07D403, C07D405, C07D409, C07D413, C07D417, C07D491